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Abstract
20-50% of patients develop pouchitis following restorative proctocolectomy for ulcerative 
colitis (UC). Pre-pouch ileitis (PPI) also develops in some of these patients.
Bacteria are implicated in the pathogenesis of pouchitis and antibiotics are the mainstay of 
treatment. Studies were performed to examine the role of bacteria in the pathogenesis of this 
disease and to develop new treatment. Further studies examined the prevalence and 
implications of PPI and the efficacy and complications associated with maintenance 
antibiotic therapy.
16s rRNA sequencing demonstrated an increase in Proteobacteria and a reduction in 
Bacteroidetes in the UC compared with the familial adenomatous polyposis (FAP) cohort, but 
only limited differences between the UC non-pouchitis and pouchitis groups. We were unable 
to identify an individual species or phylotype specifically associated with pouchitis.
Treatment with elemental diet produced a symptomatic improvement in 71% of chronic 
pouchitis patients but none entered clinical remission.
Patients with PPI were identified, the prevalence, symptoms and short term outcomes of this 
group  were  studied.  PPI  was  identified  in  5.7%  of  patients  with  UC.  All  patients  had 
associated  pouchitis  but  not  all  were  symptomatic.  PPI  was  not  associated  with 
reclassification to Crohn’s disease. A subgroup of patients with symptomatic pre-pouch ileitis 
were treated with combination antibiotic therapy and 86% entered remission.
Faecal samples from patients with antibiotic resistant pouchitis were grown on agar and 
sensitivity patterns identified. Following guided antibiotic therapy 80% of patients entered 
remission. Stool analysis also identified the presence of extended spectrum beta-lactamase 
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(ESBL) resistant coliforms in 35% of patients with chronic pouchitis. Not all were 
symptomatic. PPI was associated with an increased risk of ESBL.
Patients treated with maintenance antibiotic therapy were identified. Pre-pouch ileitis was 
associated with an increased risk of relapse. Reported side effects were rare and treatment 
was associated with an improved quality of life.
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1.1 Background to ileal-pouch surgery
About  a  third  of  patients  with  ulcerative  colitis  (UC)  will  eventually  require 
surgery  (Hendriksen,  Kreiner  et  al.  1985;Langholz,  Munkholm  et  al.  1992). 
Three  operations  are  available  including  conventional  proctocolectomy, 
restorative  proctocolectomy  with  ileal  pouch-anal  anastomosis  (RPC)  and 
colectomy  with  ileorectal  anastomosis  (IRA).  The  last  of  these  is  only 
suitable  for  the  few  patients  whose  rectum  is  relatively  free  of  inflammation 
and  where  there  is  no  dysplasia  or  established  cancer  in  the  large  bowel. 
Conventional  proctocolectomy  leaves  the  patient  with  a  permanent  ileostomy 
which  most  patients  wish  to  avoid.  RPC  or  “the  pouch  operation”  (Parks  & 
Nicholls  1978)  is  now  the  procedure  of  choice  for  patients  who  require 
surgery for UC. 
The  same  choices  apply  to  patients  with  familial  adenomatous  polyposis 
(FAP).  The  emphasis  for  each  is  different  with  conventional  proctocolectomy 
being  rarely  indicated  and  the  surgical  options  largely  lie  between  colectomy 
with IRA and RPC.
(i). Indications and contraindications
Indications
Familial  Adenomatous Polyposis (FAP)
Colectomy  with  IRA is  the  preferred  operation  in  many  younger  patients,  but 
meticulous  long  term  surveillance  of  the  rectum  is  necessary.  RPC  is 
recommended  for  patients  over  25  years,  those  with  a  severe  phenotype 
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(>1000  colonic  adenomas,  >  20  rectal  adenomas)  or  a  genotype  predicting 
severe disease. 
The  incidence  of  rectal  cancer  after  colectomy markedly increases  beyond the 
age  of  50  years(Nugent  &  Phillips  1992).  But  conversion  to  RPC  can  be 
undertaken at  a later  date if  the rectal  adenomas become unmanageable.
Ulcerative Colitis
The indications for surgery in UC include:
(i) Disease refractory to medical  therapy.  
(ii)  Dysplasia or carcinoma found during screening colonoscopy.  
(iii)   Retardation of growth in a child or adolescent.  
In any of these circumstances  conventional  or restorative proctocolectomy are 
available  to  the  patient  including  following  an  initial  subtotal  colectomy 
where the rectum is not suitable  for IRA.
Contraindications to RPC 
Absolute
( i ) Carcinoma in the low rectum requiring a total  anorectal  excision.  
( i i ) Incompetent  anal sphincter.  
( i i i ) Emergency presentation.  Patients  presenting  as  an  emergency should be 
treated with a colectomy and ileostomy with preservation of the rectum. 
An  interval  of  at  least  three  months  should  elapse  before  undertaking 
RPC.
16
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Relative
(i) Crohn’s  disease  (CD):   Most  patients  with  CD  who  have 
undergone RPC were  originally  thought  to  have  UC. In  these,  the 
failure  rate  ranges  from  20%  to  over  60%  (Lovegrove, 
Constantinides  et  al.  2006;Chambers  &  Mortensen  2007). 
Complications  including  pelvic  sepsis,  stricture,  fistulation  and 
pouchitis  are  increased  (Reese,  Lovegrove  et  al.  2007).  Function 
is  worse  with  increased  urgency  and  incontinence  (Hahnloser, 
Pemberton  et  al.  2007).  In  one  unit  selected  patients  known  to 
have  CD  have  been  offered  RPC  (Regimbeau,  Panis  et  al.  2001) 
with  similar  results  to  patients  with  UC.  It  has  been  suggested 
that  some  of  these  patients  may have  had  what  other  pathologists 
would term indeterminate  colitis.  
(ii)  Indeterminate  colitis  (IC):  The  term  describes  an  inability  of  the 
histopathologist  to distinguish between UC and CD since features of each may 
be present in the same surgical  or biopsy specimen (Price 1978). The dilemma 
usually  arises  from  examination  of  colectomy  specimens  removed  as  an 
emergency.   In  such  patients  clinical  and radiological  assessment  of  the  small 
intestine  and  anus  may  allow  the  categorisation  of  IC  into:  IC  probably  CD, 
IC  probably  UC  or  definite  IC.  On  long  term  follow-up  of  the  last  two,  CD 
rarely  develops  (Wells,  McMillan  et  al.  1991;Ravishankar,  Armstrong  et  al. 
2007).  Complications  and  failure  after  RPC  are  slightly  higher  than  for  UC 
(Tekkis,  Heriot  et  al.  2005)  (Hahnloser,  Pemberton,  et  al .  2007)  although  the 
long-term outcome is similar  (Hahnloser, Pemberton et al.   2007).
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(iii)  Primary sclerosing cholangitis  (PSC):  The cumulative risk of pouchitis  is 
approximately  twice  that  of  patients  without  PSC  (Penna,  Dozois  et  al. 
1996;Zins,  Sandborn  et  al.  1995).  There  is  also an  increased  risk  of  dysplasia 
in  the  ileal  mucosa  of  the  pouch  (Stahlberg,  Veress  et  al.  2003;Gullberg, 
Stahlberg  et  al.  1997)
(iv) Pre-reproductive  females:   In  an  epidemiological  study,  fecundity  in  a 
cohort  of  patients  with  UC  compared  with  the  general  population 
was  the  same  before  and  after  diagnosis  but  fell  to  50%  following 
RPC  (Olsen,  Joelsson  et  al.  1999).  A  meta-analysis  demonstrated 
that  females  having  RPC  for  UC  had  an  infertili ty  rate  of  48% 
compared  with 15% of  age-matched normal  controls  (Waljee,  Waljee 
et  al.  2006).  This  was  thought  to  be  due  to  adhesions  around  the 
fallopian  tubes  (Oresland,  Palmblad  et  al.  1994)  but  there  must  also 
be  a  disease-related  factor  since  after  RPC  for  FAP  the  fall  in 
fecundity  was  significantly  less  than  for  UC  (Olsen,  Joelsson,  et  al. 
1999).  Patients  with  FAP  had  the  same  fecundity  as  the  general 
population  following   colectomy with  IRA indicating  that  the  pelvic 
dissection was likely to  be responsible  for the reduction in  fecundity 
(Olsen,  Joelsson,  et  al.  1999).  In  vitro  fertilisation  can  be  effective 
(Cornish,  Tan  et  al.  2007;Ording,  Juul  et  al.  2002)  and  patients 
unable  to  conceive  naturally  following RPC should  be  referred  early 
for this  treatment.
Women  of  childbearing  age  must  be  informed  of  these  facts.  The  options 
include  RPC accepting  the risk of  reduced fertili ty  or  a  colectomy to treat  the 
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disease  followed  by  RPC  at  the  patient’s  convenience  after  having  children. 
The discussion should be recorded in the case notes. 
(ii). Operative Technique
RPC involves  removal  of  the  colon  and rectum,  construction  of  a  reservoir  or 
‘pouch’ from the last  30-40 cm of ileum followed by an ileoanal anastomosis.
Figure 1.1. Ileo-anal pouch anatomy.  
Today  most  surgeons  use  a  ‘J’  or  two  loop  pouch  configuration  owing  to  the 
ease  of  construction  although  other  designs  such  as  the  ‘W’  or  four  loop 
pouch may result  in  lower  frequency of  defaecation.  It  is  however  technically 
more difficult  to construct.  
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In  forming  the  ileo-anal  anastomosis  the  surgeon  can  either  staple  or  hand 
sew  the  pouch  to  the  anal  canal.  This  is  an  important  difference  because 
stapling  leaves  a  1-2cm  cuff  of  residual  rectum  in-situ,  which  may  become 
symptomatic  and  is  at  risk  of  dysplasia.  The  hand  sewn  technique  includes  a 
mucosectomy  to  remove  virtually  all  anorectal  mucosa  and  places  the 
anastomosis  just  above  the  dentate  line  (see  figure  1.1)  but  it  may  be 
associated  with  a  higher  incidence  of  minor  anal  leakage  (Lovegrove, 
Constantinides,  et al.  2006;Chambers & McC Mortensen 2007) .
RPC is  only undertaken  as  an  elective  procedure,  in  acutely  unwell  patients  a 
subtotal  colectomy with end ileostomy and preservation  of  the  rectal  stump is 
performed  and  RPC undertaken  following  an  interval  of  at  least  3  months.  In 
systemically  well  patients  RPC  is  usually  undertaken  in  two  stages,  however 
some  surgeons  use  a  one  stage  technique  to  avoid  a  defunctioning  ileostomy. 
When  an  ileostomy  is  performed,  it  is  closed  at  about  8  weeks  provided  the 
anastomosis  has  healed  as  judged  by  digital  examination  and  a  contrast 
enema.  In  a  meta-analysis  of  17  studies  (7  high  quality)  the  incidence  of 
anastomotic  leakage was 4.3% and 9.4% and perianal  sepsis  1.6% and 5.1% in 
patients  having  either  an  ileostomy  or  no  ileostomy  (Weston-Petrides, 
Lovegrove  et  al.  2008). Studies reporting the outcome of  a selective policy on 
defunctioning  have  showed  similar  complication  rates  between  a  one  and  a 
two stage strategy with the  advantage  of  an  overall  shorter  hospitalisation  for 
the  former  (Remzi,  Fazio  et  al.  2006;  Gorfine,  Gelernt  et  al.  1995). 
Conversely other  studies  have shown an increased risk of anastomotic  leakage 
(Sugerman,  Sugerman  et  al.  2000)  resulting in  pelvic  sepsis  with an increased 
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risk  of  subsequent  failure  in  the  long-term (Tulchinsky,  Hawley  et  al.  2003a; 
Heuschen, Allemeyer  et al.  2002). 
Some  surgeons  undertake  RPC  laparoscopically.  The  short  term  results  are 
comparable  to  the  open  operation  (Larson,  Cima  et  al.  2006;  Larson,  Dozois 
et al.  2005). 
(iii). Morphological changes in the mucosa of the ileo-anal pouch following ileostomy 
closure
 Following closure  of  the  ileostomy,  the  ileal  mucosa  in  the  pouch is  exposed to  faeces 
containing bacterial concentrations a million or more times greater than found in the normal 
terminal ileum (Philipson, Brandberg et al. 1975; Nicholls, Belliveau et al. 1981; Apel, Cohen 
et al. 1994). During the first six months thereafter villous atrophy takes place in both UC and 
FAP patients. In UC patients mainly, infiltration of the ileal pouch mucosa by inflammatory 
cells is common. Colonic metaplasia may be seen with the sialomucin staining characteristics 
of colonocytes, and disaccharidase activity may be lost. This process is patchy (Shepherd, 
Jass et al. 1987). Morphological changes begin within the first days to weeks after closure of 
the ileostomy (de Silva, Millard et al. 1991; Setti Carraro, Talbot et al. 1994; Herbst, Ciclitira 
et al. 2000; Arai, Koganei et al. 2005).
Two groups independently  studied the histological pattern of pouch mucosal inflammation 
through serial biopsies taken over two years or more  (Veress, Reinholt et al. 1990; Veress, 
Reinholt et al. 1995)  (Setti Carraro, Talbot, & Nicholls 1994).  The patients fell into three 
broad groups designated Types A, B and C. In Type A (50%), mucosal biopsies showed little 
or no inflammation or villous atrophy.  Type B patients  (40%) had fluctuating changes of 
varying severity and in the Type C patients (10%) all biopsies consistently showed severe 
villous atrophy and acute and chronic inflammation. Many in this last group were diagnosed 
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as having chronic unremitting pouchitis.  The groups had become differentiated within six 
months of closure of the ileostomy.
1.2 Small bowel inflammation in ulcerative colitis and definition of pouchitis
Although UC is generally defined as a disease affecting only the large bowel there are several 
clinical situations where small bowel inflammation is accepted as part of this disease, these 
are:
1. Backwash ileitis: histological evidence of backwash ileitis has been identified in 10-
18% of patients at colectomy (Price & Morson 1975), its aetiology is thought to be 
secondary to reflux of large bowel contents into the small bowel via an incompetent 
ileo-caecal valve (Haboubi 2006). 
2. Pre-stomal ileitis: Now rare, pre-stomal ileitis was common occurring in some patients 
with  granulation  and  scarring  of  the  exposed  serosa  who  developed  stricturing 
following conventional proctocolectomy and ileostomy,  it is characterised by linear 
ulcers of the ileum and jejunum and carries the risk of perforation and consequent 
peritonitis. The condition is thought to be secondary to stasis in those with pre-stomal 
narrowing given that  dilatation  is  curative  (Warren & Mckittrick  1951).  Since the 
widespread use of the everted Brooke ileostomy (Brooke 1952) this  condition  has 
become uncommon (Scott & Phillips 1989).
3. Pre-pouch  ileitis:  this  condition  has  been  recently  characterised  and  has  been 
described as mucosal inflammation extending proximally from the neo-terminal ileum 
with histological features similar to pouchitis.  In this study only 50% of cases had 
concomitant pouchitis and it was found to occur in 2.6% of patients (Bell, Price et al. 
2006).  The only other published study found an incidence of 14% in 107 patients 
followed up for a mean of 7.5 years,  in contrast  to the first  study all patients  had 
associated pouchitis (Kuisma, Jarvinen et al. 2004).
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4. Pouchitis:  Inflammation of the pouch mucosa was first described by Kock  et al in 
1977  and  termed  ‘pouchitis’   when  histological  and  endoscopic  evidence  of 
inflammation was associated with symptoms of frequency,  urgency and fluid stool 
consistency in patients with a Kock continent ileal reservoir (Kock, Darle et al. 1977). 
This  condition  was  later  described  in  patients  who  underwent  restorative 
proctocolectomy  with  ileal  pouch-anal  anastomosis.  Studies  have  reported  a 
cumulative  incidence  of  pouchitis  of  20-50%  (Moskowitz,  Shepherd et  al. 1986; 
Luukkonen, Valtonen et al. 1988; Oresland, Fasth et al. 1989; O'Connell, Rankin et  
al. 1986)  and over  time  pouchitis  is  responsible  for  about  10% of  pouch failures 
(Tulchinsky, Hawley, & Nicholls 2003a). In clinical practice most patients respond to 
a  two  week  course  of  a  single  antibiotic.  The  prevalence  of  chronic  persisting 
pouchitis (and thus of patients suffering significantly) is much lower, being around 5% 
(Salemans, Nagengast et al. 1992; Hurst, Molinari et al. 1996; Hahnloser, Pemberton, 
et al.  2007; Lovegrove, Tilney et al. 2006).
(ii). Clinical presentation
Patients suffering from pouchitis usually present with symptoms of increased stool frequency, 
reduced stool consistency and urgency (Pardi & Sandborn 2006b). The presence of anaemia is 
strongly associated with pouchitis, and is the presenting symptom in a minority of patients 
(Pastrana,  Torres et  al. 2007),  bleeding  occurs  in  some patients  but  is  uncommon.  Some 
patients also experience abdominal cramping and rarely patients present with dehydration or 
fever.
 (iii). Diagnosis and classification
In  clinical  practice  the  diagnosis  of  pouchitis  requires  a  triad  of  compatible  symptoms, 
endoscopic and histological  findings. Several  scoring systems have been devised to grade 
pouchitis. These include the St. Mark’s score (Moskowitz, Shepherd, et al. 1986), the PDAI 
(Sandborn, Tremaine et al. 1994), the Heidelberg system (Heuschen, Allemeyer et al. 2002) 
23
Background to ileal-pouch surgery Chapter 1
and the Objective Pouchitis Score (OPS) (Johnson, Maestranzi et al. 2008). The PDAI and 
Heidelberg  Pouchitis  Activity  Score  (PAS)  give  numbers  to  clinical,  endoscopic  and 
histological features. These systems, however, contain the fallacy that histological evidence of 
acute inflammation is not an essential requisite for the diagnosis (see table 1.1). 
Table 1.1 
Table to illustrate the different pouchitis scoring systems.
Clinical
PDAI PAS OPS St. Mark’s score
Stool frequency 0-2 0-6
Symptoms  present 
or absent
Symptoms  present 
or absent
Faecal urgency
or abdo cramps
0-2 0/3
Rectal bleeding 0/1 0/3
Fever 0/1 N/A
Endoscopic inflammation
PDAI PAS OPS St. Mark’s score
Oedema 0-1 0-1 1 1
Granularity 0-1 0-1 1 1
Friability 0-1 0-2 1
Loss  of  vascular 
pattern
0-1 N/A 1 1
Mucous exudate 0-1 N/A 1 N/A
Ulceration 0-1 2-3 1 1
Mucosal flattening N/A 1-2 N/A N/A
Erythema N/A 0-3 N/A N/A
Mucosal 
haemorrhages
N/A N/A N/A 1
Contact bleeding N/A N/A N/A 1
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Histopathological criteria
PDAI PAS OPS St. Mark’s score
Mild  polymorph 
infiltrate
1 1 1 1
Moderate  infiltrate 
with  crypt 
abscesses
2 2 2 2
Severe  infiltrate 
with  crypt 
abscesses
3 3 3 3
Ulceration (per low 
power field) <25%
1 1 1 1
25-50% 2 2 2 2
>50% 3 3 3 3
Diagnosis of pouchitis
Diagnosis  of 
Pouchitis
Total Score ≥7* Moderate   13-
24*
Severe 25-36*
Symptoms  and 
endoscopic 
score  ≥3  and 
histological
 score ≥2
Symptoms  and 
endoscopic signs 
and  histological 
score ≥4
*Histology not necessary for the diagnosis of pouchitis
PDAI=  Pouch  disease  activity  index  (Sandborn,  Tremaine,  Batts,  Pemberton,  &  Phillips 
1994)
PAS= Pouchitis  activity score (Heuschen et al.2002)
OPS= Objective pouchitis score (Johnson, Maestranzi et al. 2008) 
St. Mark’s score (Moskowitz,  Shepherd et  al.  1986)
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All  patients  should  have  a  flexible  pouchoscopy and biopsy as  symptoms  do not  always 
correlate with the endoscopic and histological findings (Sandborn 1994; Shen, Achkar et al. 
2001a; Moskowitz, Shepherd et al. 1986). Other disorders can present with poor function and 
may temporarily respond to antibiotics.  For patients  with frequent episodes of established 
pouchitis  it  is  reasonable  to  start  antibiotics  without  repeating  the  pouchoscopy.  Many 
patients have asymptomatic inflammation in the pouch. Some will have inflammation along a 
suture line, this is a normal variant and not pouchitis (Shen, Fazio et al. 2005b). Inflammation 
may be patchy in distribution and biopsies may therefore not be representative.
Classification 
For practical purposes pouchitis can be classified as:
1. Acute;   less than 4 weeks in duration, responding to a single antibiotic and occurring 
less than three times per year. This category includes the majority of patients.
2. Chronic;  
(i) Chronic relapsing; three or more episodes per year which respond to antibiotic 
treatment.
(ii)  Chronic  antibiotic  dependent;  symptoms  controlled  when maintained  on  a 
single antibiotic, but promptly return when this is withdrawn.
(iii) Chronic antibiotic  refractory;  most  authors define this  where the patient  no 
longer responds to a single antibiotic (Shen, Fazio et al. 2005b; Mahadevan & 
Sandborn 2003).
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(iv). Differential diagnosis of pouchitis
(a). Pre-pouch ileitis
A few patients develop inflammation in the ileum immediately proximal to the pouch. This is 
usually  associated  with  pouchitis  (McLaughlin,  Clark et  al. 2009),  but  it  may  occur  in 
isolation (Bell, Price et al. 2006). Symptoms include those of pouchitis and also of intestinal 
obstruction.  Pre-pouch ileitis  occurs in about 3% of patients  after  RPC (Bell,  Price et al.  
2006).  Ileo-pouchoscopy or  video-capsule  endoscopy (Calabrese,  Fabbri et  al. 2007)  will 
determine the extent of inflammation. CD should be considered in patients with extensive pre-
pouch  ileitis,  those  who  do  not  respond  to  antibiotics  or  where  skip  lesions  are  evident 
particularly in the presence of a normal pouch.
Treatment
Various treatments have been described including oral steroids, 5-ASA drugs and antibiotics 
(Bell, Price et al. 2006). There are no controlled studies however treatment with ciprofloxacin 
and metronidazole is usually effective (McLaughlin, Clark et al. 2008).
(b). Inflammation of the Residual Anorectal Mucosa (‘strip proctitis’ or ‘cuffitis’)
A stapled ileo-anal anastomosis  leaves a variable  length of anorectal  mucosa  in situ.  The 
surgeon aims to site this at the level of the anorectal junction or more distally. At times this 
may not be achieved and some patients (up to 15% in some reports (Lavery, Sirimarco et al. 
1995)) may be left with an anorectal stump sometimes a few centimetres long. The persisting 
proctitis and incomplete pouch emptying may produce bleeding and urgency and the frequent 
passage of small volumes of stool. This complication is rare following a manual anastomosis 
with mucosectomy.
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The condition may be mistaken for pouchitis but the ileorectal anastomosis is easily felt on 
digital examination. A contrast enema or pouchoscopy will demonstrate a high anastomosis 
and the presence of inflamed rectal  mucosa can be confirmed in a biopsy taken from the 
retained rectal stump. Local anti-inflammatory treatment with steroid or 5-ASA suppositories 
may relieve  the symptoms  (Shen,  Lashner et  al. 2004).  In  patients  with persistent  severe 
symptoms or where there is a long rectal stump, a pouch revision removing the remaining 
rectum  has  about  a  70-90%  chance  of  achieving  satisfactory  anal  function  (Tulchinsky, 
McCourtney et al. 2001; Tekkis, Heriot et al. 2006). It is important to recognise this cause of 
poor function since it can be corrected in the majority of cases. 
(c). Crohn’s disease 
About 2% to 3% of patients diagnosed with UC preoperatively are subsequently found to 
have  CD  (Hahnloser,  Pemberton et  al.  2007).  When  fistulation  or  chronic  unremitting 
pouchitis develop CD should be considered. The presence of inflammation in the pre-pouch 
ileum is not diagnostic of CD (Tekkis, Heriot et al. 2006). 
(d). Specific Infection   
Certain  infective  agents  including  Cytomegalovirus  and  Clostridium  difficile may  cause 
pouch inflammation. They are rare but should be excluded (Mann, Pitt et al. 2003; Moonka, 
Furth et al. 1998) by histopathology, stool culture and antigen testing.
(e). Mechanical Causes of Poor Function
Outflow Obstruction at the Ileo-anal Level
Mechanical obstruction at the level of the ileo-anal anastomosis can occur due to stricture 
formation or to the presence of a long retained rectal cuff (see above). Symptoms include the 
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frequent passage of small volumes of stool and difficulty in evacuation. A functional outflow 
obstruction should be excluded by clinical examination and contrast radiology (defaecating 
pouchogram) (Lovegrove, Heriot et al. 2007). A flexible pouchoscopy should be carried out 
to exclude pouchitis.
When  severe  obstructive  symptoms  persist,  an  abdomino-anal  surgical  revision  may  be 
indicated with success achievable in 80-90% of patients (Tekkis, Heriot et al. 2006).
Weak sphincter
Sphincter  weakness can cause frequent  small  volume incontinence.  The patient  may have 
been poorly selected having already a weak sphincter or damage may have occurred during 
RPC. Unrecognised sphincter damage may also occur during vaginal delivery (Oberwalder, 
Connor et al. 2003). Investigation with ano-rectal physiology will confirm the diagnosis.
Treatment  is  difficult.  Referral  for  biofeedback  may  be  considered  however  there  is  no 
evidence  that  this  treatment  is  effective.  Anti-diarrhoeal  agents  such  as  codeine  and 
loperamide  should be recommended.  If  these are  ineffective  then the establishment  of an 
ileostomy may be necessary. 
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Small Volume Pouch
The normal J-pouch volume is approximately 400ml (Kartheuser, Stangherlin et al. 2006), 
construction of a pouch which is of inadequate volume will cause high stool frequency; this 
may be evident on an X-ray contrast enema (pouchogram) and on pouch volumetry carried 
out by the measured inflation of a balloon introduced into the pouch per anum. An operation 
to enlarge the pouch should be considered in selected patients.
Irritable pouch syndrome
This  is  a  term  given  to  describe  poor  function  where  there  is  no  evident  endoscopic, 
mechanical or histological abnormality to explain it (Shen, Achkar et al. 2002). Other causes 
of  stool  frequency  should  be  considered  such  as  small  bowel  bacterial  overgrowth  and 
pancreatic  insufficiency.  Management  is  difficult.  Codeine,  loperamide  and  other  IBS 
treatments may be useful, referral to a dietician to try an exclusion diet (e.g.wheat/dairy) may 
be beneficial. Timing of meals e.g. not eating late in the evening may help reduce nocturnal 
frequency. Biofeedback may help encourage a better bowel routine and help patients cope 
better with their symptoms. Good counselling prior to RPC by an experienced pouch/stoma 
nurse  specialist  is  important  to  ensure  patients  are  fully  informed  of  the  wide  range  of 
function that can occur thus avoiding unrealistic expectations.
(v). Investigation of ileal pouch dysfunction
There is considerable overlap of symptoms between the various causes of pouch dysfunction 
which can make diagnosis difficult. 
Important points to establish from the case notes
-Surgical technique used; stapled or hand-sewn anal anastomosis. A stapled anastomosis is 
associated with a potential retained rectal cuff and a hand sewn anastomosis is associated with 
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an increased risk of sphincter  incompetence (Lovegrove,  Constantinides et al.  2006). The 
histology following colectomy should be reviewed.
A thorough history should be taken, important points in the history are:
-establish the patient’s previous normal pouch function.
The nature of the difficulty should then be explored:
-degree of urgency
-any bleeding; suggesting retained rectal cuff inflammation or pouchitis
-sensation of incomplete emptying, straining or defaecatory difficulty: suggesting pouch-anal 
anastomotic stricture or functional outflow obstruction
Examination:
A general physical and abdominal examination should be performed.
During digital anal examination sphincter tone should be assessed and ano-rectal physiology 
requested if there is a suspicion of a weak sphincter.
The level  of the pouch-anal anastomosis  should be assessed digitally;  a high anastomosis 
suggesting the possibility of a retained anorectal cuff.
The initial investigation should include stool culture and antigen testing for CDT and other 
pathogens. Coeliac serology should be performed in patients presenting with frequency given 
the high incidence of coeliac disease in the UK population.
Flexible pouchoscopy with biopsy is essential to assess the pouch and pre-pouch ileal mucosa. 
It is the most useful first-line investigation (the technique and its clinical use are described 
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later). A pouchogram may demonstrate a small reservoir and delineate inlet or outlet strictures 
and  tracks  and  sinuses.  A  defaecating  pouchogram  will  demonstrate  functional  outflow 
obstruction. Physiology of the sphincter and pouch balloon volumetry will give an objective 
assessment of sphincter competence and pouch capacitance.
Magnetic  resonance imaging (MRI) of the pelvis  will  exclude or confirm the presence of 
pouch-anal  anastomotic  leakage  and  a  pelvic  collection.  MRI  will  also  delineate  pouch 
vaginal/perineal fistulae.
The algorithm shown in Figure 1.2 is suggested for the investigation of patients in whom the 
cause of dysfunction is not clear.
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Figure 1.2. Algorithm for the investigation of ileal pouch dysfunction
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(vi). Flexible pouchoscopy; endoscopic technique
Pouch  dysfunction  following  RPC  is  common,  with  most  cases  secondary  to  pouchitis. 
Flexible pouchoscopy is the most useful first line investigation with a high diagnostic yield. 
Indications for flexible-pouchoscopy
1. Surveillance
2. Investigation of pouch dysfunction
3. Iron deficiency anaemia
4. Dilatation of symptomatic strictures
Surveillance
Ulcerative colitis
There are no national guidelines for surveillance following RPC. To date about 20 cases of 
cancer in the pouch or residual anorectal mucosa have been reported in the literature and in 
almost  all  of  these  patients  dysplasia  or  invasive  cancer  was  identified  at  the  time  of 
colectomy. Furthermore all developed cancer more than 10 years after the onset of UC (Das, 
Johnson et al. 2007).
The following groups are at increased risk of developing dysplasia:
(i) Dysplasia or adenocarcinoma in the original colectomy specimen
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(ii) Type C histological changes (persistent subtotal villous atrophy associated 
with chronic pouchitis) (Veress, Reinholt, et al. 1995; Setti Carraro, Talbot 
et al. 1994).
(iii)  Associated Primary Sclerosing Cholangitis (Stahlberg, Veress et al. 2003; 
Gullberg, Stahlberg et al. 1997).
(iv)  Ileal pouch-rectal anastomosis (i.e. significant retained rectal mucosa).
Although there  is  no evidence  base for  the  timing  of  surveillance  we suggest  patients  at 
increased risk as itemised above should undergo annual surveillance pouchoscopy. In all other 
patients surveillance pouchoscopy appears not to be  necessary.
Familial adenomatous polyposis
Despite having undergone proctocolectomy, about 80% of FAP patients develop adenomas 
within the pouch body. There have also been reports of adenomas and cancer in the residual 
anorectal  mucosa  below  the  distal  anastomosis  (which  includes  the  anal  transition  zone 
(ATZ)), the risk is about twice as high with a stapled anastomosis (von Roon, Tekkis et al. 
2007;  Remzi,  Church et  al. 2001;van  Duijvendijk,  Vasen et  al. 1999).  Annual  pouch 
surveillance  is  therefore  advised.  Any adenomas  should  be  destroyed  with  argon  plasma 
coagulation. Where the polyp load is high (>100) or the rate of polyp formation increases 
treatment with celecoxib should be considered (Phillips, Wallace et al. 2002).  
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Causes of pouch dysfunction diagnosed at flexible-pouchoscopy
-Pouchitis
-Inflammation of retained anorectum (strip proctitis or cuffitis)
-Pre-pouch ileitis 
-Crohn’s Disease
-Strictures; pouch-anal anastomosis (most common site), ileal-pouch anastomosis, mid-pouch 
stricture.
Types of pouch
Many  types  of  pouch  have  been  described  but  two  have  been  performed  in  significant 
numbers. It is often possible to identify the pouch configuration at endoscopy. This may be 
useful in facilitating comfortable efficient pouchoscopy and in understanding the potential 
complications which occur with each type.
‘J’ pouch
This is now the most commonly formed pouch, it is constructed from a double loop of ileum 
each  measuring  about  20  cm (Utsunomiya,  Iwama et  al. 1980).  It  is  easily  identified  at 
pouchoscopy  due  to  the  presence  of  a  blind  limb.  Both  limbs  should  be  intubated  at 
pouchoscopy, the presence of a long blind limb (>5cm) may be associated with incomplete 
pouch emptying.
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‘W’ pouch
This is made by manual suture from four loops of ileum, with the aim of creating a reservoir 
with greater capacity to minimise frequency of defaecation (Nicholls, Pescatori et al. 1984). 
At pouchoscopy it appears as a large single lumen reservoir. The proximal inlet of the pouch 
is often hidden beneath a pool of stool when the patient is in the left-lateral position and may 
be difficult to locate. It is generally positioned one third of the way down from the top of the 
pouch. If location of the pre-pouch ileum is difficult repositioning the patient on their back is 
often helpful. 
Preparation and patient positioning
A single phosphate enema usually provides adequate bowel preparation. 
Pouchoscopy is performed with the patient in the left-lateral position.
The  use  of  2%  lignocaine  gel  (or  Instillagel)  is  recommended  to  reduce  discomfort  on 
insertion of the endoscope as anal soreness due to frequent defaecation or stricturing at the 
anastomosis may be present.
 
Sedation and instruments
Similar to flexible sigmoidoscopy most patients tolerate the procedure well and do not require 
sedation.
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Pouchoscopy  may  be  performed  with  a  standard  colonoscope,  however  a  paediatric 
colonoscope or gastroscope is better tolerated as many patients have some stricturing at the 
anal anastomosis
.
Procedure technique and practical tips
In all patients the following areas should be assessed carefully;
1. Anal canal
2. Pouch-anal anastomosis
3. Pouch (and blind limb in ‘J’ pouches).
4. Pre-pouch ileum
Anal Canal
A digital examination must be performed, to assess both the anal canal and the anastomosis. 
Tenderness in the anal canal or at the anastomosis suggests ulceration or sepsis at these sites. 
The anastomosis is usually palpable and may feel like a ‘step’ or a ring of delicate fibrous 
tissue. An estimate of its distance from the dentate line (normal = 0.5-1.5cm) is important in 
patients with a stapled anastomosis who may have symptoms from a long retained anorectal 
cuff (cuffitis or strip proctitis) where the anastomosis has been placed more proximally. It is 
common for a degree of stricturing to occur at the anastomosis and may be considered normal 
if it will admit an index finger. 
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Pouch-anal anastomosis
The anastomosis may be fashioned manually or by stapling:
1. Manual
The  pouch  is  sutured  to  the  anal  canal  by  the  insertion  of  interrupted  sutures  placed 
endoanally after carrying out a mucosectomy of the distal anorectal stump, with the aim of 
eliminating residual disease in this segment. There is a risk of sphincter damage particularly if 
the surgeon is not experienced in this technique.  
2. Stapled 
A circular stapling device is used to form the anastomosis. This requires the preservation of at 
least a 1-2cm cuff of rectum which is left in-situ. Since a mucosectomy is not performed 5-
15% of patients with severe inflammation of the distal rectum may experience symptoms of 
proctitis and incomplete emptying (Lavery, Sirimarco et al.  1995) which may result in poor 
function. A stapled anastomosis is however associated with better continence than a manual 
anastomosis (Lovegrove, Constantinides et al. 2006). 
Inflamed mucosa below the anastomosis with normal or mildly inflamed mucosa in the pouch 
above in a patient with a stapled anastomosis is strongly suggestive of ‘cuffitis’.  Biopsies 
from this segment demonstrating inflamed anorectal mucosa with normal biopsies from those 
taken from the pouch above the anastomosis are diagnostic.
Pouch
The pouch mucosa should be examined (including the blind limb of a J pouch) to look for 
inflammation (pouchitis), ulceration and polyps. Inflammation associated with pouch suture 
39
Background to ileal-pouch surgery Chapter 1
lines is due to a normal foreign body reaction and does not indicate pouchitis (Shen et al. 
2005b).
 
Pre-pouch ileum
The pre-pouch ileum should always be intubated to confirm that complete pouchoscopy has 
been achieved. In patients with pouch dysfunction it is important to exclude a stricture at the 
entry of the neo-terminal ileum into the pouch or inflammation or stricturing of the pre-pouch 
terminal ileum (Bell, Price et al. 2006) and to look for signs of Crohn’s disease. If the pre-
pouch ileum is inflamed (pre-pouch ileitis) it is important to measure its linear extent.
Biopsy protocol
During surveillance pouchoscopy four quadrant biopsies should be taken from the upper and 
lower pouch, and a further four biopsies targeted at just below the anastomosis (anorectal 
remnant). Biopsies should not be taken from pouch suture lines as these will have histological 
features of inflammation which may lead to a false positive diagnosis of pouchitis. In patients 
with  macroscopic  inflammation  in  the  pre-pouch  ileum,  biopsies  should  be  taken  to 
differentiate  between pre-pouch ileitis  and  Crohn’s  disease.  These  disorders  appear  to  be 
different pathologies (Bell, Price et al. 2006).
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Therapeutic pouch endoscopy
Techniques; balloon and manual dilatation
Patients  with  symptomatic  strictures  can  be  dilated  in  the  endoscopy  department  under 
sedation.  A stricture  of the pouch-anal  anastomosis  can be dilated  with a combination  of 
gentle manual digital  dilatation and balloon dilatation using a ‘through the scope’ balloon 
(Shen, Fazio et al. 2004). Strictures within the pouch or at the ileal-pouch anastomosis (pouch 
inlet)  which are not passable with a gastroscope should be delineated with a small  bowel 
follow-through and pouchogram to demonstrate the anatomy and to assess for the possibility 
of Crohn’s disease before dilatation is attempted. Strictures commonly recur and those with a 
recurrent anal-anastomotic stricture should be given a Hegar dilator and taught to dilate the 
stricture regularly.
Figure 1.3.  Normal J-pouch 
41
Background to ileal-pouch surgery Chapter 1
Figure 1.4.  Normal W-pouch 
Figure 1.5. Pouch suture line inflammation
Figure 1.6. Pouch suture line inflammation
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Figure 1.7. Normal pouch suture line 
Figure 1.8. Pre-pouch ileitis 
Figure 1.9. Pouchitis in a ‘J’ Pouch 
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Figure 1.10. Inflamed retained rectum
(vii). Incidence of pouchitis
Pouchitis is the most common long-term complication in patients following RPC (Shen, Fazio 
et al. 2005a). 
The incidence of pouchitis is markedly different between patients with UC and FAP. 
In UC the quoted incidence varies from 20-50% between studies  (Stahlberg, Gullberg et al. 
1996; Romanos, Samarasekera et al. 1997;Hahnloser, Pemberton et al.  2007).  In FAP the 
incidence of pouchitis is much lower than in UC and varies from 0-11% (Kartheuser, Parc et  
al. 1996; Nyam, Brillant et al. 1997; Dozois, Kelly et al. 1989; Fazio, Ziv et al. 1995; Barton, 
Paden et al. 2001). 
This large intra-disease variation in incidence is explained by; 
(i) The differences in definition;  some studies have based the diagnosis  on symptoms 
alone  whereas  others  correctly  have  required  a  triad  of  symptoms,  endoscopic 
findings and compatible histology. 
(ii) Length of follow-up; since the risk of pouchitis increases over time, studies of a longer 
duration are more likely to demonstrate a higher incidence of pouchitis.
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About  39% of  patients  who develop pouchitis  will  have a  single  episode which is  easily 
treated, the remaining 61% will suffer at least one further episode (Lohmuller, Pemberton et  
al. 1990)  and  about  5-19%  of  patients  will  develop  chronic  relapsing  pouchitis 
(Mowschenson, Critchlow et al. 2000; Hurst, Chung et al. 1998; Madiba & Bartolo 2001).
1.3. The aetiology of pouchitis; 
(a). The dysbiosis theory
An  abnormal  host-microbial  interaction  has  long  been  implicated  in  all  forms  of  IBD 
including pouchitis (Sartor 2008). Evidence suggesting a role for bacteria in the pathogenesis 
of inflammatory bowel disease (IBD) has been demonstrated by animal  models of colitis, 
including  HLA-B27  transgenic  rats  (Rath  2002),  germ-free  knock-out  mice  (Sellon, 
Tonkonogy et  al. 1998)  and  clinical  improvement  in  humans  following  faecal  diversion 
operations  (Harper,  Lee et  al. 1985).There  is  evidence  from clinical  practice  to  implicate 
bacteria in pouchitis; mucosal inflammation (in common with UC and CD) is localised to the 
area of gut with the highest concentration of bacteria (Sartor 2008), antibiotics are effective 
treatment for both pouchitis and pre-pouch ileitis (Madden, McIntyre et al. 1994; Shen, Fazio 
et al. 2007a; McLaughlin, Clark, Bell, Tekkis, Ciclitira, & Nicholls 2008) and probiotics have 
been shown to reduce  disease relapse (Gionchetti, Rizzello et al. 2000b; Mimura, Rizzello et  
al. 2004), reduce the risk of disease onset (Gionchetti, Rizzello et al. 2005) and to be effective 
in mild to moderate pouchitis (Gionchetti, Rizzello et al. 2007a).
Based on the response of peripheral and local mononuclear cells our group have previously 
demonstrated that the inflammatory response in pouchitis appears to be at the local mucosal 
level and is not a general systemic reaction (Thomas, Forbes et al. 2002) and that pouchitis-
derived  bacterial  sonicates  from  metronidazole  sensitive  bacterial  species  can  stimulate 
healthy  patients’  mononuclear  cells  significantly  more  than  corresponding  sonicates  from 
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non-pouchitis patients (Bell, Nicholls et al. 2004). Both studies providing indirect evidence to 
implicate bacteria (Thomas, Forbes et al. 2002).
(b). Previous studies of ileo-anal pouch microbiota
The  interpretation  of  early  work  to  establish  the  potential  differences  in  bacterial  flora 
between pouchitis and non-pouchitis patients is limited by the lack of universally accepted 
criteria for pouchitis prior to the PDAI being described in 1994 (Sandborn, Tremaine et al.  
1994). Many of these early studies were also limited by comparing well functioning to poorly 
functioning  pouches  rather  than  non-pouchitis  and  pouchitis  groups.  Also  many  of  the 
patients with a history of pouchitis were asymptomatic at the time of the study.
The  majority  of  studies  to  establish  the  microbiota  of  the  ileo-anal  pouch  have  been 
performed using culture methods. However it is now known that only approximately 40% of 
gut bacterial  species can be cultured (Suau, Bonnet et al. 1999; Hayashi,  Sakamoto et al. 
2002).
Estimates of the presence of 200-300 colonic species derived from culture based studies have 
been revised to about 15,000 to 36,000 individual species following the introduction of 16s 
ribosomal RNA PCR techniques (Frank, St Amand et al. 2007). There are several different 
PCR techniques each with a different sensitivity. Cloning and high-throughput sequencing of 
the 16s gene is accepted as the ‘gold standard’ molecular method (Lim, Sagar et al. 2006).
Studies using culture methods
Santavirta and colleagues (Santavirta, Mattila et al. 1991) studied faecal samples from 30 UC 
patients with IPAA and 10 with a conventional ileostomy, 9 had a history of pouchitis defined 
as increased stool  frequency,  bleeding and abdominal  cramping,  however  only 3 of these 
patients  were symptomatic  at  the time of the study and only 2 patients  with a history of 
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pouchitis had faecal samples analysed.  The authors found no difference in the numbers of 
anaerobes and aerobes in those with a history of pouchitis compared with those who had no 
history  of  pouchitis  but  did  report  an  increase  in  the  total  bacterial  count,  numbers  of 
anaerobes  and  ratio  of  anaerobes  to  aerobes  compared  to  patients  with  a  conventional 
ileostomy.
Ruseler-van Embden  and colleagues  (Ruseler-van Embden,  Schouten et  al. 1994)  studied 
faecal  samples  of  14 patients  (12 with UC IPAA and 2 with FAP IPAA).  Pouchitis  was 
defined  by  clinical,  endoscopic  and  histological  criteria.  Five  patients  were  classified  as 
pouchitis and 9 non-pouchitis. Of the pouchitis patients two were symptomatic when studied. 
The authors found no differences in the total numbers of bacteria between pouchitis and non-
pouchitis patients but found an increase in the number of aerobes, Clostridium perfingens was 
found in over 75% of the pouchitis samples but less than 25% of the non-pouchitis samples 
and  Bifidobacterium and Lactobacillus was  found in  only  one  pouchitis  sample  but  was 
present in 84% of non-pouchitis samples.
Duffy and colleagues (Duffy, O'Mahony et al. 2002) studied 25 patients (10 UC IPAA, 7 FAP 
IPAA,  8  ileostomy)  none  of  whom had  a  previous  history  of  pouchitis.  The  differences 
between  FAP and UC faecal  microbiology were  studied;  80% of  the  UC IPAA samples 
contained sulphate reducing bacteria in contrast  to none of the FAP samples or ileostomy 
samples.  The  authors  found  no  significant  difference  between  counts  for  Lactobacilli,  
Clostridum Perfingens, Bacteriodes and Bifidobacterium or enterococci and coliform counts 
in pouches constructed for UC and FAP.
Sandborn and colleagues (Sandborn, Tremaine et al. 1995) cultured the stool from 30 patients 
(10  UC IPAA non-pouchitis,  10  UC IPAA pouchitis,  5  FAP IPAA non-pouchitis  and  5 
ileostomy).  Pouchitis  was  defined  as  a  PDAI  ≥7.  The  authors  found  a  higher  ratio  of 
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anaerobic gram-negative rods in IPAA patients compared to ileostomy patients, there were no 
differences between pouchitis and non-pouchitis samples or between FAP and UC samples.
Ohge and colleagues (Ohge, Furne et al. 2005) studied 50 patients (9 UC IPAA with previous 
pouchitis but no active disease for one year), (9 UC IPAA with pouchitis in the last year, but 
inactive for 6 weeks or more), (8 UC IPAA more than 2 years ago and no previous pouchitis), 
(11 UC IPAA pouchitis  with ongoing antibiotic  treatment).  Stool samples  were collected, 
counts of sulphate reducing bacteria and output of hydrogen sulphide were measured. The 
authors found a 5 times greater release of hydrogen sulphide gas in all UC samples compared 
to the FAP samples except the UC patients  receiving antibiotic  treatment,  where this  was 
similar  to  the  FAP group.  Those who had recently  had  pouchitis  had  a  higher  hydrogen 
sulphide gas production than those who had pouchitis more than one year previously which 
was higher than those who had never had pouchitis. Bacterial counts of SRB bacteria were 
higher in samples from active pouchitis patients than all other groups.
Gosselink and colleagues cultured faecal samples from 13 patients with active pouchitis prior 
to  antibiotic  treatment,  during  treatment  and  following  treatment.  Comparison  with  non-
pouchitis patients was not undertaken. They found that during an episode of pouchitis there 
was an increase in aerobes and decrease in anaerobes (Gosselink, Schouten et al. 2004b).
Kuisma  and  colleagues  (Kuisma,  Mentula et  al. 2003)  studied  faecal  microbiology  and 
mucosal  microbiology in 32 patients  (11 non-pouchitis  and 21 with a previous history of 
pouchitis). No patient had active pouchitis.  The authors found a significantly increased total 
number  of faecal anaerobic  and aerobic bacteria  in patients  with a history of pouchitis  as 
compared  with  non-pouchitis  patients,  but  no  difference  in  the  bacteria  from  mucosal 
samples.
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Kmiot and colleagues (Kmiot, Youngs et al. 1993) studied 46 UC patients (10 end ileostomy, 
12 RPC pouchitis,  12 non-pouchitis  good function  and 12 non-pouchitis  poor  function)  . 
Pouchitis was defined as endoscopic and histological inflammation; patients did not need to 
be symptomatic.
Bacterial counts of stool samples were performed on 6 non-pouchitis and 6 pouchitis patients 
before and following metronidazole.  The authors found no significant difference in the total 
aerobic or anaerobic bacterial counts between the non-pouchitis and pouchitis groups, there 
were also no differences between the numbers of  E. coli, S faecalis or  Bacteriodes in each 
group.
Bacteriodes  were  not  present  in  any  samples  following  metronidazole.  There  was  no 
significant  difference  in counts of  E. coli and  S. faecalis between the pouchitis  and non-
pouchitis groups following metronidazole.
O’Connell and colleagues (O'Connell,  Rankin et al.  1986) studied 20 UC patients (8 non-
pouchitis with good function, 6 non-pouchitis poor function and 6 pouchitis). Good function 
was defined  as  <6 stools  per  24hrs,  poor  function  as  >6 stools  per  24hrs.  Pouchitis  was 
defined as episodic bloody diarrhoea and malaise. 3 patients had active pouchitis and 3 did 
not. 
Jejunal aspirates and stool samples were analysed, there was no difference in the numbers of 
aerobic  and anaerobic  bacteria  between pouchitis  and  non-pouchitis  groups  in  the  jejunal 
aspirates  and the values  were within the normal  range for healthy controls.  Stool  culture 
showed overgrowth of both aerobic and anaerobic bacteria in all samples compared to values 
for ileal chyme in health. There were no differences between the pouchitis and non-pouchitis 
groups.
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Iwaya and colleagues cultured stool samples from 22 UC IPAA patients (9 pouchitis, 13 non-
pouchitis).  Pouchitis  was  diagnosed  using  the  PDAI.  The  authors  found  a  significant 
reduction in the Bifidobacteria, Bacteriodaceae and Lactobacillus in the pouchitis group. 
Studies of ileo-anal pouch microbiota using molecular methods
Falk and colleagues (Falk, Olsson et al. 2007) studied two UC IPAA patients from the time of 
stoma closure for one year with repeated mucosal biopsies using terminal restriction fragment 
length polymorphism (T-RFLP), cloning and sequencing. Neither patient developed pouchitis 
during  this  time.  They  found  that  the  microflora  evolved  during  this  time  and  differed 
between the two patients. The microfloral composition was similar to normal colon except for 
the presence of C. perfringens and Turicibacter.
Kuchbacher and colleagues (Kuhbacher, Ott et al. 2006) studied the differences in microflora 
between patients with chronic pouchitis who were treated with the probiotic VSL#3 and those 
treated with a placebo following a successful remission induced by antibiotic treatment with 
ciprofloxacin  and metronidazole.  This  study did not  compare  non-pouchitis  and pouchitis 
microflora  and did not study the flora of pouchitis  patients  before antibiotic  therapy.  The 
authors used real-time PCR, denaturing gel gradient electrophoresis (DGGE) and fluorescent 
in-situ hybridisation  (FISH) to  study the microflora.  The authors  found that  patients  who 
relapsed on placebo had a lower bacterial diversity and increased fungal diversity than those 
who maintained remission with VSL#3, with an increase in the diversity of Lactobacilli  and 
Bifidobacteria  species.  However  the  authors  state  that  the  methods  used  do  not  reliably 
identify all bacteria present.
Komanduri and colleagues (Komanduri, Gillevet et al. 2007) studied ileal biopsies and faecal 
samples from 33 patients (13 non-IBD patients, 5 UC pouchitis, 15 non-pouchitis), pouchitis 
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was classified using the PDAI. Ileal biopsies were taken from the non-IBD patients who had 
an intact colon. Length heterogeneity polymerase chain reaction (LH-PCR) was performed, 
output  data  was  expressed  as  electropherograms  with  the  peaks  representing  different 
populations of microflora with amplicons of different length in base pairs.  
The LH-PCR products from three non-IBD controls, 5 UC non-pouchitis and 3 UC pouchitis 
patients were pooled and cloned using the dye terminator technique. Data from these was then 
filtered so that only phylotypes which represented more than 5% of the total clone library 
were analysed using the ribosomal database project (RDP) database (Cole, Chai et al. 2007). 
This approach identified 61% of the clones in the non-IBD control mucosa and 80% in the 
lumen, 73% in non-pouchitis controls and 73% in the active pouchitis microbial communities.
Principle coordinate analysis  of LH-PCR profiles demonstrated that each patient had their 
own different microflora, but individuals within the same group formed a general clustering 
pattern which was different between groups.
The authors found significant differences in the microbial patterns between healthy non-IBD 
controls  and pouch controls,  pouchitis  and pouch control  samples.   Cloning identified  an 
increase in  the bacterial  diversity in pouchitis  samples  compared  to non-IBD controls,  an 
increase in the proportion of  Enterobacters and  Fusobacter (proteobacteria),  reduction in 
Streptococci (firmicutes) and a difference in the Rumicoccus species associated with pouchitis 
(R. obeum) and non-pouchitis (R. gnavus).
Casadesus  and  colleagues  (Casadesus,  Tani et  al. 2007)  studied  the  possible  role  of 
Cytomegalovirus  (CMV) in  pouchitis.  34  UC IPAA patients  were  studied.  Pouchitis  was 
diagnosed using the modified PDAI (Shen, Achkar et al. 2003) and Japanese classification of 
pouchitis (JCP) (Fukushima, Fujii et al. 2007). The JCP defines pouchitis as a condition with 
severe endoscopic findings or with two or more clinical symptoms and moderate endoscopic 
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findings. Endoscopic biopsies were taken on multiple occasions in each patient, in total 473 
specimens were evaluated; 103 from pouchitis patients, 370 from non-pouchitis patients.
CMV  was  detected  in  both  pouchitis  and  non-pouchitis  pouch  biopsies  using  PCR  and 
sequencing, and no significant difference was found between the incidence of CMV in each 
group when classified using the modified PDAI, but CMV was present in significantly more 
samples from pouchitis patients than from non-pouchitis patients when classified using the 
JCP.  In all pouchitis biopsies where CMV was detected it was the first episode of pouchitis, 
and was not detected in earlier samples from the same patients. 
In  conclusion  the  results  from  culture-based  studies  of  pouch  microbiota  using  culture 
methods are varied and inconclusive.  So far two studies have used a molecular biological 
method to establish the differences between the microbiota in pouchitis and non-pouchitis 
patients. The first study demonstrated the presence of a dysbiosis but was limited by the use 
of pooled data for each group and according to the authors at most identified 73% of the 
microbial population. In the first bacterial DNA from mucosal biopsy samples from 11 RPC 
patients was sequenced and cloned with apparent significant differences between pouchitis 
and  non-pouchitis  groups  (Komanduri,  Gillevet  et  al.  2007).  The  second (from our  unit) 
studied 32 RPC patients using terminal-restriction fragment length polymorphism (TRFLP) 
(Johnson,  Rogers  et  al 2009).  In  this  study  no  differences  between  pouchitis  and  non-
pouchitis groups were found, Both of these studies, however, had significant limitations. In 
the first study (Komanduri, Gillevet et al. 2007) bacterial DNA from each patient sample was 
pooled and cloned and each of the disease groups were cloned and sequenced together. In 
addition according to the authors the technique used identified at most 73% of the microbial 
population.  In  the second study (Johnson,  Rogers  et  al 2009)  the authors  firstly  cultured 
biopsy samples  on agar before extracting  the bacterial  DNA, thus potentially limiting the 
bacteria identified to those supported by the culture conditions, In addition the technique used 
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(TRFLP) was only able to identify dominant  species groups and was not able  to identify 
individual  bacterial  species. Further molecular studies with cloning and sequencing of the 
complete microbial flora are needed to establish the detail of any potential dysbiosis.
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Table 1.2.  
Culture studies comparing the microbiota of UC pouchitis to non-pouchitis patient samples
Author Patient 
numbers
Faecal/mucosal 
study
Histological 
Pouchitis?
Symptomatic 
pouchitis Y/N
Findings
Santavirta 30  UC-RPC (9= 
Hx of pouchitis), 
10 ileostomy
Faecal No Yes but only 3 
were 
symptomatic
No differences
Ruseler-van 
Embden
12  UC-RPC,  2 
FAP-RPC
Faecal Yes Yes but only 2 
of  5  were 
symptomatic 
Increase  in  no.  of 
aerobes  &  C. 
perfingens  in 
Pouchitis
Sandborn 10 UC-RPC non-
pouchitis,  10 
UC-RPC 
pouchitis,  5 
FAP-RPC  non-
pouchitis,  5 
ileostomy
Faecal Yes Y es
(PDAI used)
No  differences 
between  pouchitis 
and non-pouchitis or 
FAP groups
Ohge 18  UC-RPC 
previous 
pouchitis,  8  UC 
non  pouchitis,  8 
UC-RPC 
antibiotic treated
Faecal No None Increased  counts  of 
SRB  in  patients 
with  active 
pouchitis
Kuisma 11  UC-non 
pouchitis,  21 
with  previous 
pouchitis
Faecal  and 
Mucosal
No None Increased aerobes & 
anaerobes  in 
pouchitis  faecal 
samples
Kmiot 6 RPC pouchitis,
6  RPC  non-
pouchitis
Faecal Yes None No differences
O’Connell 14  non-
pouchitis,  6 
pouchitis
Faecal No Yes No differences
Iwaya 9  pouchitis,  13 
non-pouchitis
Faecal Yes Yes 
(PDAI used)
Reduction  in 
Bifidobacteria,  
Bacteriodaceae and 
Lactobacillus  in the 
pouchitis group.
Table 1.3
Studies comparing the microbiota of UC to FAP patient samples (no pouchitis group)
Author Patient no.s Faecal/mucosal Histological 
Px?
Symptomatic 
pouchitis Y/N
Findings
Duffy 10  UC-RPC,  7 
FAP-RPC,  8 
ileostomy
F None Increased  SRB 
in UC patients
Sandborn 10  UC-RPC 
non-pouchitis, 
10  UC-RPC 
pouchitis,  5 
FAP-RPC  non-
pouchitis,  5 
ileostomy
Faecal Yes Y es
(PDAI used)
No  differences 
between 
pouchitis  and 
non-pouchitis or 
FAP groups
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(c). Pathological similarities to UC and CD
Ulcerative colitis
Like  UC and CD the inflammation  occurs  in  the  areas  with  the highest  concentration  of 
bacteria.
There is a ten-fold increased risk of pouchitis in patients who undergo RPC for UC compared 
to FAP. Therefore it has been suggested that pouchitis represents reactivation of UC in the 
colonised small bowel of the pouch. 
Pre-pouch ileitis (inflammation proximal to the pouch inlet) is known to occur in some RPC 
patients with UC (Slatter, Girgis et al. 2008; Calabrese, Fabbri et al. 2007; Kuisma, Jarvinen 
et al. 2004; Iwata, Yamamoto et al. 2007). It has previously been suggested that inflammation 
proximal to the pouch is indicative of Crohn’s disease or associated with the use of non-
steriodal  anti-inflammatory  drugs  (Shen,  Fazio et  al. 2006a;  Wolf,  Achkar et  al. 2004). 
However recent work by our group has demonstrated that histologically pre-pouch ileitis is a 
distinct entity which can be differentiated from CD (Bell, Price et al. 2006) and it is therefore 
possible that pre-pouch ileitis is similar to backwash ileitis seen in UC, providing evidence of 
similarity to UC.
Despite  this   there  are  a  number  of  similarities  between  pouchitis  and  CD;  both  are 
inflammatory  conditions  which  can  affect  the  small  bowel,  both  conditions  respond  to 
treatment with antibiotics,  and both conditions improve with divergence of the faecal stream 
(importantly these treatments are not effective in ulcerative colitis). There is also evidence at 
an immunological level that pouchitis has a similar pathogenesis to CD; in UC inflammation 
is  predominately  Th2-cytokine  driven,  whereas  in  CD a  Th1-mediated  immune  response 
predominates (Sartor 1991; Gately, Renzetti et al. 1998; Fiocchi 1998; Kobayashi, Fitz et al. 
1989a; Wolf, Temple et al. 1991). Therefore it would be expected that pouchitis would be 
associated with a Th2-cytokine activation. However, an increase in the Th1 cytokine IFN-γ 
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has been described in acute and chronic pouchitis (Stallmach, Schafer et al. 1998). Our group 
previously investigated the association between CD30 and pouchitis. CD30 has been shown 
to be upregulated in UC but not in CD (Giacomelli, Passacantando et al. 1998b; Elewaut, De 
Keyser et al. 1998). Our group showed that CD30 was elevated in acute pouchitis but not in 
those with chronic pouchitis (Thomas, Forbes et al. 2001b) and therefore it was postulated 
that this may be due to a more Crohn-type disease occurring in these individuals.
(c). Evidence for pouchitis being a novel third form of IBD
It has been suggested that pouchitis may represent a novel third-form of IBD (Sandborn & 
Pardi 2004).
The differences in treatment  response seen in pouchitis  patients  compared to UC and CD 
could be considered to fit with this.  Although antibiotics are of some clinical benefit in CD, 
they are much less efficacious than in those with pouchitis where they are more effective than 
any other therapy. Interestingly there is no evidence that immunomodulators are effective in 
pouchitis, however two groups have reported the development of pouchitis in patients treated 
with azathioprine for PSC (Rowley, Candinas et al. 1995; Zins, Sandborn, Penna, Landers, 
Targan, Tremaine, Wiesner, & Dozois 1995) suggesting that immunomodulators may not be 
effective in pouchitis. Infliximab was shown to be beneficial in one study of patients with 
pouchitis and extensive pre-pouch ileitis however given that these patients were found to have 
pan-small  bowel inflammation (demonstrated by video-capsule endoscopy)  it is likely that 
this patient group had CD rather than UC (Calabrese, Gionchetti et al. 2008).
Therefore it appears that the pathogenesis of pouchitis is more complicated than simply the 
recurrence of IBD in those with a previous diagnosis of UC. Nevertheless because RPC is 
performed in both patients with and without a previous history of IBD and because not all UC 
RPC patients develop pouchitis it provides an excellent model to study the pathogenesis of 
IBD.
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1.4 Treatment of pouchitis
Before  drug  treatment  is  initiated  other  precipitants  should  be  considered; 
NSAIDs  are  associated  with  pouchitis  and  withdrawal  may  induce  remission 
(Shen,  Fazio  et  al.  2007b).  Infectious  agents  such  as  Clostridium  difficle  
should be excluded with standard stool  testing and CMV should be considered 
in  those  with  pouchitis  which  fails  to  respond  to  antibiotics  (Pfau  & 
Lichtenstein 2000).
Antibiotics  remain  the  mainstay  of  treatment,  there  are  no  controlled  studies 
of effective treatments for patients  who do not respond to antibiotics.
(a). Treatment with antibiotics
Ciprofloxacin  or  metronidazole  for  14  days  should  be  used  as  first  line 
treatment,  data  from several  studies  demonstrate  efficacy  (Madden,  McIntyre, 
&  Nicholls  1994;  Shen,  Achkar  et  al.  2001c).  Both  are  effective  however 
ciprofloxacin  is  better  tolerated  and  led  to  a  greater  reduction  in  the  PDAI, 
furthermore  it  does  not  cause  peripheral  neuropathy  (Shen,  Achkar  et  al. 
2001b).   In  patients  intolerant  to  oral  metronidazole  but  where  ciprofloxacin 
is  ineffective,  good  results  may  be  obtained  with  metronidazole  administered 
per  anum  (Johnson,  Carlsen  et  al.  2001).  In  a  randomised  placebo  controlled 
study  of  18  patients  rifaxamin  when  used  as  a  single  agent  for  the  treatment 
of pouchitis  was associated with an increased frequency of remission however 
this  was not statistically different to placebo.
Where  a  single  antibiotic  agent  fails  or  early  relapse  occurs,  combination 
antibiotic  regimes  such  as  ciprofloxacin  and  rifaximin  and  ciprofloxacin  and 
metronidazole  have  been  shown  to  achieve  remission  in  63%  and  82%  of 
57
Background to ileal-pouch surgery Chapter 1
patients  with  refractory  pouchitis  (Gionchetti,  Rizzello  et  al.  1999;  Mimura, 
Rizzello  et  al.  2002).  
Other  antibiotic  agents  including  tetracycline,  clarithromycin,  co-amoxiclav 
and  doxycycline  may  be  useful.  However  there  are  no  published  controlled 
studies (Pardi & Sandborn 2006b).
(b). Other agents for the treatment of pouchitis
Budesonide  has  been  shown to  be  effective  in  those  with  refractory  pouchitis 
who  do  not  respond  to  a  single  antibiotic  in  an  open  label  study  (Gionchetti, 
Rizzello  et  al.  2007c)  but  a  randomised  double  blind  study  found  it  no  more 
effective  than  metronidazole  (Sambuelli,  Boerr  et  al.  2002).  Its  efficacy  in 
those  who  fail  to  respond  to  ciprofloxacin  and  metronidazole  or  other 
combination regimes has not been demonstrated.  
Bismuth  was  shown  to  be  effective  in  an  open  label  study  using  bismuth-
citrate carbomer enemas with 83% of patients  entering remission after 45 days 
treatment  (Gionchetti,  Rizzello  et  al.  1997),  however  a  subsequent  double-
blind  randomised  trial  found  no  difference  when  compared  to  placebo 
(Tremaine,  Sandborn  et al.  1997). 
There  are  no  controlled  trials  of  oral  or  topical  mesalamine  for  treating 
pouchitis.  A  study  which  compared  the  efficacy  of  a  combination  of 
ciprofloxacin  and  tinidazole  in  patients  with  pouchitis  to  a  historical  cohort 
treated  with  mesalamine  found  that  50% achieved  clinical  remission  and  50% 
had a  clinical  response.  Overall  there  was a  significant  reduction  in  the PDAI 
but  no  improvement  in  quality  of  life  as  measured  with  the  Cleveland  global 
quality  of  life  (CGQoL)  score,  whereas  of  those  patients  treated  with 
ciprofloxacin  and  tinidazole  87.5%  achieved  a  clinical  remission  and  87.5% 
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achieved  a  clinical  response  with  a  significant  reduction  in  PDAI  and 
improvement in CGQoL score (Shen, Fazio et al.  2007a).
Allopurinol  was  found  to  be  ineffective  in  preventing  the  onset  of  pouchitis 
when given  in  a  randomised  placebo  controlled  study (Joelsson,  Andersson  et  
al.  2001).  Treatment  with short  chain fatty acids (SCFAs) has also been found 
to be ineffective in uncontrolled studies (de Silva,  Ireland  et al.  1989).
Other  therapies  that  have  been  suggested  include  oral  prednisolone  and 
azathioprine  however  there  is  no  good  evidence  for  these  therapies  (Pardi  & 
Sandborn 2006b) .  
Treatment of patients who fail  to respond to combination antibiotics
Successful  treatment  is  difficult  in  those  patients  in  whom  treatment  with 
combination  antibiotics  fails.  There  is  no  evidence  based  treatment,  many 
treatments  have  been  tried  and have  been  found to  be ineffective  (see  below). 
Infliximab  has  recently  been  shown  to  be  effective  in  patients  with  pouchitis 
that  did  not  respond  to  a  single  antibiotic  (either  ciprofloxacin  or 
metronidazole)  and  extensive  pre-pouch  ileitis  (with  video-capsule  evidence 
of  small  bowel  inflammation  from  the  duodenum  to  the  ileum)  highly 
suggestive  of  Crohn’s  disease  (although  this  had  been  excluded  on 
histological  grounds).  Given that extensive pre-pouch ileitis  is uncommon and 
the  Crohn’s  phenotype  of  this  cohort,  it  is  unproven  whether  infliximab  is 
beneficial  in  patients  with  pouchitis  resistant  to  antibiotics  uncomplicated  by 
pre-pouch ileitis.
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Maintenance therapy
Patients  with  chronic  pouchitis  who  achieve  remission  following  antibiotic 
therapy  but  relapse  more  than  three  times  per  year  should  be  treated  with 
maintenance therapy (Pardi & Sandborn 2006b).Ciprofloxacin (250-500mg bd) 
appears  to  be  safe  and  well  tolerated  although  there  are  no  published  long-
term  data.  It  may  be  possible  to  reduce  the  dose  to  250mg  daily  (Pardi  & 
Sandborn  2006b).  This  treatment  and  maintenance  treatment  with  VSL#3  is 
recommended  in  the  British  Society  of  Gastroenterologists  IBD  guidelines 
(Carter,  Lobo  et  al.  2004).
The  probiotic  VSL#3 has  been  shown  in  two  randomised  controlled  trials 
(RCT)  to  maintain  remission  in  85% of  patients  with  chronic  pouchitis  up  to 
one  year  (Gionchetti,  Rizzello  et  al.  2000a;  Mimura,  Rizzello  et  al.  2004).  It 
should  be  noted,  however,  that  patients  who  did  not  achieve  endoscopic  as 
well  as  clinical  remission  were  excluded  from  this  study.  Unfortunately 
results  obtained  in  clinical  practice  have  been  disappointing.  In  a  North 
American  study  (Shen,  Brzezinski  et  al.  2005)  25  (80%)  of  31  patients  after 
antibiotic-induced  remission  rapidly  relapsed  following  treatment  with 
VSL#3. 
Conclusion 
Antibiotics  remain  the  mainstay  of  treatment  for  pouchitis.  The  majority  of 
patients  will  enter  a  clinical  remission  following  single  agent  or  combination 
antibiotic  therapy.  About  5-19%  of  patients  will  develop  chronic  relapsing 
pouchitis  (Mowschenson, Critchlow,  & Peppercorn 2000;Hurst,  Chung, Rubin, 
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&  Michelassi  1998;Madiba  &  Bartolo  2001),  these  patients  should  be  treated 
with maintenance therapy in order to maintain symptomatic  remission.
 The  treatment  of  patients  who  are  refractory  to  antibiotic  regimes  remains 
difficult  and  new  treatment  modalit ies  are  desperately  needed  to  improve  the 
symptoms  and  quality  of  life  for  affected  patients  and  reduce  the  long-term 
risk of pouch failure.  
The  management  of  patients  with  chronic  pouchitis  is  difficult  and  until 
recently,  maintenance  antibiotic  therapy  was  the  only  treatment  option 
available.  This  has  been  used  for  many  years  and  is  recommended  in  the 
British Society of Gastroenterology IBD guidelines (Carter,  Lobo et  al.  2004). 
However  clinicians  and  patients  are  concerned  about  the  potential  risk  of 
developing antibiotic  resistance or Clostridium difficile  colonisation
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Figure 1.11. Algorithm for the treatment of pouchitis 
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1.5 The pathogenesis of Pouchitis –hypothesis and outline of investigation
Bacterial dysbiosis has long been thought to be involved in the pathogenesis of all forms of 
inflammatory bowel disease (IBD), including pouchitis (Tamboli, Neut et al. 2004). Evidence 
suggesting a role for bacteria in the pathogenesis of IBD has been demonstrated by animal 
models of colitis, including HLA-B27 transgenic rats (Rath 2002) and germ-free knock-out 
mice (Sellon,  Tonkonogy et al.  1998).  Further  evidence from clinical  practice in humans 
includes  the  beneficial  effects  of  faecal  diversion  operations  for  Crohn’s  disease  (CD) 
(Harper, Lee et al.  1985), the beneficial effects of antibiotics in CD (Rutgeerts, Hiele et al. 
1995; Stringer, Nicholson et al. 2005), and probiotics in preventing ulcerative colitis (UC) 
disease relapse (Kruis, Fric et al. 2004).
In pouchitis, evidence from clinical practice to implicate bacteria in the disease pathogenesis 
includes the observation that the mucosal inflammation (in common with UC and CD) is 
localised  to  the  area  of  bowel  with  the  highest  concentration  of  bacteria.  Furthermore, 
antibiotics improve symptoms of pouchitis (Madden, McIntyre et al. 1994; Mimura, Rizzello 
et al. 2002; Bernstein, Frank et al. 1980) and probiotics have been shown to prevent disease 
relapse (Gionchetti, Rizzello et al. 2000b; Mimura, Rizzello et al. 2004), to reduce the risk of 
disease  onset  (Gionchetti,  Rizzello et  al.  2005)  and  to  treat  mild  to  moderate  pouchitis 
(Gionchetti, Rizzello et al. 2007a).
The inflammatory response in pouchitis appears to be at the local mucosal level rather than a 
general systemic reaction, providing further indirect evidence to implicate bacteria (Thomas, 
Forbes et al.  2002). It has been demonstrated that sonicated bacterial samples grown from 
mucosal  biopsies  of  pouchitis  patients  can  stimulate  healthy  patients’  mononuclear  cells 
significantly  more  than  non-pouchitis  sonicates  from non-pouchitis  samples.  Furthermore 
when the sonciated bacteria were grown on metronidazole impregnated agar they failed to 
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stimulate  mononuclear  cells,  demonstrating  metronidazole  sensitivity  consistent  with  the 
beneficial clinical effect of metronidazole seen in clinical practice (Bell, Nicholls et al. 2004).
In  patients  successfully  treated  with  VSL#3  there  is  an  increase  in  bacterial  diversity, 
compared to those treated with placebo, which is not accounted for by the bacteria present in 
the  probiotic  preparation  (Kuhbacher,  Ott et  al. 2006)  providing,  further  evidence  for  a 
bacterial dysbiosis in this disease.
As outlined in Chapter 1.3 many culture-based studies have been undertaken with the aim to 
establish  the  potential  differences  in  bacterial  flora  between  pouchitis  and  non-pouchitis 
patients. These have produced inconsistent results because of poorly defined patient groups 
and  also  because  culture-based  studies  are  unable  to  identify  more  than  40%  of  gut 
microbiota.
In the last few years molecular studies using 16s rRNA sequencing of the gut microflora have 
demonstrated that more than 99% of the gut microbiota is composed of four bacterial phyla; 
Firmicutes,  Bacteriodetes,  Proteobacteria  and Actinobacteria  (Eckburg  &  Relman  2007; 
Frank, St Amand et al.  2007). Of these,  Firmicutes (64%) and Bacteriodetes (23%) are the 
dominant colonic species (Frank, St Amand et al. 2007). Recently polymerase chain reaction 
(PCR) studies have demonstrated changes in the composition of mucosal-adherent flora in 
patients with CD and UC. A large study of resected tissue specimens from 190 UC, CD and 
healthy control patients demonstrated a significant reduction in bacteria from the Firmicutes  
and Bacteriodetes  phyla and a significant increase in bacteria from the  Proteobacteria  and 
Actinobacteria phyla (Frank, St Amand et al. 2007). 
The only published study to use a completely molecular technique to compare the microbiota 
in pouchitis and non-pouchitis patients demonstrated significant differences in the microbial 
patterns between pouchitis and non-pouchitis samples with an increase in the proportion of 
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bacteria from the Proteobacteria phyla (Enterobacters and Fusobacter) and a reduction in the 
proportion of bacteria from the  Firmicutes  phyla;  Streptococci and also a difference in the 
Rumicoccus species  associated  with  pouchitis  compared  to  non-pouchitis  samples 
(Komanduri, Gillevet et al.  2007).  Interpretation of this study is limited by the pooling of 
samples before analysis and its small sample size; only five UC non-pouchitis and three UC 
pouchitis samples were studied, however it provides good evidence for a bacterial dysbiosis 
occurring in pouchitis.
The ten-fold increased risk of pouchitis in UC patients compared to FAP patients  may be 
explained  by  a  different  gut  microbiota  population  in  UC patients  which  predisposes  to 
inflammation  of  the large  bowel  (UC) and persists  following restorative  proctocolectomy 
(RPC), predisposing to inflammation of the ileo-anal reservoir (pouchitis). 
It has been proposed that an individual’s gut microbiota may at least in part be genetically 
determined (Van de Merwe, Stegeman et al. 1983) and that close relatives of IBD patients 
have  alterations  in  their  flora.  Data  from  animal  work  add  weight  to  this  hypothesis 
(Dombrowicz, Nutten et al. 2001). However environmental factors shared by relatives may 
also be important (Tamboli, Neut et al. 2004).
During the first year after RPC the the pouch microbiota evolves to a composition similar to 
colonic flora (Falk, Olsson et al.  2007). This in combination with metaplasia of the pouch-
ileum (colonisation) may predispose the mucosa of the pouch to inflammation in UC patients. 
The luminal microbiota in RPC patients can be modified with probiotics and this is associated 
with disease remission. However, this change is not permanent and the microbiota quickly 
reverts  to  its  previous  composition  following withdrawal,  such reversion being associated 
with subsequent disease relapse (Kuhbacher, Ott et al. 2006). 
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It is possible that a further change in the microbiota may occur and that this causes pouchitis. 
It is known for example that super-infection with intestinal pathogens can cause exacerbations 
of IBD (Sartor 2008) and is implicated in up to 50% of relapses (Nayar & Rhodes 2004), 
infection with an enteric pathogen or indeed another stimulus could occur in RPC patients 
causing a dysbiosis. 
In order to evaluate this hypothesis we studied four groups of patients (UC non-pouchitis, UC 
pouchitis, FAP non-pouchitis, FAP pouchitis) using high-throughput 16s rRNA sequencing, 
to compare and contrast the microbiota in mucosal biopsies and to establish whether there are 
differences in the microbiota between each of these groups (Chapter 2).
In the last few years the probiotic VSL#3 was shown to be effective maintenance treatment 
for  patients  who  achieved  clinical  and  endoscopic  remission  following  combination 
antibiotics in two RCTs (Mimura, Rizzello et al.  2004; Gionchetti,  Rizzello et al.  2000b). 
However  a  later  American  study failed  to  replicate  these  results  (Shen,  Brzezinski et  al.  
2005). Both this later study and the original studies could be criticised for several limitations 
(see section 1.4c) which may explain the discrepancy between the studies and may limit the 
use of VSL#3 in clinical practice.  
Because of the obvious advantages of using a probiotic rather than antibiotics as continuous 
maintenance  therapy and the uncertainty  of  its  efficacy,  we performed a  further  study to 
evaluate VSL#3 as maintenance therapy in patients with chronic pouchitis. 
We also evaluated the rate of mucosal healing following combination antibiotic therapy in 
patients with chronic pouchitis. The importance of this is that earlier studies have shown that 
despite  achieving  clinical  remission  not  all  patients  achieve  endoscopic  remission  with 
antibiotics (Madden, McIntyre et al 1994). 
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The two randomised controlled trials  demonstrating the effectiveness of VSL#3 (Mimura, 
Rizzello et al. 2004; Gionchetti, Rizzello et al. 2000b) excluded patients who did not achieve 
mucosal healing but the number of patients who were excluded from the study because of this 
was not stated. In the later clinical study (Shen, Brzezinski et al. 2005) which demonstrated a 
much lower efficacy, repeat endoscopic assessment was not performed and VSL#3 was given 
to all patients who entered clinical remission. It is possible, therefore, that in this group of 
patients the efficacy of VSL#3 was low because the incidence of non-mucosal healing was 
high.  
We studied patients with chronic pouchitis using the same entry criteria as Gionchetti and 
Mimura, treated these patients with the same antibiotic regime as Mimura and performed a 
repeat endoscopic assessment at four weeks prior to prescribing VSL#3. Using this method 
we were able to establish the incidence of non-mucosal healing prior to the administration of 
VSL#3. We were also able to assess whether endoscopic assessment should be performed in 
routine clinical practice before prescribing VSL#3 or whether the incidence of non-mucosal 
healing was insufficient to warrant this procedure before prescribing VSL#3. We also aimed 
to establish the efficacy of VSL#3 in clinical practice at our hospital (Chapter 3).
Some patients with pouchitis are resistant to antibiotics. In this situation there are no other 
proven therapies and patients must either consider conversion to an ileostomy or continue to 
suffer. 
Elemental  diet  has  been  shown to  be efficacious  in  patients  with  Crohn’s  disease  and is 
routinely used to establish remission in paediatric gastroenterology. Its mechanism of action 
is  unknown,  but  there  is  evidence  that  elemental  diet  may  modulate  gut  flora  and  gut 
immunological function (Menezes, Andrade et al. 2006a). Certainly its effect in reducing gut 
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inflammation is well demonstrated (Teahon, Smethurst et al. 1991b; Fell, Paintin et al. 2000b; 
Sanderson, Boulton et al. 1987) and it has been shown to reduce bacterial load in small bowel 
bacterial overgrowth (Pimentel, Constantino et al. 2004b). 
There are several similarities between pouchitis and Crohn’s disease (CD) which suggest that 
an elemental diet may be effective in pouchitis. Both diseases affect the small bowel, both 
respond to treatment with antibiotics, and both improve with diversion of the faecal stream (it 
is of note these treatments are not effective in ulcerative colitis). There is also evidence at an 
immunological level that pouchitis has a similar pathogenesis to CD. In UC inflammation is 
predominately  Th2-cytokine  driven,  whereas  in  CD  a  Th1-mediated  immune  response 
predominates (Sartor 1991; Gately, Renzetti et al. 1998; Fiocchi 1998; Kobayashi, Fitz et al. 
1989b; Wolf, Temple et al. 1991b). Therefore it would be expected that pouchitis would be 
associated with aTh2 cytokine activation. However an increase in the Th1 cytokine IFN- 
has  been  described  in  acute  and  chronic  pouchitis  (Stallmach,  Schafer et  al. 1998). 
Furthermore the lymphocyte activation marker CD30 has been shown to be upregulated in 
UC but not in CD (Giacomelli, Passacantando et al. 1998a; Elewaut, De Keyser et al. 1998). 
This is elevated in acute pouchitis but not in chronic pouchitis (Thomas, Forbes et al. 2001a), 
and accordingly the authors postulated that this may be due to a more Crohn-type disease 
occurring in the individuals with chronic pouchitis.
The advantage of using an elemental diet in pouchitis is that it may offer a novel treatment 
strategy for those patients for whom there is currently no effective treatment and reduce the 
risk  of  antibiotic  resistance  in  individuals  who  require  frequent  courses  of  antibiotics  or 
continuous antibiotic treatment. 
We performed an open-label study of elemental diet in patients with pouchitis  to establish 
whether this could be tolerated by patients without a colon and to determine whether it was 
68
Background to ileal-pouch surgery Chapter 1
effective and  had an impact on the patient’s quality of life given that an elemental diet is 
often poorly tolerated in adults (Chapter 4).
Pre-pouch ileitis was recently characterised by our group. Its true prevalence and implications 
are unknown and some authors have suggested that its presence indicates Crohn’s disease. We 
studied the prevalence within our pouch population over a 3 year period and also aimed to 
establish associated symptoms and whether it predicted reclassification to Crohn’s disease or 
pouch failure (Chapter 5). 
Infliximab is the only treatment that has been reported to be effective in the treatment of pre-
pouch  ileitis,  but  this  treatment  is  expensive  and  is  associated  with  significant  potential 
complications. We sought to establish whether antibiotic therapy might be effective treatment 
for pre-pouch ileitis (Chapter 6).
Following  on  from our  work  in  trying  to  develop  new treatment  strategies  for  pouchitis 
(Chapter 4), we aimed to show that simple microbiological stool coliform sensitivity testing 
could demonstrate resistance and sensitivity patterns and predict effective antibiotic treatment 
regimes  for patients  with antibiotic-resistant  pouchitis,  particularly  for  those patients  who 
relapse on antibiotic maintenance therapy and currently present a difficult clinical problem 
(Chapter 7)
Some  patients  with  chronic  pouchitis  require  long-term  maintenance  treatment  with 
ciprofloxacin  or  other  antibiotics.  Many  clinicians  and  patients  are  concerned  that  this 
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treatment may lead to the development of antibiotic resistance or infection with Clostridium 
difficile,  particularly  since  the  incidence  of  Clostridium  difficile infection  in  hospitalised 
patients seems to be increasing with the incidence doubling between 1993-2003 (McDonald, 
Owings et al. 2006; Pepin, Valiquette et al. 2004). Treatment with fluoroquinolones appears 
to be a significant risk factor (Pepin, Saheb et al. 2005) and there appears to be an increased 
mortality in IBD patients compared to non-IBD patients infected with  Clostridium difficile  
(Ananthakrishnan, McGinley et al. 2008). Recently the prevalence of Clostridium difficile in 
RPC patients undergoing pouchoscopy was reported to be 18% (Shen, Jiang et al. 2008).
Following on from our work where we demonstrated that  patterns of antibiotic  resistance 
could be demonstrated in stool samples and that some patients had highly resistant organisms 
(extended  spectrum  beta  lactamase  resistant  bacteria  -ESBL),  we  performed  a  study  of 
chronic  antibiotic-dependent  pouchitis  patients  to  establish  the  prevalence  of  Clostridium 
difficile infection, antibiotic resistance patterns and to determine the incidence of side effects 
and other factors associated with this treatment (Chapter 8). Prompted by our concerns that 
ESBL-producing  bacteria  may  be  associated  with  an  increased  risk  of  pouch  failure  we 
studied  the  prevalence  of  ESBL-producing  bacteria  in  RPC  patients  with  recurrent  or 
refractory  pouchitis  to  establish  whether  ESBL-producing  bacteria  were  common  in  this 
patient  group  and  to  establish  factors  that  may  be  associated  with  an  increased  risk  of 
developing ESBL-producing bacteria (Chapter 9).
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Chapter 2
The bacteriology of pouchitis: a molecular phylogenetic analysis
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2.1 Introduction
Restorative  proctocolectomy with ileal  pouch-anal  anastomosis  (RPC) is  the procedure of 
choice in patients with ulcerative colitis (UC) and selected patients with familial adenomatous 
polyposis (FAP).  As pouchitis is a form of inflammatory bowel disease (IBD) and occurs 
predominantly in patients operated on for UC it may provide a model to study the underlying 
pathogenesis of IBD. 
Whether a dysbiosis or an abnormal host immune response to normal commensal microbiota 
is the cause of IBD has been the subject of many studies (Sartor 2008).  There is evidence 
from clinical practice to implicate bacteria in pouchitis. Mucosal inflammation is localised to 
the area of gut with the highest concentration of bacteria (Schultz & Sartor 2000). Antibiotics 
have been reported to be effective treatment for both pouchitis and pre-pouch ileitis in up to 
87.5% of patients (Shen 2003; McLaughlin, Clark et al. 2008). Probiotics have been shown to 
reduce disease relapse (Gionchetti, Rizzello et al. 2000b; Mimura, Rizzello et al. 2004), and 
reduce  the  risk  of  disease  onset  (Gionchetti,  Rizzello et  al. 2003).  We have  previously 
demonstrated that the inflammatory response in pouchitis appears to be at the local mucosal 
level providing indirect evidence to implicate bacteria (Bell, Nicholls et al. 2004).
However, the microbiology of pouchitis is still poorly understood. Results from early studies 
of  pouch microbiota  using culture  methods  are  varied and inconclusive  demonstrating  no 
strong evidence that dysbiosis is the cause of pouchitis (Lim, Sagar et al. 2006).
Since the introduction of molecular techniques for the study of gut microbiology, however, it 
has been appreciated that culture-based studies fail to identify up to 90% of gut microbiota 
(Zoetendal, Rajilic-Stojanovic et al. 2008).  
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Studies  using molecular  techniques  have demonstrated  changes  in  the composition  of gut 
microbiota in IBD patients, when compared to non-inflammatory controls. Many investigators 
report a reduction in bacterial diversity in samples from IBD patients, often with increased 
Enterobacteriaceae,  including  E.  coli,  and  a  reduction  in  Firmicutes including  Clostridia 
(Hooper & Gordon 2001; Gophna, Sommerfeld et al. 2006; Manichanh, Rigottier-Gois et al. 
2006; Martinez-Medina, Aldeguer et al. 2006; Swidsinski, Weber et al. 2005). Both increased 
(Bibiloni, Mangold et al. 2006; Swidsinski, Ladhoff et al. 2002; Swidsinski, Weber et al.  
2005; Kleessen, Kroesen et al. 2002) and decreased (Baumgart, Dogan et al. 2007; Frank, St 
Amand et al. 2007) levels of Bacteroidetes have been reported, likewise some studies report 
differences  in microbiota  in active and inactive disease (Swidsinski,  Ladhoff et al.  2002; 
Baumgart, Dogan et al.  2007; Darfeuille-Michaud, Boudeau et al. 2004) whereas others do 
not (Bibiloni, Mangold et al. 2006). 
Two studies  have  used  a  molecular  technique  to  compare  ileo-anal  pouch  microbiota  in 
pouchitis and non-pouchitis patients.  In the first bacterial DNA from mucosal biopsy samples 
from 11 patients was sequenced and cloned  (Komanduri, Gillevet et al. 2007) with apparent 
significant differences between pouchitis and non-pouchitis groups. The second studied 32 
RPC  patients  using  terminal-restriction  fragment  length  polymorphism  (TRFLP).   No 
differences between pouchitis and non-pouchitis groups were found (Johnson, Rogers  et al 
2009). Both of these studies, however, had limitations. First the technique used by Johnson et  
al was limited to only being able to identify dominant species groups and was not able to 
identify individual bacterial species and secondly in the study of Komanduri  et al  samples 
from groups of patients with or without pouchitis were pooled before cloning. There is a wide 
variation in gut microbiota between individuals (Zoetendal, Akkermans et al. 1998; Eckburg 
& Relman 2007), therefore pooling samples is not justified; comparisons can only be made 
between  groups  comprised  of  data  from  different  individuals.  16  rRNA  cloning  and 
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sequencing is accepted as the current best technique to identify and compare gut microbiota 
(Lim, Sagar  et al. 2006) The advantages of this technique over other molecular techniques 
such as TRFLP, LH-PCR and DGGE are that cloning and sequencing allows the idenfication 
of individual gut micro-organisms by comparing the 16s ribosomal sequence against those in 
large databases such as the National Center for Biotechnology Information (NCBI) BLAST 
database.  In  comparison  neither  DGGE,  LH-PCR nor  TRFLP allow  identification  of  the 
bacteria present. Both DGGE and LH-PCR produce “fingerprints” which allow comparison 
between samples  but do not  allow identification  of the individual  bacteria  present.  TRFP 
allows estimation of the number of dominant species and the degree to which these species 
are present in equal numbers to be compared between samples found (Johnson, Rogers et al 
2009). 
In the present study bacterial 16S rRNA gene cloning and sequencing was used and patient 
samples were analysed individually to avoid the above possible sources of error. The results 
were compared to those obtained from FAP-RPC patients with and without pouchitis.
Aim 
Identify, compare and contrast the microbiota in patients with and without pouchitis having 
undergone RPC for UC and FAP to establish whether a dysbiosis occurs in pouchitis. 
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2.2 Method 
Patients and samples
Ethical permission for the study was granted by the local ethics committee (ethics no. 3238). 
RPC patients with UC and FAP attending the hospital surgical department either for routine 
annual  review  or  with  symptoms  of  pouchitis  were  recruited.  All  underwent  flexible 
pouchoscopy  with  biopsy.  Chronic  pouchitis  was  defined  as  three  or  more  episodes  of 
pouchitis  per year  (DeSantis,  Hugenholtz et al. 2006) and active pouchitis  was diagnosed 
when the pouch disease activity index (PDAI) (Sandborn, Tremaine et al. 1994) was ≥7.
Four groups of patients were studied:
UC RPC non-pouchitis patients
UC RPC patients with active pouchitis (PDAI ≥7) and a history of chronic pouchitis 
FAP RPC non-pouchitis patients 
FAP RPC patients with active pouchitis (PDAI ≥7)  
Those  with  pouchitis  were  treated  with  four  weeks  of  antibiotic  treatment  (500mg 
ciprofloxacin and metronidazole  400mg twice daily)  after  which they underwent a second 
clinical  and  endoscopic  assessment.  Biopsies  were  taken  before  repeat  pouchoscopy  and 
discarded in those where follow-up pouchoscopy failed to demonstrate mucosal healing in 
order to exclude antibiotic-resistant pouchitis cases from this study. Inclusion criteria for UC 
and FAP non-pouchitis included patients with good pouch function, no previous history of 
pouchitis and PDAI < 7. FAP pouchitis included patients with active pouchitis (PDAI ≥7). 
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Patients  with  complications  including  retained  ano-rectal  cuff  inflammation,  stricture, 
anastomotic  leakage,  fistula,  a  history  of  non-steroidal  anti-inflammatory  drug  use, 
immunomodulator or other IBD therapy in the previous two months and those on antibiotic or 
probiotic therapy within the preceding two weeks were excluded from the study.
Mucosal biopsy sampling
Each patient received a phosphate enema (Forest, UK) prior to the procedure. Two mucosal 
biopsies (each approximately 1 x 2 mm) were collected during pouchoscopy approximately 
10cm from the anal verge away from suture or staple lines. Each sample was placed in a 
sterile cryovial without preservative, snap frozen in liquid nitrogen and stored at –70ºC until 
analysis. Four biopsies for routine histological examination were taken and examined by a GI 
histopathologist. A medical history was taken, hospital records were reviewed and the PDAI 
calculated for each patient.
DNA extraction and PCR amplification of bacterial 16S rRNA genes
DNA extraction  was performed on single  biopsy specimens  using the DNeasy blood and 
tissue kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions. 
The  broad-range  bacterial  primers  Bact-7F  (5'-AGAGTTTGATYMTGGCTCAG-3'’)  and 
Bact-1510R (5'-ACGGYTACCTTGTTACGACTT-3') were used to amplify community 16S 
rRNA genes. Each 100μl PCR mixture contained 20µl of Go-Taq Buffer (Promega, UK), 
3mM  MgCl2,  200µM  dNTPs,  0.4µM  primer  F,  0.4µM  primer  R,  0.5µl  Go-Taq  DNA 
polymerase (Promega, UK), 47.5µl nuclease free water and 2µl of the sample DNA solution. 
The control contained 2µl of nuclease free water in place of sample DNA.
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PCR amplification was performed using a Hybaid Px2 Thermal Cycler (Thermo Scientific, 
Waltham, USA) with one denaturation step at 95°C for 5min followed by 30 cycles of  95°C 
for 30 seconds, 58°C for 30 seconds and 72°C for 2 minutes with a final elongation step at 
72°C for 10 minutes.
Clone library construction and sequence analysis
Clone library construction and sequencing were performed as described previously. (Stecher, 
Robbiani et al. 2007) 192 colonies were randomly selected for sequencing from agar plates. 
Sequences  were aligned using the  NAST aligner  (DeSantis,  Hugenholtz et  al.  2006)  and 
extensive manual curation of alignments was performed using the ARB package (Ludwig, 
Strunk et  al. 2004).  Sequences  were  tested  for  chimeras  using  Mallard  (Ashelford, 
Chuzhanova et  al. 2006)  Bellerophon,  (DeSantis,  Hugenholtz et  al.  2006),  and  Pintail 
(Ashelford, Chuzhanova et al. 2005) and chimeric sequences were removed. After removal of 
chimeras  and other  suspect  sequences  an average  of  133 sequences  per  sample  remained 
(3184  full-length  sequences  in  total).  These  sequences  (deposited  in  GenBank  under 
GQ156578-GQ159761) were given a broad classification at  the phylum and family levels 
using the Classifier tool at the RDPII website (Wang, Garrity et al. 2007). To obtain more 
detailed  taxonomic  information  the  sequences  were  divided  into  phylotypes.  Distance 
matrices were generated with ARB using the Olsen correction and entered into the DOTUR 
program (Schloss  & Handelsman  2005)  set  to  the  furthest  neighbour  and  99%-similarity 
setting.  Resulting  phylotypes  were  then  assigned  similarities  to  nearest  neighbours  using 
MegaBLAST (Johnson, Zaretskaya et al. 2008). The Shannon diversity index (SDI) for each 
individual sample was calculated using DOTUR. (Schloss & Handelsman 2005).
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Statistical analysis
SPSS version 15 (SPSS inc.  Chicago,  USA) was used for  all  statistical  analysis.  For  the 
description of data, the median and range were calculated.  The Mann-Whitney U test was 
used to compare groups. A two-tailed p-value <0.05 was considered significant.
2.3 Results
Biopsy specimens were obtained from eight UC RPC non-pouchitis patients, eight UC RPC 
patients  with active chronic pouchitis  who later  entered clinical  and endoscopic remission 
following antibiotic  treatment,  five  FAP RPC non-pouchitis  patients  and  three  FAP RPC 
patients with active pouchitis. Clinical and demographic details are shown in Table 2.1.
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Table 2.1.
Demographic details of study patients. 
Values shown are medians with range in parentheses
UC FAP
Non-pouchitis
n=8
Pouchitis 
n=8
Non-pouchitis
n=5
Pouchitis 
n=3
Age in years 51 (19-63) 39 (19-64) 40 (25-72) 32 (30-54)
Median  interval 
since  RPC  in 
months
103 (35-325) 119 (10-1234) 124 (42-203) 50 (25-53)
Sex 6 males 5 males 4 males 1 male
Pouch 
configuration
4 ‘W’
3 ‘J’
1 ‘S’
1 ‘W’
7 ‘J’
1 ‘W’ 
4 ‘J’
3 ‘J’
24hr  Stool 
frequency
5 (2-9) 12 ( 8-16) 4 (3-7) 12 (6-21)
PDAI 0 (0-3) 11 (8-14) 0 (0-1) 12 (9-12)
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Sequence analysis
In total, 3184 full-length sequences were generated from the twenty-four clone libraries. In 
common with other gut bacterial surveys (Eckburg & Relman 2007; Frank, St Amand et al.  
2007) the  majority  of  the  sequences  (99.8%)  corresponded  to  just  four  bacterial  phyla: 
Firmicutes,  Bacteroidetes,  Proteobacteria and  Actinobacteria.  A  very  small  number  of 
sequences corresponded to Verrucomicrobia and Fusobacteria. As has been repeatedly shown 
in other studies of the gut microbiota (Frank, St Amand et al. 2007; Zoetendal, Akkermans et  
al. 1998) we also found a large inter-individual variation.
Phylum level analysis between groups
Although the four phyla above were predominant in our samples it is clear that the pouch 
microbiota,  particularly  in  patients  with  UC,  is  drastically  different  from  that  typically 
encountered in the colon. Normally the gut microbiota is dominated by  Bacteroidetes and 
Firmicutes. In contrast, samples taken from UC RPC patients were marked by unusually high 
proportions of Proteobacteria (mean of around 60% of total clones) while Bacteroidetes and 
the  major  Firmicutes families  Lachnospiraceae and  Ruminococcaceae were,  for  the  most 
part,  greatly  reduced.  The  FAP  RPC  samples,  while  still  harbouring  relatively  high 
Proteobacteria proportions,  generally  appeared to be composed of microbial  communities 
more  typical  of  a  normal  colon.  When comparing  the UC and FAP cohorts,  there  was a 
significant increase in the proportion of sequences in the  Proteobacteria (p= 0.019) and a 
significant  decrease  in  the  proportion  of  Bacteroidetes (p=  0.001)  phyla  in  the  total  UC 
compared with the total FAP patient cohort (Figure 2.1). Similar differences were identified 
when the  UC pouchitis  group was compared  to  the  FAP pouchitis  group,  with increased 
Proteobacteria (p= 0.041) and reduced Bacteroidetes (p= 0.014). When the UC non-pouchitis 
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group  was  compared  with  the  UC  pouchitis  group,  however,  there  were  no  significant 
differences in the proportion of sequences from the any of the phyla (Figure 2.2).  There was 
also no significant difference between FAP pouchitis and FAP non-pouchitis groups (Table 
2.2). Therefore, at the phylum level, although we could demonstrate differences between the 
two different patient cohorts we were unable to demonstrate a dysbiosis within each of the 
two disease groups.
Table 2.2.
Table to demonstrate difference in median proportion of clones belonging to each phylum
81
UC FAP UC FAP
UC 
Pouchitis 
FAP 
pouchitis
Species Non-
pouchitis
Pouchitis P-
value
Non-
pouchitis
Pouchitis P-
value
All All P-
value
P-value
Bacteroides  
vulgatus 0 0 0.538 3.52 0 0.093 0 1.00 0.031 0.545
Bacteroides  
fragilis 0 0 0.144 0 0 1.0 0 0 0.307 0.364
Faecalibacterium 
prausnitzii 0 0 0.783 1.69 0 0.453 0 1.56 0.029 0.604
Escherichia coli
17.37 8.47 1.0 5.65 1.84 0.655
12.7
0
0 0.118 0.414
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Figure  2.1.  Box  plot  comparing  the  percentage  of  sequences  identified  from  the  four 
predominant bacterial phyla in UC patient samples compared with FAP patient samples
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Figure  2.2.  Box  plot  comparing  the  percentage  of  sequences  identified  from  the  four 
predominant  bacterial  phyla  in  UC  pouchitis  patient  samples  compared  with  UC  non-
pouchitis patient samples
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Family level analysis
We then attempted to pinpoint the significant differences between the samples by examining 
the sequence data at the family level (Figure 2.3). These results showed that the differences at 
the phylum level between the UC and FAP cohorts corresponded to significant increases in 
the levels of the proteobacterial families Comamonadaceae (p= 0.007), Moraxellaceae (p= 
0.027) and Alcaligenaceae (p= 0.03) in tandem with a significant reduction in the 
Bacteroidetes families Bacteroidaceae (p= 0.013) and Prevotellaceae (p= 0.023) and the 
Firmicutes family Ruminococcaceae (p= 0.007) in UC. The other families identified are 
illustrated in Tables 10.1-10.3 (supplementary material).
When comparing the UC pouchitis to the UC non-pouchitis groups we found that streptococci 
and Alcaligenaceae were reduced in patients with pouchitis (p= 0.04 and p= 0.026 
respectively). Enterobacteriaceae, including E. coli, accounted for the highest proportion of 
proteobacterial sequences and were increased in both UC pouchitis versus UC non-pouchitis 
and FAP pouchitis versus FAP non-pouchitis. Due to the large degree of inter-individual 
variation between patients, however, these differences did not reach significance.
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Figure 2.3.  Bar chart to show the median percentage of clones identified from each bacterial 
family  in  samples  from  UC  pouchitis,  UC  non-pouchitis,  FAP  pouchitis  and  FAP  non-
pouchitis patients.
Species level analysis
Each  patient  sample  was  analysed  at  the  species  level  by  splitting  the  sequences  into 
phylotypes comprised of >99%-identical sequences using DOTUR (Schloss & Handelsman 
2005) (complete details of each patient sample and the species present are provided in Tables 
10.4-10.15,  supplementary  data).  When  comparing  the  UC  and  FAP  cohorts, 
Faecalibacterium prausnitzii, which has been postulated to have anti-inflammatory properties 
and may be reduced in IBD patients, was detected in 6 out of 8 FAP patients but only 4 out of 
16 UC patients (p=0.029).  Bacteroides vulgatus was also significantly increased in the FAP 
group compared to the UC group (p =0.031). 
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There were, however, no individual species or phylotypes that significantly differed between 
the UC pouchitis and UC non-pouchitis  cohorts.  This included both  F. prausnitzii and  B. 
vulgatus as  well  as  other  species  that  have  previously  been  implicated  in  IBD  such  as 
Bacteroides fragilis (Martinez-Medina, Aldeguer et al. 2006) and E. coli (Table 2.3). Further 
bacteria that have been implicated in the pathogenesis of IBD such as Mycobacterium avium 
subspecies paratuberculosis, sulphate-reducing bacteria,  Listeria and Yersinia spp. (Eckburg 
& Relman 2007) were not detected in any of the samples. 
Shannon Diversity Index (SDI)
Using the phylotypes generated by DOTUR we calculated the SDI,( Eckburg, Relman 2007) 
which is a measure of the number of different species and their relative abundance in a given 
environment, for each sample and for each patient group (Figures 2.4-5). These are given in 
Table 2.3 (median and range shown). The median SDI for all UC RPC patients was 2.61 
compared to 3.2 for all FAP RPC patients and this difference was statistically significant (p= 
0.004). The median SDI in the FAP non-pouchitis group was significantly higher than in the 
UC non-pouchitis group (p= 0.019) however no difference was observed between the FAP 
pouchitis and UC pouchitis group (p= 0.066), overall indicating that a less diverse bacterial 
community exists in UC RPC patients than in FAP RPC patients. 
Comparison within disease groups showed the median SDI in the UC non-pouchitis group 
was 2.70 and in the UC pouchitis group 2.32. This difference was statistically significant (p= 
0.009). The median SDIs in the FAP non-pouchitis and pouchitis groups were 3.19 and 3.34 
(p= 0.18).  These results demonstrate that, overall, there was a simpler, less diverse bacterial 
community in the UC group in comparison to the FAP group, and that a further reduction in 
diversity of the bacterial community occurs in patients with pouchitis.
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Figure 2.4. Box plot comparing the Shannon Diversity index in samples from UC pouchitis 
patients compared to UC non-pouchitis patient samples
Figure 2.5. Box plot comparing the Shannon Diversity Index in the total UC cohort and total 
FAP cohort
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Table 2.3. 
Shannon diversity index (SDI) by patient group
Shannon diversity index
Patient group Pouchitis Non-pouchitis P-value All patients
UC
2.32
(2.10-2.66)
2.70
(2.17-3.11)
0.009
2.61
(2.10-3.09)
FAP
2.79
(2.55-3.22)
3.34
(2.72-3.46)
0.18
3.20
(2.72-3.46)
P-value 0.066 0.019 0.004
Values shown are medians with range in parentheses
2.4 Discussion
It has been suggested that the term pouchitis describes a spectrum of diseases (Shen & 
Lashner 2005). In this study we attempted to reduce heterogeneity by studying only UC 
pouchitis patients with chronic pouchitis rather than all types of pouchitis. We repeated 
clinical and endoscopic assessment following treatment with standard combination antibiotic 
therapy to ensure the study group entered both clinical and endoscopic remission and to 
exclude patients with antibiotic resistant pouchitis. The inclusion of FAP pouchitis and FAP 
non-pouchitis patients is novel and allows comparison between patients with a previous 
history of IBD and those without. Pouchitis in FAP patients has not been well studied and its 
incidence is about ten times lower than in UC patients (McLaughlin, Clark et al. 2008a), the 
reasons for this are unclear. 
As in other studies we analysed the mucosal adherent microbiota since these are likely to be 
more important than luminal microbiota in the pathogenesis of IBD (Frank, St Amand et al.  
2007; Swidsinski, Ladhoff et al.2002; Swidsinski, Weber et al.2005). The particular strengths 
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of the present study are that we have studied pouchitis in both IBD and non-IBD RPC patients 
and that each sample was cloned individually and sequenced to the species/phylotype level. 
To the best of our knowledge this is the first investigation in which this has been undertaken. 
We performed a power calculation of the study data whichhas shown that an estimated sample 
size of eight patients per group was required to demonstrate a 5% statistical significance and 
80% power in SDI between the UC pouchitis (2.35±0.26) versus UC non-pouchitis groups 
(2.75 ±0.31).
Similarly an estimated sample size of seven patients per group was required to demonstrate a 
5% statistical significance and 80% power in SDI between all UC patients (2.55±0.35) versus 
FAP patients (3.12 ±0.41). 
There are, however, limitations to this present study. First, 16S rRNA gene sequencing results 
represent gene copy number, not true bacterial counts, and may also be biased by differential 
DNA extraction and PCR amplification rates.  The methodology is currently, however, the 
best available and regarded as the “gold standard” for the analysis of gut-associated 
microbiota (Zoetendal, Rajilic-Stojanovic et al.2008). Secondly, the study included small 
numbers of patients. This is due to difficulty in accrual since patients with chronic antibiotic-
dependent pouchitis are uncommon and represent about 5% of all patients. FAP pouchitis, 
particularly, is rare (Romanos, Samarasekera et al.1997;Stahlberg, Gullberg et al.1996; 
Salemans, Nagengast et al.1992; Hurst, Molinari et al.1996; Lovegrove, Tilney et al.2006). 
Thirdly, we included patients with chronic pouchitis who had not received antibiotic therapy 
for a minimum of two weeks. This might have influenced the gut microbiota but this cut-off 
was chosen for practical and ethical reasons. Others have done the same, for example in the 
study by Komanduri et al one patient had been treated with antibiotics two weeks prior to 
sampling. These authors reported that there was no difference in the microbiota identified in 
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this patient when compared with those who had not received an antibiotic for four weeks and 
concluded that a two week wash-out period was sufficient (Zoetendal, Akkermans et al.1998). 
Around 99% of gut microbiota are contained in four phyla; Firmicutes, Bacteroidetes, 
Proteobacteria and Actinobacteria (Eckburg & Relman 2007; Frank, St Amand et al.2007). 
At the species level however, each individual has his or her own unique gut microbiota 
(Komanduri, Gillevet et al.2007). This causes difficulty in studying gut microbiota and also 
demonstrates the importance of cloning and sequencing individual samples rather than 
analysing pooled samples. The present study has shown that the ileal pouch microbiota is 
different from the normal large intestine. UC pouches in particular, with or without pouchitis, 
appear to harbour more unusual microbiota than FAP pouches. Proteobacteria, which 
normally account for only a small proportion of the microbiota in the healthy colon (Eckburg, 
Bik et al. 2005) and up to 20% of the microbiota in IBD patients (Frank, St Amand et  
al.2007) comprised up to 90% (median = 66.6%) of the microbiota in the UC RPC patients in 
the study. There were also lower than normal proportions of Bacteroidetes, Lachnospiraceae 
and Ruminococcaceae. Comparison of the two study cohorts showed that UC RPC patients 
have increased proportions of the phylum Proteobacteria and decreased levels of 
Bacteroidetes compared with FAP RPC patients. A similar pattern was reported in a recent 
study in which surgical specimens from IBD (UC and Crohn’s disease) and non-IBD patient 
controls were compared. There was a reduction in the numbers of Bacteroidetes and 
Lachnospiraceae and an increase in Proteobacteria in a subset of IBD patients (Frank, St 
Amand et al.2007). In other studies increases in Proteobacteria in IBD patients have also 
been demonstrated (Gophna, Sommerfeld et al.2006; Seksik, Rigottier-Gois et al. 2003) and 
the Enterobacteriaceae family of Proteobacteria have often been shown to be increased in 
IBD patients compared with controls (Baumgart & Carding 2007; Martinez-Medina, 
Aldeguer et al.2006).
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Bacterial diversity was significantly lower in UC RPC patients, with or without pouchitis, 
than for FAP RPC patients. Furthermore, diversity was significantly reduced in UC pouchitis 
patients compared to those without. It has previously been shown that VSL#3 increases 
bacterial diversity in pouchitis (Kuhbacher, Ott et al.2006) and perhaps this may account for 
the reduced risk of relapse. A reduction in bacterial diversity has also been reported in both 
CD (Ott, Musfeldt et al. 2004) and UC (Andoh, Sakata et al. 2007; Sokol, Lepage et al. 
2006). The results of the present study therefore are further evidence of the importance of 
bacterial diversity in maintaining normal gut homeostasis.
Although the study aimed to establish whether a dysbiosis might be associated with pouchitis 
only minor differences between UC pouchitis and UC non-pouchitis were found; comparisons 
revealed only borderline significance between a very small number of bacterial groups. We 
recognise that when comparing multiple groups, significance may occur in a limited number 
simply by chance and have taken care not to overstate the importance of these observations. 
There was, however, a difference in the microbiota between the total UC RPC and FAP RPC 
cohorts with a reduction in F. prausnitzii and B. vulgatus in the UC RPC patient group. This 
is an interesting finding, given that F. prausnitzii has previously been postulated to have anti-
inflammatory properties and may be reduced in IBD patients (Sokol, Pigneur et al. 2008; 
Sokol, Seksik et al. 2009).
In a recent study Komanduri et al compared the microbiota after RPC for UC in patients with 
and without pouchitis (Komanduri, Gillevet et al.2007). Patients were studied using length 
heterogeneity polymerase chain reaction (LH-PCR). Because this technique provides limited 
information about the bacterial differences at a species/phylotype level, the LH-PCR products 
from three non-IBD controls, five UC non-pouchitis and three UC pouchitis patients were 
pooled before cloning and data were then filtered.  As a consequence only phylotypes 
representing more than 5% of the total clone library were analysed and only 73% of the 
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microbiota were identified. Principle coordinate analysis of LH-PCR profiles demonstrated 
that each patient had his or her own different microbiota. Cloning and sequencing identified 
an increase in the proportion of Enterobacteriaceae and Fusobacteria, a reduction in 
streptococci and a difference in the Ruminococcus species associated with pouchitis (R. 
obeum) and non-pouchitis (R. gnavus).  In our study we avoided pooling the samples and did 
not filter our data to avoid these disadvantages. Thus, using this methodology, we were 
potentially able to implicate individual species/phylotypes in the pathogenesis of pouchitis. 
However, despite extensive analysis of the data, no such species/phylotype was identified.
The differing experimental approaches may also explain the dissimilar results between the 
study of Komanduri et al and this study, in which Fusobacteria were not detected in the UC 
RPC samples and where there was no difference in the proportions of Clostridium 
paraputrificum or Ruminococcus species in pouchitis and non-pouchitis. There was a 
doubling in the median proportion of Enterobacteriaceae in UC and FAP patients with 
pouchitis but this was not significant owing to the high variance between patients, again 
indicating the danger of pooling samples. Indeed individual variation between patients is so 
great that the numbers of patients required to detect any statistically significant difference in 
microbiota within UC patients would be too large to be practicable.
In agreement with Komanduri et al, however, we did observe a reduction in streptococci in 
the UC pouchitis patients compared with non-pouchitis. 
This study has demonstrated that a dysbiosis occurs in UC RPC patients when compared with 
a non-IBD (FAP) population. We identified a reduction in diversity but only minor 
compositional differences between the microbiota of UC patients with active pouchitis and 
those with no history of pouchitis. This suggests that either this dysbiosis predisposes UC 
patients to pouchitis by increasing the likelihood of immune system stimulation or that the 
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reduction in diversity is sufficient to stimulate the immune system and lead to mucosal 
inflammation.
The failure to identify a particular bacterial species associated with pouchitis is in keeping 
with clinical experience where antibiotics with very different spectra of antimicrobial activity 
are equally effective in pouchitis. We have recently shown that many patients with pouchitis 
refractory to empirical antibiotic treatment have antibiotic resistant coliforms and 
microbiological testing is able to predict an effective antibiotic regime (McLaughlin, Clark et  
al. 2009a). This, taken with the findings of the present study, suggests that antibiotic therapy 
is effective in pouchitis by reducing the total gut microbial load and therefore the stimulus to 
the immune system rather than the elimination of a specific disease-activating bacterial 
species. 
2.5 Conclusion
This is the first study to compare the microbiota in individual UC and FAP RPC pouchitis and 
non-pouchitis patients using 16S rRNA sequencing. UC RPC patients have a different and 
less diverse gut microbiota than FAP RPC patients. A further reduction in bacterial diversity 
but only minor compositional changes occurs in those with active pouchitis. The study 
suggests, therefore, that a dysbiosis occurs in UC RPC patients which predisposes to, but does 
not directly cause, pouchitis.
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Chapter 3
Maintenance treatment with the probiotic VSL#3
[Type text] Pre-pouch ileitis; incidence and implications Chapter 4
3.1 Introduction
As described in Chapter 1 the probiotic VSL#3 was shown to maintain remission in 85% of 
patients  with  refractory  pouchitis  who  had  entered  clinical  and  endoscopic  remission 
following four weeks treatment with ciprofloxacin and rifaxamin in a randomised placebo 
controlled study of 40 patients (Gionchetti,  Rizzello et al.2000b), whilst a later two centre 
randomised placebo controlled study of 36 patients found that 85% of patients could maintain 
remission following four weeks  treatment  with ciprofloxacin  and metronidazole  (Mimura, 
Rizzello et al.2004).  However a subsequent eight month open-label clinical study reported 
that  in clinical  practice less than 20% of patients  were able to maintain remission (Shen, 
Brzezinski et al.2005).  
The reason for the significant difference in results is not clear but several differences between 
the methods of the controlled trials and the later clinical study may have contributed.  The 
most important and modifiable factors were that;
1. Both  Gionchetti  and  Mimura’s  studies  excluded  patients  who  did  not  achieve 
complete or near-complete endoscopic remission with a score of ≤3 in the clinical 
component of the pouch disease activity index (PDAI)), whereas Shen  et al did not 
repeat the pouchoscopy after clinical remission. It is known that some patients do not 
achieve endoscopic remission despite clinical remission following antibiotic treatment 
(Madden, McIntyre, Nicholls.1994) and it is possible that this subset of patients has a 
disease is more difficult to treat and may not respond to probiotics. 
2. The  studies  of  Gionchetti  and  Mimura  used  a  combination  of  ciprofloxacin  and 
rifaxamin or metronidazole for four weeks whereas Shen et al used a two week course 
of ciprofloxacin only to induce remisison. It is possible that probiotic therapy is more 
effective following a combination of two different antibiotics for a prolonged period.
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3. Gionchetti’s and Mimura’s studies recruited patients with refractory pouchitis, defined 
as three or more episodes of pouchitis per year, whereas Shen’s study only recruited 
patients with chronic antibiotic dependent pouchitis, defined as four or more episodes 
of pouchitis per year. Thus many of the patients included in Gionchetti and Mimura’s 
studies had less aggressive disease in which maintenance of remission may have been 
easier to achieve. 
The treatment of patients with chronic pouchitis remains difficult with most patients requiring 
maintenance  therapy  or  regular  two  week  courses  of  ciprofloxacin.  Therefore  probiotic 
therapy with VSL#3 is a potentially important alternative to long-term antibiotic treatment 
with the theoretical risks of antibiotic resistance.
VSL#3 is  now available  to  purchase in  the UK without  a  prescription.  Importantly  these 
sachets are a different strength to those used in the original studies; each sachet is 4.4g and 
contains  a  total  of  450 billion  bacteria.  The sachets  used in  the original  studies  were 3g 
sachets and contained 300 billion bacteria per gram (900 billion bacteria per sachet).  The 
VSL-pharma website (www.vsl3.com) advises using a maintenance dose of 900-1800 billion 
bacteria per day (2-4 sachets).  
Aims
(i). To perform an open label clinical study to further establish whether VSL#3 is effective 
maintenance therapy in patients with chronic relapsing pouchitis who achieved endoscopic 
and clinical remission following four weeks antibiotic treatment. 
(ii).  To determine  the proportion of patients  who achieve endoscopic remission following 
antibiotic therapy and thus what proportion of patients would be eligible for this treatment in 
clinical practice. 
Primary end point
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The number of patients who remained in clinical remission on VSL#3 at 6 months.
3.2 Method 
25  patients  with  symptomatic  refractory  pouchitis  (defined  as  three  or  more  episodes  of 
pouchitis per year which responded to antibiotics (Mimura, Rizzello et al.2004) presenting to 
St. Mark’s hospital outpatient clinic or the pouch-nurse telephone help line were recruited to 
this study. Ethical permission had been granted by the hospital ethics committee and the drugs 
and therapeutics committee had approved the use of VSL#3. VSL#3 was provided free of 
charge  by  the  manufacturer  and  was  dispensed  by  the  hospital  pharmacy.  Patients  were 
excluded from the study if they had taken antibiotics in the preceding two weeks, if they took 
non-steriodal  anti-inflammatory  drugs  or  if  another  cause  of  pouch  dysfunction  (such  as 
retained rectal cuff inflammation, pelvic sepsis or anastomotic stricturing) was identified.
The PDAI was calculated and a flexible pouchoscopy with mucosal biopsies for histology 
was performed at baseline. Active pouchitis was defined as a PDAI of 7 or more. Following 
the clinical and endoscopic diagnosis of pouchitis, four weeks treatment was commenced with 
ciprofloxacin  500mg twice  daily  and metronidazole  400mg twice  daily.  A repeat  clinical 
assessment  and flexible  pouchoscopy was performed after  four weeks  and the PDAI was 
recalculated. 
Clinical remission was defined as a combined PDAI symptom and endoscopic score of ≤3. 
Relapse was defined as a PDAI symptom score of >2 with both endoscopic and histological 
signs  of  pouchitis  and  total  PDAI  ≥7.  Patients  who  achieved  both  symptomatic  and 
endoscopic remission were treated with VSL#3; those who achieved symptomatic remission 
but  not  endoscopic  remission  were  treated  with  ciprofloxacin  maintenance  therapy (usual 
care). 
All patients underwent repeat pouchoscopy at three months or earlier  if pouchitis or other 
adverse symptoms developed. Patients who relapsed whilst taking VSL#3 were treated with a 
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further four weeks of ciprofloxacin and metronidazole,  following which ciprofloxacin was 
continued at a dose of 500mg bd. Similar to Shen’s study and  as recommended by the VSL-
pharma website we advised our patients who were intolerant of the 1800 billion bacteria dose 
to reduce this to 900 billion bacteria.
3.3 Results
All twenty-five patients with chronic pouchitis were in clinical  remission after four weeks 
treatment  with  ciprofloxacin  and  metronidazole.  Twelve  (48%)  were  also  in  endoscopic 
remission (clinical PDAI ≤3) following antibiotic treatment and thirteen (52%) of twenty five 
had continuing endoscopic signs of pouchitis (PDAI >3).
Thus twelve patients were suitable for treatment with VSL#3. Eight of these received VSL#3 
1800 billion bacteria and seven patients received VSL#3 900 billion bacteria per day. (Three 
patients were treated on separate occasions with both doses).
At the end of the 6 month study two (13%) patients were still in remission in the 1800 billion 
bacteria  group (primary  end-point).  No patient  remained  in  remission  taking  VSL#3 900 
billion bacteria. The median time until relapse was 56 days in the 900 billion bacteria group 
and 31 days in the 1800 billion bacteria group. Of the three patients treated with both doses 
only one patient remained in remission longer on the higher dose.
All patients  who relapsed successfully entered remission with combined ciprofloxacin and 
metronidazole and remained in remission at six months on ciprofloxacin 500mg twice daily 
maintenance therapy.
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Table 3.1 
Table of PDAI values before and after antibiotic treatment in patients who achieved mucosal 
healing.
Before antibiotic treatment After antibiotic treatment
Subject 
no.
Clinical Endoscopic Histological Total 
PDAI
Clinical Endoscopic Histological Total 
PDAI
1 2 6 2 10 0 2 1 3
2 4 6 4 14 0 2 3 5
3 4 6 3 13 0 0 3 3
4 2 4 2 8 0 1 1 2
5 4 5 4 13 0 0 1 1
6 4 5 1 10 0 0 2 2
7 4 6 1 11 0 0 2 2
8 5 6 1 12 0 2 0 2
9 5 6 1 12 0 0 0 0
10 4 5 2 11 0 2 1 3
11 3 6 4 13 0 2 1 3
12 5 6 2 13 0 0 1 1
13 2 6 2 10 0 2 1 3
14 4 3 1 8 0 0 1 1
15 4 6 1 11 0 0 2 2
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Table 3.2.
Table of PDAI values before and after antibiotic treatment in patients who did not achieve 
mucosal healing 
Before antibiotic treatment After antibiotic treatment
Subject 
no.
Clinical Endoscopic Histological Total 
PDAI
Clinical Endoscopic Histological Total 
PDAI
1 2 6 3 11 0 6 3 9
2 2 6 1 9 0 4 2 6
3 4 6 3 13 0 5 2 7
4 2 4 2 8 0 4 1 5
5 2 4 1 7 0 4 3 7
6 3 5 3 11 0 5 2 7
7 3 5 1 9 0 6 3 9
8 4 6 3 13 0 6 4 10
9 4 6 3 13 0 6 0 6
10 2 6 3 11 0 4 3 7
11 3 6 3 12 0 3 0 3
12 3 6 6 15 0 6 5 11
13 4 6 3 13 0 6 0 6
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Table 3.3.
No. of days until relapse in patients treated with VSL#3 (450 Billion bacteria)
Subject 
no.
Days
1 14
2 38
3 39
4 56
5 81
6 95
7 144
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Table 3.4. 
Days until relapse in patients treated with VSL#3 (900 Billion bacteria)
Subject no. Days
1 7
2 14
3 17
4 31
5 34
6 95
7 >180
8 >180
3.4 Discussion
VSL#3  was  shown  in  two  randomised  placebo-controlled  studies  to  be  effective  in 
maintaining remission in 85% of patients with refractory pouchitis who achieved endoscopic 
and clinical  remission (clinical  PDAI ≤3) with combination antibiotic  therapy (Gionchetti, 
Rizzello et al. 2000a;Mimura, Rizzello et al. 2004b). However a later clinical study where 
patients who had entered remission following ciprofloxacin were treated with VSL#3 without 
confirming endoscopic remission found that only 19.4% of patients  were able to maintain 
remission.  Furthermore,  the  present  study  has  demonstrated  that  if  the  protocol  of  the 
randomised trials is followed carefully,  less than 50% of patients achieve mucosal healing 
after antibiotic treatment (thus becoming eligible for maintainence treatment with VSL#3). 
This significantly limits the use of VSL#3 in clinical practice. Given the low rate of mucosal 
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healing  following  antibiotics,  and  the  cost  of  VSL#3,  a  flexible  pouchoscopy  should  be 
performed in all patients before considering treatment with VSL#3.  
Our study is in keeping with the clinical experience of others (Shen, Brzezinski et al.2005) 
and  demonstrates  that  despite  treating  patients  with  a  combination  of  ciprofloxacin  and 
metronidazole  for  four  weeks  and  excluding  patients  who  do  not  achieve  endoscopic 
remission, only a minority of patients are able to maintain remission with VSL#3. The two 
patients who were able to maintain remission with VSL#3 for six months both had had only 
three  episodes  of  pouchitis  within  the  previous  year  and  were  treated  with  1800  billion 
bacteria per day. Interestingly, the median time to relapse was lower in the group treated with 
the higher dose of VSL#3 and of the three patients treated with both doses the higher dose 
maintained remission longer in only one patient.  The number of patients in the study was 
small but these results suggest that a higher dose of VSL#3 may not be more effective and 
that the type of pouchitis may be more important in predicting whether individual patients 
will maintain remission. This theory is supported by the fact that Mimura’s study included 
only ten (28%) patients with four or more episodes of pouchitis per year whereas 26 (72%) 
had only three episodes per year. In addition Shen’s study specifically excluded patients with 
less than four episodes per year. Gionchetti’s study does not report these details.
From a clinical perspective an alternative therapy (such as probiotic bacteria) would be more 
useful in patients who require continuous antibiotic therapy to maintain remission, rather than 
in those who only need intermittent short courses of antibiotics, because in this group there is 
increased potential for the development of antibiotic resistant bacteria and Clostridium difficle  
colonisation. Unfortunately this group appear least likely to maintain remission with VSL#3. 
In patients where treatment with VSL#3 is being considered, a repeat flexible sigmoidoscopy 
should be performed to ensure that mucosal healing has occurred and a dose of 1800 billion 
bacteria should be prescribed. 
Elemental diet for pouchitis Chapter 4
Chapter 4
A pilot study of elemental diet for the treatment of chronic pouchitis
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4.1 Background
In most cases treatment of pouchitis with antibiotics (such as metronidazole or ciprofloxacin) 
will induce a remission (Mimura, Rizzello et al. 2002). Unfortunately some patients will go 
on to suffer from frequent episodes which remain responsive to antibiotics and others will 
require continuous antibiotic or probiotic treatment to maintain a remission (Mimura, Rizzello 
et al. 2004). A proportion of patients will not respond to antibiotics. These are difficult to 
manage as there is little evidenced-based treatment (Pardi & Sandborn 2006a). Alternative 
treatment strategies are limited. Topical budesonide is occasionally used, however this has 
been shown to be no more effective than metronidazole (Sambuelli, Boerr et al. 2002). Other 
treatments  such  as  5-ASAs,  bismuth  carbomer  enemas,  systemic  steroids  and 
immunosuppressants have not been of proven benefit (Pardi & Sandborn 2006c). The only 
proven treatment for these individuals is conversion to a permanent ileostomy although it is 
noteworthy that  long-term follow-up studies demonstrate that pouchitis accounts for only 
10% of pouch failures (Tulchinsky, Hawley et al. 2003b).
Meta-analyses  have  shown  that  treatment  with  elemental  diet  is  effective  in  inducing 
remission in both children and adults with Crohn’s disease (Zachos, Tondeur et al. 2001). The 
mechanism of action is unknown, but there is evidence that it may modulate gut flora and gut 
immunological function (Menezes, Andrade et al. 2006b). Certainly its effect on reducing gut 
inflammation is well demonstrated (Teahon, Smethurst et al. 1991a; Fell, Paintin et al. 2000a; 
Sanderson, Boulton et al. 1987) and it has also been shown to reduce bacterial load in small 
bowel bacterial overgrowth (Pimentel, Constantino et al. 2004a).
Although there is no evidence that treatment  with elemental  diet  is effective in ulcerative 
colitis (Hartman, Eliakim et al. 2009) a number of similarities between pouchitis and Crohn’s 
disease  suggest  that  treatment  with an elemental  diet  may be effective  in  pouchitis:  both 
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conditions  affect  the  small  bowel,  both  respond  to  treatment  with  antibiotics,  and  both 
improve with divergence of the faecal stream.
Aim
To establish whether an elemental diet could serve as an effective treatment for patients with 
chronic pouchitis. 
Primary end point
The number of patients in clinical remission after 4 weeks treatment with elemental diet.
4.2 Method
Ethical  permission  for  this  study was  granted  by  the  Brent  and  Harrow Research  Ethics 
Committee (ethics no. 06/Q0405/89). 
To be included in the study patients had to have symptomatic pouchitis with a pouch disease 
activity index (PDAI) (Sandborn, Tremaine et al.1994) ≥7. In addition patients had to have 
continued  symptoms  of  pouchitis  despite  four  weeks  treatment  with  a  combination  of 
ciprofloxacin  and  metronidazole  (Mimura,  Rizzello et  al.2002)  or  chronic  antibiotic 
dependent pouchitis (defined as four or more episodes of pouchitis per year which responds to 
antibiotic treatment  but recurs on withdrawal of antibiotic treatment)  (Shen, Brzezinski et  
al.2005). Patients had to be willing and well motivated to comply with the restrictions of an 
elemental diet treatment regime.
Exclusion criteria included a diagnosis of indeterminate colitis or Crohn’s disease, treatment 
with antibiotics or probiotics within the preceding two weeks, concurrent non-steriodal anti-
inflammatory drugs, corticosteroids or immunosuppressants.
A  flexible-pouchoscopy  was  performed,  the  Cleveland  Global  Quality  of  Life  score 
(CGQoL), Pouch Disease Activity Index (PDAI), and BMI were recorded.  In addition C-
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reactive protein (CRP) and haemoglobin were measured at baseline and repeated following 28 
days of elemental diet.
All patients were assessed by a dietitian and were prescribed elemental diet (E0208 SHS) as 
exclusive nutrition for 28 days according to their nutritional requirements. The only other 
food or liquids allowed were water, black tea and black coffee.
Patients  were  asked  to  keep  a  diary  to  include  symptoms  of  stool  frequency,  bleeding, 
abdominal cramps, amount of elemental diet consumed and any food eaten.
Statistical analysis
SPSS version 15 (SPSS inc. Chicago, Illinois, USA) was used for all statistical analysis. For 
the description of data, the median was calculated. Wilcoxon’s signed-ranks test was used to 
compare clinical  data before and after treatment with elemental  diet.  A two-tailed p-value 
<0.05 was considered significant.
4.3 Results
Nine patients  were recruited to the study,  of whom two were subsequently excluded, one 
because initial assessment suggested a diagnosis of Crohn’s disease, which was subsequently 
confirmed following further investigation, whilst the other withdrew from the study shortly 
after  starting  the intervention.  Therefore  seven patients  were studied,  of whom four were 
male. The median age was 41 (range 30-63) and the median number of years since RPC was 
10 (range 4-22). 
Clinical  data  for  each  patient  before  and  following  treatment  with  elemental  diet  are 
illustrated in table 4.1.
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Table 4.1.
Clinical data before and following treatment with elemental diet
Treatment with elemental diet resulted in a significant reduction in stool frequency (p= 0.028) 
and the PDAI symptoms score (P =0.039) and a trend towards an increase in the ability to 
defer defaecation (p= 0.078) but not the CGQOL score. In addition there was a trend towards 
an increase in CRP.  Two patients were in clinical remission following four weeks treatment 
with ED (primary end-point).
Pre-treatment Post-treatment
Patient 1 2 3 4 5 6 7 Median 1 2 3 4 5 6 7 Median P-
Value 
Ability to 
defer 
(minutes)
25 10 30 30 60 5 10 25 90 60 5 60 60 5 60 60 0.078
24hr. 
stool 
frequenc
y
11 10 12 11 13 14 31 12 6 3 8 6 5 15 15 6 0.028
PDAI 11 10 7 12 14 12 12 12 9 10 12 8 8 11 8 9 0.248
Clinical 
PDAI
3 4 2 3 4 4 4 4 0 1 2 1 1 4 0 1 0.039
CRP 10 17 11 <5 13 6 5 10.5 12 16 76 21 16 <5 13 16 0.063
CGQOL 0.5 0.5 0.4 0.3 0.5 0.6 0.4 0.5 0.
7
0.
7
0.
1
0.
5
0.
7
0.
2
0.
9
1 0.606
BMI 23.
5
26.
8
24.
5
20.
5
27.
5
28.
9
20.
8
24.5 23 26 23 20 24 27 20 23 0.018
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Figure 4.1. Clinical PDAI pre and post elemental diet
Figure 4.2. Stool frequency before and after elemental diet
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Figure 4.3 CGQOL before and following elemental diet
 
Figure 4.4.  BMI before and following elemental diet
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4.4 Discussion
Patients with chronic pouchitis are difficult to manage. Antibiotics remain the mainstay of 
treatment, however some patients develop side effects from antibiotic treatment and others do 
not respond to antibiotic therapy. In addition antibiotic resistance can develop in those treated 
with frequent courses of antibiotics or antibiotic maintenance therapy. Elemental diet is safe, 
free of side effects and if effective it could offer an alternative treatment for patients who 
develop antibiotic resistance or experience side effects to antibiotics. 
Although polymeric diets are more palatable (Zachos, Tondeur et al.2001), we chose to treat 
patients  with  elemental  diet  because  this  formulation  is  antigen  free  whereas  polymeric 
formulations contain whole proteins which may provoke immune mediated damage to pouch 
mucosa.  In  addition  although two weeks  treatment  has  been  reported  to  be  effective  for 
inducing remission (Riordan, Hunter et al. 1993) others have described a four week treatment 
regimen (Gorard, Hunt et al. 1993). We opted to treat patients for four weeks in order to 
maximise the opportunity for treatment success.
To the best of our knowledge this is the first study reporting the outcome of patients treated 
with elemental diet for pouchitis.  We have demonstrated that despite having undergone a 
colectomy well-motivated RPC patients are able to tolerate elemental diet. 
Five of the seven patients treated (71%) reported a reduction in stool frequency and there was 
also a significant reduction in the PDAI symptom score in these patients. In addition these 
five  patients  reported  an increase  in  their  quality  of  life  but  this  did  not  reach  statistical 
significance; this is important and may be related to the restrictive nature of elemental diet 
treatment and emphasises the importance of measuring quality of life in studies where the 
treatment  or intervention may have an independent impact  on quality of life.  All but one 
patient experienced a reduction in BMI following treatment with ED, both this and the quality 
of life scores recorded almost certainly reflect difficulty tolerating sufficient quantities of the 
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elemental formula. Indeed previous studies comparing liquid diet therapy and treatment with 
corticosteroids in adult patients report withdrawal rates of over 40% due to intolerance of the 
liquid diet (Malchow, Steinhardt et al. 1990), (Gorard, Hunt, et al.1993).
Despite symptomatic improvement there was no reduction in endoscopic or histological signs 
of  inflammation  suggesting  that  the  improvement  in  symptoms  which  occurred  in  some 
patients may be due to the effect  of consuming a low residue diet and not the underlying 
inflammatory  process.  However  it  should  be  appreciated  that  a  significant  proportion  of 
patients who achieve clinical remission following antibiotic treatment for chronic pouchitis do 
not  achieve  endoscopic  remission.  In  the  study described  in  Chapter  4  less  than  50% of 
patients who achieved clinical remission also achieved endoscopic remission. This has also 
been reported by others following both antibiotic and probiotic treatment (Madden, McIntyre 
et al.1994; Shen, Brzezinski et al.2005).
Treatment with elemental diet is very restrictive and consequently recruitment to this study 
was difficult.  In addition  for ethical  reasons only patients  who had failed or were poorly 
tolerant to antibiotic treatment were recruited to the study. Therefore the numbers included in 
this study were small and it is possible that the study may lack sufficient power to identify 
significant differences in the variables recorded.
In conclusion treatment with four weeks elemental diet appeared to improve the symptoms of 
chronic pouchitis in some patients but is not an effective strategy for inducing remission and 
cannot be recommended for the routine treatment of pouchitis. 
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Chapter 5
The prevalence and implications of pre-pouch ileitis
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5.1 Introduction
Several  studies have suggested that inflammation proximal  to the pouch, pre-pouch ileitis 
(PPI) occurs in patients with CD and not UC (Shen, Fazio et al. 2006b; Wolf, Achkar et  
al.2004). Other authors have reported PPI occurring in UC patients who were not taking non 
steriodal  anti-inflammatory drugs (Slatter,  Girgis et  al.2008; Calabrese,  Fabbri et  al.2007; 
Kuisma,  Jarvinen et  al.2004; Iwata,  Yamamoto et  al.2007). Inflammation proximal  to the 
pouch in UC patients has only recently been characterised. We have previously reported the 
histological findings associated with PPI and demonstrated that PPI is a histological entity 
distinct from Crohn’s disease (Bell, Price et al.2006). The incidence or prevalence of PPI has 
not been well studied and there are few published data on this condition. In one study of 107 
RPC patients, 14 percent developed PPI (Kuisma, Jarvinen et al.2004). In an earlier study by 
our group we demonstrated a prevalence of PPI of 2.6 percent. However the accuracy of these 
data was limited by the fact that it was not routine practice to assess prospectively all patients 
for PPI when the database at our institution was constructed. 
Flexible pouchoscopy is performed at our unit annually for FAP patients and UC patients with 
a previous history of dysplasia. In other patients it is performed every three years or at the 
time of pouch dysfunction.  It  is routine practice at  our institution to assess the pre-pouch 
ileum during flexible pouchoscopy.  The patients included in the study represent all pouch 
patients  who  were  endoscoped  during  the  study  period  and  include  patients  who  were 
asymptomatic  and  were  undergoing  pouch  surveillance  as  well  as  those  with  symptoms. 
Importantly,  as recommended by others (Shen, Achkar et al.2001a),  we prefer to confirm 
pouchitis with pouchoscopy and biopsy before starting treatment. Therefore we believe the 
patients in this study are representative of our RPC patient cohort. 
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Aim
To identify the prevalence of PPI found during pouchoscopy and to define the symptoms and 
outcome.
5.2 Method
A prospective database of all endoscopic procedures (Endosoft, Utech products, New York, 
USA) has been maintained at our institution since April 2004. Ethical permission to collect 
prospective and retrospective data  in RPC patients  was granted by the Brent  and Harrow 
Research Ethics Committee. We searched the endoscopy database for the terms “pouchitis” 
and “ileitis” in all pouchoscopy procedures performed between April 2004 and September 
2007. Individual reports were then checked and the hospital records reviewed. Patients with 
known Crohn’s disease and those taking non steroidal anti-inflammatory drugs were excluded 
from the study.
Chronic relapsing pouchitis  was  defined  as three or more  episodes  of pouchitis  per  year; 
chronic antibiotic dependent pouchitis as symptoms which were controlled when the patient 
was  maintained  on  a  single  antibiotic  but  promptly  returned  when  this  was  withdrawn; 
chronic  antibiotic  refractory pouchitis  as symptomatic  pouchitis  which did not respond to 
antibiotics (McLaughlin, Clark et al. 2008a); simple pouchitis as pouchitis which responded 
to a two week course of either ciprofloxacin or metronidazole and occurred less than three 
times  per  year;  asymptomatic  pouchitis  as  endoscopic  signs  of  inflammation  in  a  patient 
without symptoms of pouchitis.
Good pouch function was defined as a 24-hour stool frequency of less than ten and urgency 
was defined as the inability to defer for more than one hour.
Crohn’s disease had been excluded in all patients by (i). Histopathologic examination of the 
resected large bowel; (ii). Histopathologic examination of biopsies taken from the pouch and 
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pre-pouch  ileum at  the  index  pouchoscopy  and  at  previous  pouchoscopies;  (iii).  Clinical 
assessment including colonoscopy and examination of the anus.
Indeterminate  colitis  was  diagnosed  by  the  histopathologist  based  on  an  inability  to 
distinguish between UC and CD because features of both were present in the same surgical 
specimen (Price 1978). 
Statistical analysis
 Spearman’s correlation test was used to estimate the level of association between length of 
PPI and histological grade of pouchitis. A 2-tailed P value < 0.05 was considered significant.
5.3 Results
1448 pouchoscopies were performed on 742 patients. A total of 576 had UC or indeterminate 
colitis (IC) and 162 had FAP or hereditary non polyposis colorectal cancer (HNPCC).
237 (41 percent) UC patients and 17 (10 percent) polyposis patients had endoscopic signs of 
pouch inflammation. PPI was seen in 34 patients including 32 with UC, one with IC and one 
with FAP. All had concurrent pouch inflammation. Of all patients with pouch inflammation, 
34 (13 percent) had PPI. The signs of pre-pouch ileal inflammation identified at pouchoscopy 
included  friable  granular  mucosa,  mucous  exudate,  superficial  ulcers,  apthoid  ulcers  and 
confluent superficial ulceration. There was no correlation between the length of pre-pouch 
ileitis and histological grade of pouchitis (P= 0.345). The types of pouchitis in the 34 patients 
with concurrent PPI are shown in table 6.1. 
The overall prevalence of PPI was 5.7 percent in UC/IC patients and 0.6 percent in FAP. The 
median age of the patients with PPI was 44 (range, 22-69) years. Thirteen were female. All 
patients had had RPC performed with a covering ileostomy and the median interval from RPC 
to the index pouchoscopy was 9.7 years (range, 2-23 years). Only one patient was a smoker.
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Histology of the terminal ileum was available in 19 patients (the remainder had undergone a 
subtotal  colectomy before  referral).  Of  these  6  (19  percent)  had  histological  evidence  of 
backwash ileitis. Three patients had endoscopic evidence of ileal stricturing. The length of the 
inflamed pre-pouch ileum was recorded in 65 percent of cases, the median length measured 
was 10cm (range, 3-70cm). 
Pre-pouch ileitis; incidence and implications Chapter 6
Table 6.1.
Table to show number of patients with each type of pouchitis
Classification of pouchitis Number  of  patients 
with PPI
Chronic relapsing pouchitis 12
Chronic antibiotic dependent 
pouchitis
8
Chronic antibiotic refractory 
pouchitis
1
Simple pouchitis 7
Asymptomatic pouchitis 6
Total 34
Symptoms
 Six (18 percent) of the patients with PPI were asymptomatic. The remainder had symptoms 
which  included  increased  stool  frequency,  urgency,  and  abdominal  cramps.   Sixteen  (47 
percent)  patients  had good function and 18 (53 percent)  had poor function at  the time of 
endoscopic diagnosis. The median 24-hour stool frequency at diagnosis was 12 (range, 5-30). 
Nine (27 percent) patients suffered from abdominal cramps, four (12 percent) experienced 
bleeding per anum, and 14 (41 percent) had urgency.
Follow-up
The median length of follow-up from the index pouchoscopy of the 34 patients with PPI was 
12 months  (range,  2-47 months).   No patient  had been reclassified to Crohn’s disease.  A 
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further  pouchoscopy following the  index pouchoscopy was performed  in  25 (74 percent) 
patients and 12 (48 percent) of these had evidence of continuing PPI.
At follow-up 21 (62 percent) PPI patients had good and 13 (38 percent) had poor function. 
The median 24-hour stool frequency was 8 (range, 4-22). Four (12 percent) patients suffered 
from abdominal  cramps  and 5 (15  percent)  experienced  urgency.  No patient  experienced 
bleeding per anum.
5.4 Discussion
Inflammation  of  the  ileal  reservoir  (pouchitis)  is  common  following  RPC  for  UC. 
Inflammation  proximal  to  the  pouch (PPI)  has  previously  been  described  (Bell,  Price et  
al.2006) and some authors have suggested that  its presence may indicate  Crohn’s disease 
(Pardi & Sandborn 2006b; Wolf,  Achkar et  al.2004). In this  study,  pre-pouch ileitis  only 
occurred in patients with concurrent pouchitis. Overall the prevalence of pouch inflammation 
was 237 (41 percent) patients out of 576 in the UC cohort and 17 (10 percent) out of 162 in 
the polyposis cohort. Many of these patients were asymptomatic and therefore do not fulfil 
the criteria for a diagnosis of pouchitis. Of the 254 patients with pouch inflammation 34 (13 
percent)  had  simultaneous  PPI,  suggesting  that  pouchitis  and  PPI  may  have  a  similar 
aetiology.  None  of  the  patients  with  PPI  in  this  study  had  Crohn’s  disease  on 
histopathological criteria and none was diagnosed with Crohn’s disease during the subsequent 
follow-up of a median period of over twelve months. One of the limitations of this study is 
that symptomatic patients are more likely to have undergone pouchoscopy than asymptomatic 
patients.  Our  findings  are,  however,  similar  to  an  earlier  study of  107 patients  (Kuisma, 
Jarvinen et al.2004). Of these 58 percent were found to have pouchitis of whom 24 percent 
developed PPI during a period of seven years from the original RPC.  In this earlier study PPI 
did not develop in any patient without pouchitis. The overall prevalence of PPI (including 
patients with and without pouchitis) was 14 percent. Our findings differ from a previous study 
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of PPI following RPC that included 87 patients with available colectomy histology (27 with 
CD, 32 with IC, and 28 with UC) (Wolf, Achkar et al.2004). In that study PPI was found in 
twelve CD patients,  eight IC patients,  and four UC patients.  All  of the UC patients  were 
taking non steriodal anti-inflammatory drugs (NSAIDs). Importantly UC patients not taking 
NSAIDs with PPI were not assessed. The authors’ concluded that the presence of PPI in 
patients not taking NSAIDs was strongly suggestive of CD.
A recent study using video capsule endoscopy in 16 patients with refractory pouchitis found 
confluent small bowel inflammation extending from the duodenum to the ileum in all cases. 
The lesions  found in  that  study included erythema/oedema,  erosions,  aphthous  ulceration, 
atrophia, scarring, cobblestone patterns and deep/fissuring ulcers with progressive worsening 
distally. There was no histological evidence of Crohn’s disease in biopsies from the pouch or 
pre-pouch  ileum  (Calabrese,  Fabbri,  et  al.2007).  In  contrast,  in  the  present  study, 
inflammation  in  the  PPI  extended  for  a  short  distance  only  beyond  the  pre-pouch  ileal 
junction, suggesting that pan small-bowel inflammation is uncommon and that in most cases 
with  PPI  the  disease  is  limited  to  the  distal  ileal  segment.   PPI  occurred  in  all  types  of 
pouchitis and not only in patients with refractory disease. It also occurred in six patients with 
asymptomatic pouch inflammation. Backwash ileitis is thought to occur secondary to reflux 
of large bowel contents into the small bowel (Haboubi 2006). In this study the presence of 
backwash ileitis prior to RPC did not seem to be related to the subsequent development of 
PPI, suggesting that PPI may also be the result  of reflux of pouch contents rather  than a 
genetic predisposition. 
Conclusion
The prevalence of PPI in patients with UC/IC after RPC is 5.7 percent, and it occurs in 13 
percent of patients with pouch inflammation. The present data have shown that PPI is often 
asymptomatic  and  that  it  is  always  accompanied  by  inflammation  in  the  ileal  reservoir. 
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Although  our  findings  suggest  that  PPI  does  not  predict  missed  Crohn’s  disease,  this 
diagnosis should be strongly considered with appropriate investigations in patients with PPI 
and pouchitis who do not respond to antibiotics.
It is likely that just as (backwash) ileitis seen at colonoscopy is not diagnostic of Crohn’s 
disease without adequate histological criteria, neither is PPI diagnostic of Crohn’s disease in 
RPC patients.
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The treatment of Pre-pouch ileitis
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6.1 Introduction
Infliximab is the only drug therapy reported to be effective in the treatment  of pre-pouch 
ileitis (PPI). In a study reporting seven patients  with chronic relapsing pouchitis  and pan-
small  bowel  inflammation  in  which  Crohn’s  disease  had  been  excluded  on  histological 
grounds, symptomatic and endoscopic resolution was demonstrated in six by video-capsule 
endoscopy (Calabrese, Gionchetti et al.2008).
UC is classically described as a disease confined to the large bowel, although inflammation 
can occur in the last few centimetres of the small intestine termed backwash ileitis (BI). The 
incidence of BI has been reported to be 18% at colectomy (Haskell, Andrews, Jr. et al. 2005). 
BI is generally accepted to be secondary to reflux of the large bowel contents into the small 
intestine (Morson BC 1980) and treatment of this condition is the same for UC uncomplicated 
by BI.
The aetiology of PPI may be similar to that of BI. Thus PPI may be secondary to reflux of 
pouch faecal  contents  into the pre-pouch ileum.  We therefore hypothesised  that  treatment 
effective  for  chronic  relapsing  pouchitis  would  be  effective  in  patients  with  pouchitis 
complicated by PPI. A series of 13 patients  treated with ciprofloxacin and metronidazole, 
followed up and assessed by flexible pouchoscopy, is reported.
Aim
To determine whether antibiotic therapy could be an effective therapy for pre-pouch ileitis.
Primary end point
Clinical remission following four weeks treatment with ciprofloxacin and metronidazole.
6.2 Method
Seventeen  consecutive  patients  with  symptomatic  PPI  undergoing  flexible  pouchoscopy 
during  the  12  month  study  period  were  identified.  Patients  were  included  if  they  had 
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macroscopic  and  microscopic  pre-pouch  ileal  inflammation.  All  patients  had  an  original 
diagnosis  of  UC.  Crohn’s  disease  had  been  excluded  by  histological  examination  of  the 
resected large bowel and by subsequent histopathological examination of biopsies taken at the 
index pouchoscopy and at previous pouchoscopies. 
PPI was defined endoscopically as continuous inflammation extending proximally from the 
pouch in a patient with proven UC. Patients were excluded from the study if they: (i). had 
received any treatment for pouchitis in the preceding month including antibiotics, probiotics, 
corticosteroids and 5-ASA medications. (ii). had taken NSAIDs in the last two months, (iii). 
had a previous history of allergy or intolerance to either antibiotic agent, or (iv). if another 
cause of pouch dysfunction was  known or later identified such as stricturing, pelvic sepsis, or 
fistulation. 
Treatment was initiated following endoscopic diagnosis of PPI with 28 days of ciprofloxacin 
500mg bd and metronidazole 400mg bd. 
Evaluation of disease activity
Symptomatic, endoscopic and histological assessment was performed before and following 
treatment. The pouchitis disease activity index (PDAI) (Sandborn, Tremaine et al.1994) was 
recorded with a score of ≥7 taken as indicative of pouchitis. A diagnosis of PPI was made 
when the presence of  macroscopic  inflammation  in  the ileum proximal  to  the pouch was 
confirmed by histopathological examination of biopsies. The extent of inflamed pre-pouch 
ileum was measured in centimetres on extubation following straightening of the colonoscope. 
Biopsies were taken from the inflamed pre-pouch ileum.
Following completion of treatment,  a repeat flexible  pouchoscopy and clinical  assessment 
were undertaken. Patients were assessed as to whether endoscopic and clinical remission had 
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been achieved. Clinical remission was defined as a clinical PDAI score of 0 (possible range 
0= asymptomatic to 6= severe symptoms) and endoscopic remission by the absence of signs 
of pre-pouch ileal inflammation at flexible pouchoscopy combined with normal histology of 
the  pre-pouch ileum.  In those who failed  to  achieve  complete  remission,  assessment  was 
made as to whether they had achieved a significant reduction in the length of inflamed pre-
pouch ileum, the clinical PDAI score and stool frequency.
Statistical analysis
Wilcoxon’s  signed-rank test  was  used  to  compare  pre-treatment  and  post  treatment  stool 
frequency,  clinical  PDAI,  histological  score,  endoscopic  score  and  the  length  (cm)  of 
inflamed pre-pouch ileum.
Spearman’s  rank  was  used  to  evaluate  for  a  correlation  between  the  pouch  histological 
inflammatory score and the length of PPI.
6.3 Results
Seventeen patients with PPI were identified during the study period. Of these, 14 (12 male) 
met  the  entry  criteria  and  were  included  in  the  study.  All  patients  were  found  to  have 
concurrent pouchitis, thirteen patients had at least three previous episodes of pouchitis, in one 
patient this was the first presentation. Only three patients had a previous history of PPI. All 
patients were non-smokers. Of the three excluded patients, one had pelvic sepsis identified on 
magnetic resonance imaging, one had a previous history of adverse effects to ciprofloxacin 
and one patient failed to attend for assessment. All patients tolerated the medication.
Patient demographics are listed in Table 6.2, and treatment results in Table 6.3.
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Pouch endoscopic and histological scores before and after treatment are listed in Table 6.4.
Table 6.1.
Clinical and demographic data of study subjects
Median (Range)
Age (years) 38 (22-58)
Interval  from  closure  of  ileostomy 
(months)
69.5 (9-289)
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Table 6.2. 
Pre-pouch ileitis disease activity before and after treatment
Table 6.3.
Pouch endoscopic and histological scores before and after treatment
Median (range)
Pre-treatment
Median (range)
Post-treatment
P-value
Pouch  histological 
score 
3  (1-4) 1.5 (0-3) 0.022
Pouch  endoscopic 
score
6 (5-6) 2 (0-6) 0.039
Pre-antibiotic treatment Post antibiotic-treatment P-value
Median Range Median Range
PPI length 10cm 3-20 1cm 0-10 0.007
24hr. stool frequency 12 8-20 6 4-17 0.002
PDAI 12 8-14 3.5 0-10 0.001
Clinical PDAI 3 2-4 0 0-2 0.002
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Figure 6.1. Length of  inflamed pre-pouch ileum (cm) before and after treatment
Figure 6.2. Stool frequency before and after treatment
Figure 6.3. Clinical PDAI before and after treatment 
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Figure 6.4. Flow chart of medium term outcomes
12 (86%) of  14 patients  entered  symptomatic  remission  with a  PDAI clinical  score of  0 
(primary end-point). The median 24hr stool frequency reduced from 12 (range 8-20) to 6 (4-
17); (p= 0.002) following treatment. The median  length of PPI decreased significantly from 
10cm (range 3-20cm) before antibiotic therapy to 1cm  (range 0-10cm) (p=0.007) following 
antibiotic therapy.
Overall nine (64%) of 14 patients had either resolution of PPI or a reduction in length of PPI 
(p= 0.007). In total seven (50%) patients had complete resolution of PPI. The pre-treatment 
median PDAI was 12 (range 8-14) and post treatment 3.5 (range 0-10) (p =0.001).  In all 
patients who achieved complete endoscopic remission this was confirmed histologically. Only 
four (31%) patients achieved resolution of pouch inflammation.
In all patients where antibiotic therapy failed to produce a reduction in length of PPI there was 
also no improvement in pouch inflammation. Despite a lack of complete mucosal resolution 
Treatment of Pre-pouch ileitis Chapter 6
of  PPI  in  seven (50%) patients  only two (18%) remained  symptomatic.  One of  the  non-
responders had a previous history of PPI and one did not.
There was no correlation between the inflammatory score of the pouch body and the length of 
inflamed pre-pouch ileum (p= 0.338).
Of  the  12  patients  who  responded  to  treatment,  nine  were  commenced  on  maintenance 
ciprofloxacin treatment because of a history of chronic relapsing pouchitis in line with our 
own and others recommended guidelines (McLaughlin,  Clark et al.2008a; Carter, Lobo et  
al.2004). Two of these nine later relapsed and seven remained in remission (median time until 
relapse 4.3 months (range 1-11 months). Three received no maintenance treatment and have 
remained in remission. The overall median length of follow-up was 11.7 months (range 1-20 
months).
6.4 Discussion
RPC may be complicated by pouchitis and PPI. The disabling symptoms associated with PPI 
are  similar  to  pouchitis  and  include  increased  stool  frequency and urgency.  Because  PPI 
seems to only occur in patients with concurrent pouchitis (McLaughlin, Clark et al.2009) it is 
difficult to differentiate symptoms arising from pouchitis and PPI. Only one other study has 
evaluated treatment for PPI. In this study all had pan-small bowel inflammation demonstrated 
by video-capsule endoscopy. Nine of ten patients entered clinical remission and eight entered 
both  clinical  and  endoscopic  remission  following  treatment  with  infliximab  (Calabrese, 
Gionchetti et al.2008).
Treatment of Pre-pouch ileitis Chapter 6
In the present open-label study we have demonstrated that a combination of ciprofloxacin and 
metronidazole  appears  effective  in  the  treatment  of  symptomatic  PPI.  Despite  entering 
symptomatic  remission 45% of the patients  treated did not achieve mucosal  healing.  This 
discrepancy between symptoms and endoscopic findings has been previously described in the 
treatment of pouchitis with both antibiotics and budesonide (Madden, McIntyre et al.1994; 
Sambuelli, Boerr et al.2002) and also in the maintenance of pouchitis remission with VSL#3 
(Shen, Brzezinski et al.2005).
It is interesting that in all patients in whom there was no reduction in the length of inflamed 
pre-pouch  ileum  there  was  also  no  improvement  in  pouch  inflammation.  These  factors 
suggest that pouchitis and PPI behave in a similar manner to treatment and may have a similar 
aetiology in which bacteria have a significant role in both conditions.
Faecal coliform testing in pouchitis Chapter 7
Chapter 7
Faecal coliform testing to identify effective antibiotic therapies for patients 
with antibiotic-resistant pouchitis
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 7.1 Introduction
There  is  good  evidence  that  treatment  of  pouchitis  with  empirical  antibiotics  such  as 
ciprofloxacin or metronidazole is effective in the majority of patients (Mimura, Rizzello et  
al.2002; Gionchetti, Rizzello et al.1999; Shen, Fazio et al.2007a). Unfortunately up to 20% of 
patients  develop  refractory  or  rapidly  relapsing  pouchitis  (Mowschenson,  Critchlow et  
al.2000; Hurst, Chung et al.1998; Madiba & Bartolo 2001).
Refractory pouchitis is defined as pouchitis which does not respond to a two week course of a 
single antibiotic agent (Mimura, Rizzello et al.2002). Combination antibiotic regimes such as 
ciprofloxacin and rifaximin, ciprofloxacin and metronidazole and ciprofloxacin and tinidazole 
have been shown to achieve remission in 63%, 82% and 87.5% of patients with refractory 
pouchitis (Mimura,  Rizzello et al.2002; Gionchetti,  Rizzello et al.1999; Shen, Fazio et al.  
2007a). However one of the limitations of these studies is that patients were not reviewed 
after  metronidazole/rifaximin/tinidazole  was  withdrawn and follow-up  was  not  performed 
after four weeks. In our clinical practice a significant number of patients relapse soon after 
withdrawal of metronidazole and this may be considered treatment failure. Metronidazole and 
tinidazole  treatment  cannot  be  given long term because  of  the  possibility  of  neurological 
complications and rifaximin is not available in the UK. Oral budesonide has been shown to be 
effective in those with refractory pouchitis who do not respond to a single antibiotic in an 
open label study (Gionchetti, Rizzello et al.2007c) but a randomised double blind study of 
budesonide  enemas  found  it  no  more  effective  than  metronidazole  (Sambuelli,  Boerr,  et  
al.2002). Its efficacy in those who fail to respond to combined antibiotic (ciprofloxacin and 
rifaximin or ciprofloxacin and metronidazole) is not known. 
Many patients with chronic pouchitis require long-term ciprofloxacin maintenance therapy, 
some  of  whom relapse  despite  continuing  ciprofloxacin.  This  presents  a  difficult  clinical 
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problem, and long term studies have shown that  up to  10% of pouch failures  are  due to 
pouchitis (Tulchinsky, Hawley et al. 2003a; Fazio, Ziv et al.1995). 
Aim
We aimed to develop a novel approach for patients with pouchitis who do not respond to 
empirical  antibiotic  therapy or  have  relapsed  on long term therapy using  faecal  coliform 
sensitivity analysis to determine the choice of antibiotic treatment.
Primary end point
Clinical  remission  following  four  weeks  treatment  with  an  antibiotic  guided  by  faecal 
coliform sensitivity testing.
7.2 Method 
Fresh faecal samples were collected from 15 symptomatic patients with active pouchitis who 
were under regular follow-up at  one institution.  All  had a history of chronic relapsing or 
chronic antibiotic dependent pouchitis. No patient took non-steriodal anti-inflammatory drugs 
in the three months before the study. All patients were non-smokers.
The presence of acute inflammation had been confirmed by endoscopy and histopathological 
examination  of  biopsies  from the  ileal  reservoir  in  all  cases.  The  patients  fell  into  three 
clinical  categories:  pouchitis  defined as a pouch disease activity index (PDAI) (Sandborn, 
Tremaine,  et  al.1994) of ≥7 not entering symptomatic  remission  following four weeks of 
treatment with ciprofloxacin and metronidazole; pouchitis which relapsed within two weeks 
of  withdrawal  of  metronidazole;  pouchitis  which  relapsed  whilst  on  maintenance 
ciprofloxacin therapy. Patients with Clostridium difficile infection and other causes of pouch 
135
Faecal coliform testing in pouchitis Chapter 7
dysfunction (e.g. retained anorectal cuff inflammation, pelvic sepsis and stricture formation) 
were excluded.
Faecal samples were inoculated onto Iso-sensitest agar (Oxoid) using a sterile swab and rotary 
spreader.  Antibiotic  discs  containing  ciprofloxacin,  trimethoprim,  cefalexin,  co-amoxiclav, 
nitrofurantoin, cefpodoxime, cefuroxime, and cefixime were added. We incubated plates at 
370 C for 18 – 24 hours and recorded the sensitivity patterns. 
Details  of symptoms, endoscopic appearances and histological features were recorded and 
combined to yield a PDAI score before treatment. The patients were then given antibiotic 
treatment based on the antibiotic sensitivity and were assessed four weeks later. 
Those  with  a  PDAI symptom score  of  0  (possible  range  0=  asymptomatic  to  6=  severe 
symptoms)  were  considered  to  be  in  clinical  remission.  Those  who  entered  remission 
continued maintenance antibiotic treatment and were continuously followed up in line with 
our usual practice which consisted of telephone or outpatient review at three to six monthly 
intervals.
Statistical analysis
Wilcoxon’s  rank-sign  test  was  used  to  compare  pre-treatment  and  post  treatment  stool 
frequency and the pre and post treatment PDAI clinical score. A probability value of <0.05 
was regarded as statistically significant.
7.3 Results
Fifteen patients  were studied, 11 (73%) were male.  One patient had familial  adenomatous 
polyposis,  one had indeterminate colitis and the remainder had UC. All patients  had RPC 
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performed with a covering ileostomy. The median age was 39 years (range 20-73) and the 
median interval from ileostomy closure was 52 months (range 20-242).
Of the 15 patients 13 (87%) had failed previous treatment with a combination of ciprofloxacin 
and metronidazole and two (13%) had relapsed whilst taking ciprofloxacin as maintenance 
treatment.  The median PDAI pre-treatment  was 12 (range 7-25). A flow chart  of patients 
tested and outcomes is included in figure 7.1.
All  stool samples grew coliforms resistant to ciprofloxacin,  6 (40%) were resistant to co-
amoxiclav, 9 (60%) were resistant to cefixime and 11 (73.3%) were resistant to trimethoprim. 
Five  (33.3%)  samples  contained  extended  spectrum  beta-lactamase  (ESBL)  producing 
organisms. The dominant organism/groups identified from culture are listed in table 7.1.
Antibiotic treatment was given as follows: 8 (53%) were treated with co-amoxiclav, 2 (13%) 
with trimethoprim and 5 (33%) with colistin.
The defaecatory frequency and PDAI data before and after treatment are illustrated in tables 
7.2  and  7.3.  After  four  weeks  of  treatment  12  (80%) patients  were  in  clinical  remission 
(clinical PDAI score= 0), (primary end-point). There was a significant reduction in the 24 
hour defaecatory frequency (p= 0.001) and the PDAI symptom score (p= 0.001).
All  patients  who responded to treatment  have remained under continuous follow-up for a 
median of 7 months (range 3-13). During this time three (20%) patients relapsed following 
19, 24 and 182 days of treatment respectively. These patients underwent repeat testing which 
confirmed the development  of resistance to the antibiotic being given and in two patients 
demonstrated  the re-development  of  sensitivity  to ciprofloxacin.  These patients  were then 
maintained on an alternating antibiotic regime cycling between two sensitive antibiotics every 
two weeks. These patients and the others remain in clinical remission. 
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Figure 7.1. Recruitment and follow-up of study patients
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Table 7.1.
Table to illustrate the organism/group identified following faecal culture in 15 patients
Dominant organism/group* Number of patients
Coliforms:
E. Coli
Klebsiella
Coliform, not classified further 
6
1
12
Pseudomonas 1
Morganella Morganni 1
* In several patients more than one group/organism was identified.
Table 7.2.
Defaecatory frequency before and following antibiotic treatment 
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Pre-antibiotic treatment Post  antibiotic-
treatment
P-value
Median Range Median Range
24hr.  stool 
frequency 
14 8-25 9 2-25 0.001
PDAI  symptom 
score
4 2-4 0 0-4 0.001
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Table 7.3.
PDAI symptom score before and following antibiotic treatment
Subject no. PDAI  symptom 
score 
Before treatment
PDAI symptom score 
After treatment
1 2 0
2 3 0
3 3 0
4 3 0
5 4 0
6 4 0
7 4 0
8 4 0
9 4 0
10 4 0
11 4 0
12 4 0
13 4 3
14 4 3
15 4 4
7.4 Discussion
The management of patients with refractory pouchitis who do not respond to conventional 
antibiotic treatment and those who relapse whilst on long-term antibiotic maintenance therapy 
presents a difficult clinical problem. 
This study has shown that when combination antibiotic treatment has been ineffective this 
appears to be due to bacterial resistance developing, probably secondary to previous antibiotic 
treatment and selection of another antibiotic based on bacterial sensitivity analysis can result 
140
Faecal coliform testing in pouchitis Chapter 7
in remission in around 80% of patients. In common with other studies, and reflecting usual 
clinical  practice,  few  of  the  patients  in  this  study  had  a  repeat  pouchoscopy  following 
treatment (Gionchetti, Rizzello et al.2000b) (Mimura, Rizzello et al.2004). Instead the PDAI 
symptom score was used to determine response. It could be argued that there may be little 
point in repeating endoscopy since many patients  do not achieve mucosal  healing despite 
entering clinical remission (Madden, McIntyre et al.1994) and the goal of this treatment was 
to achieve symptom control.
The microbiological method described in this study is simple and although unable to identify 
the  bacterial  species  responsible  for  the  inflammatory  process,  the  correlation  between 
identifying bacterial resistance to ciprofloxacin and the prediction of which new antibiotic 
would be clinically beneficial was high. 
It has previously been suggested that pouchitis may represent a spectrum of diseases leading 
some authors to classify patients as antibiotic responsive and antibiotic resistant (Yu, Shao et  
al. 2007). The knowledge that bacteria resistant to certain antibiotics are the cause of failure 
in most patients who do not respond to empirical antibiotic treatment suggests that this is not 
the case. It is likely that all forms of pouchitis are due to bacteria and the difference in clinical 
response is due to the varying resistance pattern of the bacteria between individuals. 
The  open-label  design,  small  sample  size  and  the  selection  of  patients  who  had  failed 
empirical antibiotic therapy were limitations of this study.
Of the three patients where treatment was unsuccessful two had ESBL-producing bacteria. 
Such organisms are difficult to treat and this may explain the lack of therapeutic benefit. The 
third patient had indeterminate colitis and thus it is possible that the lack of response may be 
because this patient has unrecognised Crohn’s disease and not UC. 
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In  conclusion  this  study demonstrates  that  faecal  coliform sensitivity  testing  and targeted 
antibiotic treatment appears highly effective in treating patients with resistant pouchitis. We 
recommend that all pouchitis patients who fail standard treatment or develop resistance whilst 
on  long-term  maintenance  treatment  undergo  faecal  coliform  sensitivity  testing  to  guide 
antibiotic therapy.  We propose an investigation and treatment  algorithm for these patients 
(figure 7.2). 
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Figure 7.2. Investigation and treatment algorithm for pouchitis patients who fail to respond to 
standard therapy or relapse on maintenance antibiotic therapy
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Chapter 8
Efficacy and Complications of maintenance antibiotic therapy
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8.1 Introduction
Following  restorative  proctocolectomy  most  patients  experience  satisfactory  function  but 
some develop pouchitis  which is the most common long-term complication.  A cumulative 
incidence of 50% has been quoted in the literature but in the majority of patients  (simple 
pouchitis)  the  condition  is  easily  treated  with  a  short  course  of  a  single  antibiotic 
(McLaughlin,  Clark et  al.2008a).  There is  good evidence  of the efficacy of antibiotics  in 
simple pouchitis, (Madden, McIntyre et al.1994) recurrent or refractory pouchitis (Mimura, 
Rizzello, et al.2002; Shen, Fazio et al.2007a) and pouchitis complicated by pre-pouch ileitis 
(McLaughlin, Clark et al.2008). However in about 5% of RPC patients, inflammation in the 
pouch becomes chronic and presents a difficult management problem (Hahnloser, Pemberton 
et  al.2007;  Lovegrove,  Tilney et  al.2006).  Most  of  these  patients  have  chronic  antibiotic 
dependent  pouchitis  (CADP)  defined  as  four  or  more  episodes  of  pouchitis  per  year  or 
persistent, rapidly relapsing pouchitis that responds to antibiotic therapy but relapses within 
two weeks of withdrawing treatment (Shen, Remzi et al. 2008). CADP accounts for about 
10% of failures after RPC (defined as indefinite diversion or pouch excision) (Tulchinsky, 
Hawley et  al.2003a).  The British Society of Gastroenterology IBD guidelines  recommend 
maintenance  therapy  with  the  probiotic  VSL#3  or  ciprofloxacin  in  patients  with  CADP 
(Carter, Lobo, & Travis 2004) with the aim to provide good function and quality of life in 
such patients and therefore to prevent pouch failure.  
The potential risks of maintenance antibiotic therapy include the development of antibiotic 
resistance  and  Clostridium difficile  infection  (CDI).  Certain  antibiotics  also  have  specific 
potential complications. Quinilones have been associated with tendon rupture (Mehlhorn & 
Brown 2007) and co-amoxiclav may cause intrahepatic cholestasis (Dowsett,  Gillow et al. 
1989).  Metronidazole cannot be used as maintenance treatment because it causes peripheral 
neuropathy. The incidence of CDI in hospitalised patients has doubled between 1993-2003 
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(McDonald,  Owings et  al.2006;  Pepin,  Valiquette et  al.2004) and  treatment  with 
fluoroquinolones  appears  to  be  a  significant  risk  factor  in  the  general  population  (Pepin, 
Saheb et  al.2005). In  RPC patients  CDI has  been  reported  in  a  significant  proportion  of 
patients without symptoms (Shen, Jiang et al.2008) but may also cause symptomatic pouchitis 
(Shen, Goldblum et al. 2006). 
Extended spectrum beta-lactamases (ESBL) produced by some bacteria inactivate beta-lactam 
type antibacterials. More than 150 ESBLs have been described and known risk factors for the 
development of ESBL-producing bacteria include the use of ciprofloxacin and metronidazole 
(Bradford 2001). Pouchitis  resulting from the development  of ESBL-producing bacteria  is 
difficult  to  treat  as  few  oral  antibiotics  available  are  effective  against  ESBL-producing 
bacteria. We have recently shown that faecal coliform sensitivity testing can detect bacterial 
resistance patterns in faecal samples from pouchitis patients who fail to respond to empirical 
antibiotic therapy or who relapse on ciprofloxacin maintenance therapy. In some cases ESBL-
producing  bacteria  were  identified.  This  approach  reliably  predicts  clinical  response  to 
specific antibiotic therapy in most cases (McLaughlin, Clark, et al.2009a) and is now used at 
our  institution  in  all  patients  who  fail  empirical  antibiotic  treatment  or  who  relapse  on 
maintenance antibiotic therapy. In patients treated with maintenance therapy the antibiotic is 
continued  if  the  patient  remains  sensitive  to  it.  Where,  however,  relapse  and  resistance 
develop, two weekly alternating antibiotics are continued as maintenance therapy.
Aim
Because  of  the  potential  complications  of  long  term  antibiotics  we  have  reviewed  our 
treatment of patients with CADP on long term maintenance therapy with particular reference 
to safety and effectiveness. 
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Primary end point
The number of patients who continued antibiotic maintenance treatment.
8.2 Method
A prospective database of all RPC patients undergoing regular follow-up is maintained at our 
institution. Ethical permission to collect prospective and retrospective data in RPC patients 
has been granted by the local ethics committee. Chronic antibiotic dependent pouchitis had 
been diagnosed in patients with a history of four or more episodes of pouchitis per year or 
those  with a  history of  persistent,  rapidly relapsing  pouchitis  that  responded to  antibiotic 
therapy but relapsed within two weeks of withdrawing treatment (Shen, Remzi et al.2008). 
Pouchitis had been diagnosed following endoscopic and histologic assessment with a pouch 
disease activity index (PDAI) (Sandborn, Tremaine et al.1994) of ≥7.
All  patients  prescribed  maintenance  antibiotic  therapy  for  chronic  antibiotic  dependent 
pouchitis  at  our  institution  are  reviewed  at  three  months,  six  months  and  then  at  least 
annually. Data including defaecatory frequency, the clinical component of the pouch disease 
activity index (PDAI), results of blood tests, side effects, the patient’s perception of treatment, 
the CQOL score as well as the dose and type of antibiotic are recorded.  Fresh faecal samples 
are tested in our hospital laboratory for Clostridium difficile toxins A and B using an enzyme 
linked immunosorbent assay (Meridian Bioscience, Cincinnati, Ohio, USA).
The case notes and database entries of all patients on maintenance antibiotic therapy were 
reviewed.  All  patients  receiving  maintenance  antibiotic  therapy  had  been  diagnosed  with 
endoscopically  proven  CADP.  Other  possible  causes  of  poor  function  such  as  retained 
anorectal  cuff  (cuffitis),  Crohn’s disease or  anastomotic  stricture  had been excluded.  Pre-
pouch  ileitis  was  defined  as  ileal  inflammation  proximal  to  the  pouch  and  mucosal 
inflammation  was defined  as  score of  >2 in  the endoscopic component  of the PDAI.  No 
patient had been taking non-steriodal anti-inflammatory drugs in the three months prior to 
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developing  CADP  and  no  patient  included  in  the  study  was  taking  non-steriodal  anti-
inflammatory drugs regularly.  Induction of remission had been achieved according to our 
previously  published  protocol  using  four  weeks  of  ciprofloxacin  and  metronidazole 
(McLaughlin,  Clark et  al.2008a)  and where  this  failed  faecal  coliform sensitivity  testing 
(McLaughlin, Clark, et al.2009b). 
Statistical analysis
SPSS version 15 (SPSS inc. Chicago, Illinois, USA) was used for all statistical analysis. For 
the description of data, the median and range were calculated. 
The Mann-Whitney U test (paired, two tailed) was used to compare the time until relapse 
between the mucosal healing and non-mucosal healing groups. Fisher’s exact test (two tailed) 
was used to compare differences in the rate of relapse between CADP pouchitis patients with 
and without pre-pouch ileitis.
A two-tailed P-value less than 0.05 was considered significant.
8.3 Results
Patients
Twenty five patients (16 males) of median age of 44 (range 21-64) years were identified. Two 
had FAP and 23 UC. All had CADP and in addition 10 (40%) had concomitant pre-pouch 
ileitis. Initial antibiotic therapy had induced endoscopic and clinical remission in 13 (52%) 
patients. All 25 patients were treated with long term antibiotics (figure 8.1, table 8.1). The 
median duration of treatment from its inception to the present assessment was 15.8 (range 3-
62) months. The antibiotics used included ciprofloxacin (14), co-amoxiclav (8), colistin (1), 
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nitrofurantoin (2), cefixime (1), trimethoprim (2) (table 8.1). Five patients were on 2 weekly 
alternating antibiotic combination therapy (Chart 1).
In total six (24%) patients developed antibiotic resistance and relapsed. The median time to 
relapse  was 6 (range 1-11)  months.  Of these,  three (50%) had  achieved mucosal  healing 
following the initial induction of remission. There was no difference in the time to relapse 
whether or not mucosal healing had been achieved (p= 0.18).  Five of the six patients who 
relapsed had pre-pouch ileitis which was significantly associated with an increased risk of 
developing antibiotic resistance and subsequent relapse (p= 0.023).  Twenty four (96%) of the 
patients subjectively reported an improved quality of life since starting maintenance therapy. 
One patient discontinued the treatment because of lack of benefit, the remainder continued 
antibiotic maintenance treatment (primary end-point). 
Efficacy of treatment 
Twenty two (88%) patients provided faecal samples and all were negative for CDI. Faecal 
coliform sensitivity testing (McLaughlin, Clark et al.2009a) confirmed the development of 
antibiotic resistance in the six (24%) patients who relapsed during the study period. Relapse 
was associated  with the development  of  ESBL-producing  bacteria  in  one patient.  All  six 
patients were subsequently treated with an antibiotic selected after faecal coliform sensitivity 
testing.  Alternating  antibiotic  combinations  included  co-amoxiclav  and nitrofurantoin,  co-
amoxiclav and trimethoprim, co-amoxiclav and cefixime. None of these six patients suffered 
a further relapse and all were in remission at the time of assessment.  
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Side effects 
Three patients developed side effects: One patient reported an episode of vaginal candidiasis 
which  responded  to  treatment  with  topical  clotrimazole.  One  experienced  intermittent 
dyspepsia and another patient  reported occasional  nausea.  Full  blood count, liver function 
tests and urea and electrolytes remained within the normal range in all patients. No patient 
stopped treatment because of side effects.
Function and Quality of life
Patients  treated  with maintenance antibiotic  therapy undergo clinical  review at  3 monthly 
intervals for 6 months, again at 12 months and then at least annually. The median frequency 
of defecation at the last clinical review was 7 (range 4-11)/24 hr. The median clinical PDAI 
was 0 (range 0-1) and the median CGQOL score was 0.72 (range 0.7-0.97).
Table 8.1. Oral antibiotics given
Antibiotic agent Dose Frequency
Ciprofloxacin 500mg Bd
Nitrofurantoin 100mg Tds
Cefixime 200mg Bd
Colisitin 3million units Tds
Co-amoxiclav 625mg Tds
Trimethoprim 200mg Bd
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Table 8.2.
Table to illustrate differences in time until relapse between patients who did and did not achieve 
mucosal healing after induction of remission.
Mucosal healing 
group
Non-mucosal 
healing group
Total
Number of 
patients
13 12 25
No. who 
relapsed
3 3 6
Median time 
until relapse 
(range)
11  (6-11) 6 (1-10) 8 (1-11)
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Table 8.3. Quality of life data
Subject 
no.
CQOL Subjective change  in  QOL (worse/ 
unsure/improved) 
1 0.8 Improved
2 0.6 Unsure
3 0.5 Improved
4 0.9 Improved
5 0.8 Improved
6 0.97 Improved
7 0.8 Improved
8 0.7 Improved
9 0.7 Improved
10 0.7 Improved
11 0.6 Improved
12 0.7 Improved
13 0.8 Improved
14 0.7 Improved
15 0.5 Improved
16 0.7 Improved
17 0.7 Improved
18 0.9 Improved
19 0.7 Improved
20 0.7 Improved
21 0.8 Improved
22 0.7 Improved
23 0.9 Improved
24 0.9 Improved
25 0.9 Improved
Median 0.73
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8.4 Discussion
The importance  of endoscopic remission following a symptomatic  episode of pouchitis  is 
unknown. Asymptomatic pouch and pre-pouch ileal inflammation are known to occur and do 
not  require  treatment  (McLaughlin,  Clark et  al.2008), and  there  is  no  evidence  that 
asymptomatic pouch inflammation predicts the development of symptomatic pouchitis.
Improvements in quality of life do not always mirror a physician’s assessment of improved 
clinical outcome perhaps because of side effects of the treatment used. The Cleveland Global 
Quality of Life score (CGQOL) is a validated score used in our own and others’ clinical 
practice to assess the quality of life of RPC patients undergoing follow-up (Fazio, O'Riordain 
et al. 1999). These data were included in this study to ensure that quality of life in our patients 
on antibiotic maintenance therapy as well as functional outcome was maintained. 
Surprisingly  there  is  no  published  study  demonstrating  that  maintenance  treatment  with 
immunomodulators is effective in pouchitis. On the contrary two groups have reported the 
occurrence of pouchitis in patients treated with azathioprine for primary sclerosing cholangitis 
(Rowley, Candinas, et al.1995; Zins, Sandborn et al.1995) suggesting that immunomodulators 
may not be effective in preventing pouchitis.
VSL#3 treatment has been shown to be effective maintenance therapy for patients with CADP 
who  respond  to  combinations  of  ciprofloxacin  and  rifaximin  and  ciprofloxacin  and 
metronidazole, but this benefit was only shown in patients with complete (a score of 0 in the 
endoscopic component of the PDAI) (Gionchetti,  Rizzello et al.2000b) or nearly complete 
mucosal healing (a score of <2 in the endoscopic component of the PDAI) (Mimura, Rizzello 
et al.2004) because patients who did not meet these criteria were excluded from the studies. 
This  limits  the use of  VSL#3 in  clinical  practice  as  not  all  patients  who achieve  clinical 
remission will also achieve endoscopic remission (Shen, Remzi et al.2008; Madden, McIntyre 
et al.1994). In addition experience with VSL#3 in clinical  practice has been disappointing 
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with less than 20% of  patients  able  to  maintain  remission (Shen, Brzezinski,  et  al.2005). 
Therefore many patients with CADP require maintenance antibiotic therapy. 
Only one other study has reported the outcome of patients with CADP treated with antibiotic 
maintenance  therapy.  In  this  study 51 patients  who had achieved clinical  and endoscopic 
remission with antibiotic monotherapy or combination therapy were treated with rifaximin 
maintenance  therapy.  Those  who  achieved  clinical  but  not  endoscopic  remission  were 
excluded. Of these 51 patients 65%, 58% and 3% were in remission at 3, 12 and 24 months 
(Shen, Remzi et al.2008). Because this study and two studies using the probiotic VSL#3 as 
maintenance treatment specifically excluded patients who did not achieve endoscopic as well 
as clinical remission following antibiotic induction treatment, there has been no evidence to 
support maintenance treatment in this patient group. 
In the current study all patients with CADP, including those who failed to enter endoscopic 
remission following induction antibiotic therapy were included. Failure to enter endoscopic 
remission did not predict an increased risk of relapse. This suggests that patients who do not 
enter endoscopic remission can be effectively treated with maintenance antibiotic therapy and 
repeat  flexible  pouchoscopy  to  confirm  endoscopic  remission  in  these  patients  is  only 
required if treatment with VSL#3 is being considered. 
In this study pre-pouch ileitis was associated with a significantly increased risk of developing 
antibiotic resistance. It is unclear why this should be the case but it is possible that pouchitis 
complicated by pre-pouch ileitis may be associated with a higher bacterial load predisposing 
to the development of bacterial resistance.
We have demonstrated that in selected RPC patients maintenance antibiotic therapy appears 
to be safe and effective at least in the medium term. The differences between our results and 
those of a study using rifaximin (Shen, Remzi et al.2008) may in part be explained by our 
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practice  of  faecal  coliform  sensitivity  testing  in  patients  who  are  resistant  to  empirical 
antibiotic  therapy  or  who  develop  resistance  and  subsequently  relapse  on  maintenance 
treatment with treatment customised to each individual’s faecal coliform sensitivity patterns 
(chapter 7) (McLaughlin, Clark et al.2009a). In the same study we demonstrated that pouchitis 
associated with ESBL-producing bacteria may be treated with colistin or nitrofurantoin. In the 
current open-label study these findings have been extended and demonstrate that these agents 
can also be used as maintenance therapy.
Reassuringly,  no patient developed  Clostridium difficile infection and only a small number 
developed side effects, none of whom required withdrawal of the treatment. All but one of the 
patients  in  the  present  study reported  an  improved  quality  of  life.  The  remainder  of  the 
patients were keen to continue treatment. Nevertheless we recommend that all patients who 
commence maintenance antibiotic therapy are kept under clinical review.  The development 
of resistance to the treating antibiotic is of concern and it is possible that further resistance 
will  occur with increased length of follow-up. We have developed what appears to be an 
effective strategy for managing this and suggest a protocol for the management of patients 
who relapse on maintenance antibiotic treatment (see figure 8.3).
There were limitations to our study. The number of patients included in the study was small, 
but this represents the small proportion of RPC patients with CADP despite recruitment from 
a  specialist  centre.  Furthermore  this  study represents  an  open-label  report  of  our  clinical 
experience. Ideally an RCT comparing antibiotic treatment with placebo should be conducted 
to validate our findings.
In summary this uncontrolled study suggests that long term maintenance antibiotic therapy is 
an  effective  treatment  for  patients  with  chronic  relapsing  or  chronic  antibiotic  dependent 
pouchitis  (CADP) including  those without  mucosal  healing.  A proportion of patients  will 
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develop antibiotic resistance. However it appears that at least in the short term this can be 
managed by faecal coliform sensitivity testing and an alternating antibiotic regime.
Figure 8.1. Pie-chart illustrating maintenance antibiotics given
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Figure 8.2. Flow chart outlining patient outcomes
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Figure 8.3.  Investigation and treatment algorithm for patients who relapse on maintenance 
antibiotic therapy.
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Chapter 9
Extended spectrum beta-lactamase producing bacteria and Clostridium 
difficile in pouchitis patients
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9.1 Background
Antibiotic  therapy  remains  the  mainstay  of  treatment  in  pouchitis.  Long-term follow  up 
studies have shown that pouchitis is responsible for 10% of all pouch failures (Tulchinsky, 
Hawley et al.2003a). The causes for this are not understood but the development of antibiotic 
resistance  is  likely  to  be  important.  Where  patients  are  exposed  to  repeated  antibiotic 
treatment, antibiotic resistance or Clostridium Difficile infection (CDI) may develop. CDI is 
an important  cause of treatment  failure in patients  presenting with symptoms of pouchitis 
(Shen, Goldblum et al.2006; Mann, Pitt et al.2003) and should be excluded in those with 
pouchitis (McLaughlin, Clark et al.2008a; Shen & Lashner 2006).
Extended  spectrum  beta-lactamases  (ESBL)  are  bacterial  enzymes  which  are  capable  of 
hydrolysing penicillins, broad-spectrum cephalosporins and monobactams. ESBL-producing 
bacteria are frequently resistant to many classes of antibiotic because other determinants of 
resistance  are  often  linked  on  the  same  plasmid  (Rupp  &  Fey  2003).  Fluoroquinilone 
resistance in particular is associated with ESBL-producing bacteria (Spanu, Luzzaro et  al. 
2002; Paterson, Mulazimoglu et al. 2000) and exposure to antibiotics including ciprofloxacin 
and  metronidazole  is  associated  with  an  increased  risk  of  developing  ESBL-producing 
bacteria (Bradford 2001).
 Recently we have shown that ESBL-producing bacteria may in some cases be associated with 
antibiotic refractory pouchitis (McLaughlin, Clark, et al.2009a). This may be particularly seen 
in  recurrent  or  refractory  pouchitis  which  may  require  frequent  courses  of  antibiotics  or 
continuous  maintenance  treatment.  In  practice  development  of  resistance  to  the  usually 
prescribed antibiotics may limit the treatment options to nitrofurantoin or colistin.  CDI has 
recently been reported to be present in 18% of stool samples from RPC patients (Shen, Jiang, 
et al.2008) but the prevalence of ESBL-producing bacteria is unknown. It is likely that ESBL-
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producing bacteria  in stool may predispose to an increased risk of resistant pouchitis  and 
pouch failure in the long-term due to failure of medical therapy. 
Aim
To assess the prevalence of ESBL and CDI in RPC patients with recurrent or refractory 
pouchitis under follow-up at our institution over a one year period.
9.2 Method
Ethical  permission  was  granted  by the  Brent  and  Harrow Research  Ethics  Committee  to 
collect prospective and retrospective data on RPC patients entered into the St Mark’s Hospital 
Pouch Registry.   Consecutive patients  with recurrent  or refractory pouchitis  attending the 
outpatient clinic with a diagnosis of recurrent or refractory pouchitis were identified over a 
one  year  period.  Demographic  details  were  recorded.  Clinical  details  were  also  obtained 
including the presence of symptomatic pouchitis at the time of testing, the interval from RPC, 
and a  previous  history of  pre-pouch ileitis.  Information  on whether  mucosal  healing  was 
achieved  following  antibiotic  treatment  and  whether  the  patient  was  taking  maintenance 
antibiotic therapy was also obtained. An enzyme linked immunosorbent assay was used to 
detect  CDI toxins A and B (Meridian Bioscience,  Cincinnati,  Ohio,  USA) and a standard 
culture  technique  (McLaughlin,  Clark et  al.2009a)  was  used  to  identity  ESBL-producing 
bacteria in fresh faecal samples.
Statistical analysis
SPSS version 15 (SPSS inc. Chicago, Illinois, USA) was used for all statistical analysis. For 
the description of data, the median and range were calculated. The Mann-Whitney U test (two 
tailed)  was  used  to  compare  continuous  data  and  a  chi-squared  test  used  to  compare 
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categorical variables between the ESBL negative and ESBL positive groups. A two-tailed P-
value less than 0.05 was considered statistically significant.
9.3 Results
Forty nine patients of median age 42 years (range 20-69) and male gender in 35 (71%) were 
studied.  Two patients had familial adenomatous polyposis, three indeterminate colitis (IC) 
and the remainder had ulcerative colitis (UC). The median interval from RPC to the present 
assessment was 8 (range 1-25).
ESBL-producing organisms  were identified  in faecal  samples  from 16 (33%) patients,  29 
(59%) were receiving treatment with maintenance antibiotic therapy and 10 (20%) of these 
patients had symptomatic pouchitis at the time of faecal testing. Clinical and statistical data 
for the ESBL positive and ESBL negative groups are shown in Table 9.1.  As can be seen 
ESBL-producing bacteria were not associated with age, sex and the number of years from 
RPC.  They  were,  however,  associated  with  a  history  of  pre-pouch  ileitis  complicating 
pouchitis and maintenance antibiotic therapy. 
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Table 9.1.
Clinical and statistical data for ESBL positive and ESBL negative groups
ESBL Negative ESBL Positive p-value
Number of patients (%) 33 (67%) 16 (33%)
Median age (range) years 42 (21-58) 45 (20-69) 0.991
Male 22 (67%) 13 (81%) 0.363
No.  of  years  from  RPC 
median(range)
8.5 (1-25) 6.5 (2-25) 0.539
History of pre-pouch ileitis (%) 8 (50%) 9 (69%) 0.033
Maintenance  antibiotic  therapy 
(%)
16 (48.5%) 13 (81.3%) 0.037
Mucosal  healing  following 
antibiotic treatment
14 (44%) 9 (56%) 0.419
9.4 Discussion
In the light of a recent report indicating that ESBL-producing bacteria may in some cases be 
the cause of antibiotic  refractory pouchitis  (Mclaughlin  S.D, Clark S.K et  al. 2009a),  we 
reviewed the prevalence of ESBL in our RPC patients with recurrent or relapsing pouchitis. 
The study has shown that ESBL-producing bacteria occur in 35% of such patients and that 
maintenance  antibiotic  therapy  and  pre-pouch  ileitis  are  associated  with  a  significantly 
increased risk of ESBL-producing bacteria. 
None of the patients studied had CDI in contrast with a recent finding by Shen et al in 115 
RPC patients  undergoing  routine  pouchoscopy  for  surveillance  or  investigation  of  pouch 
dysfunction.  These  authors  reported  a  prevalence  of  18% of  which  5% of  patients  were 
symptomatic. In a univariate analysis male gender and a previous history of left sided colitis 
were associated with an increased risk of CDI after RPC.  Surprisingly the previous use of 
antibiotics was not (Shen, Jiang et al.2008). The reasons for the difference in the prevalence 
of  CDI  in  the  present  study  and  that  of  Shen  et  al are  unclear  but  could  be  related  to 
differences in antibiotic use and the prevalence of CDI in the local hospital and community 
population.  Alternatively  differences  in  methodology might  have  been responsible.  In  the 
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present study fresh faecal samples were analysed in an on-site microbiology laboratory on the 
day of collection whereas in the study by Shen et al samples were temporarily stored and then 
sent by overnight courier for analysis at an off-site laboratory. There were limitations to the 
study, the number of patients was small but this reflects the fact that recurrent or refractory 
pouchitis is uncommon in the general RPC population.
It is known that exposure to antibiotics is associated with an increased risk of developing 
ESBL-producing bacteria (Bradford 2001) therefore the finding in the present study is not 
surprising. Why ESBL-producing bacteria are more common in patients with pre-pouch ileitis 
is less clear. Pre-pouch ileitis may be due to reflux of pouch contents into the pre-pouch ileum 
(McLaughlin,  Clark,  et  al.2009).  It  can  be  treated  with  combination  antibiotic  therapy 
(McLaughlin, Clark et al.2008), suggesting that bacteria are important in its aetiology. The 
present  study  has  also  shown  that  patients  with  pre-pouch  ileitis  or  those  treated  with 
maintenance antibiotic therapy are at increased risk of developing ESBL-producing bacteria, 
it is possible that pouchitis complicated by pre-pouch ileitis may be associated with a higher 
bacterial load predisposing to the development of bacterial resistance (McLaughlin, Clark et  
al.2009)
The  majority  of  patients  in  the  present  study  with  ESBL-producing  bacteria  were 
asymptomatic.  It  is possible,  however,  that  over time symptomatic  pouchitis  secondary to 
ESBL-producing bacteria (ESBL pouchitis) may occur. Treatment of ESBL pouchitis with 
nitrofurantoin or colistin is effective in most but not all cases (Mclaughlin S.D, Clark S.K et  
al.2009a)  and it  is  likely that  resistance  to  these antibiotics  may develop  over  time.  It  is 
therefore possible that the carriage of ESBL-producing coliforms may be associated with an 
increased risk of pouch failure.
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Strategies  to  reduce  antibiotic  use  and therefore  to  reduce  the  risk of  developing  EBSL-
producing bacteria and CDI should be considered. We have now adopted the practice that all 
patients  with  symptoms  of  pouchitis  undergo  endoscopy to  confirm the  diagnosis  before 
initiating  antibiotic  treatment  and  we  have  been  careful  not  to  treat  patients  before  the 
diagnosis is confirmed.in patients where a flexible pouchoscopy cannot be arranged promptly 
measurement of faecal calprotectin to confirm a clinical diagnosis of pouchitis is a reasonable 
alternative (Johnson, Maestranzi et al.2008). Non antibiotic treatment such as corticosteroids 
would clearly reduce the risk but while oral budesonide was shown to be effective in patients 
with refractory pouchitis who did not respond to single antibiotic therapy in an open label 
study (Gionchetti,  Rizzello et  al.2007c) unfortunately a randomised double blind study of 
budesonide  enemas  found  it  no  more  effective  than  metronidazole  (Sambuelli,  Boerr et  
al.2002). 
The  probiotic  VSL#3 has  been  shown to  be  effective  in  patients  with  mild  to  moderate 
pouchitis (defined as a PDAI between 7-12). In an open-label study Gionchetti  et al studied 
23 patients who were treated with VSL#3 (900 billion bacteria) twice daily for four weeks. 
Sixteen (69%) entered remission. Following this, maintenance treatment was continued with 
1800  billion  bacteria  per  day,  and  all  16  patients  maintained  remission  for  6  months 
(Gionchetti,  Rizzello et  al. 2007b).  It  is  possible  that  VSL#3  may  be  an  alternative  to 
antibiotic agents in the treatment of mild to moderate pouchitis.
Maintenance therapy with an antibiotic or VSL#3 is recommended in patients with chronic 
antibiotic  dependent  pouchitis  (Carter,  et  al.2004).  Treatment  with  VSL#3  rather  than 
ciprofloxacin  maintenance  therapy  may  reduce  the  risk  of  developing  ESBL-producing 
bacteria  or  CDI,  evidence  of   efficacy  is  limited  to  patients  with  complete  (Gionchetti, 
Rizzello et al.2000b) or near-complete mucosal (Mimura, Rizzello et al.2004) healing. This 
may partly explain the disappointing results reported in an open-label clinical study (Shen, 
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Brzezinski et al.2005). A further trial of probiotics in preventing pouchitis was reported by 
Gosselink et al (Gosselink, Schouten et al. 2004a). In this non-randomised study 39 patients 
were treated with 300mg of Lactobacillus GG for 3 years following closure of the ileostomy. 
The control group was an historical cohort of 127 patients who had previously undergone 
RPC. The prevalence of pouchitis at three years was 7% in the treated compared with 29% in 
the untreated group. Importantly, however, there was no difference in the number of patients 
who developed recurrent pouchitis.  In a double-blind, placebo controlled trial to study the 
efficacy  of  VSL#3 in  preventing  the onset  of  pouchitis  following RPC, 40 patients  were 
randomised  to VSL#3,  3 g  per day (900 billion  bacteria)  or placebo for 12 months.  The 
former group had a significantly lower prevalence of pouchitis compared with the latter (10% 
vs  40%;  P  < 0.05)  (Gionchetti,  Rizzello et  al.2005).  Studies  with  longer  follow-up  are, 
however, required to establish whether VSL#3 can reduce the risk of developing recurrent 
pouchitis and more importantly the risk of refractory pouchitis and possible pouch failure. 
Surprisingly there is no evidence that immunomodulators are useful in pouchitis. Although 
there  are  no  controlled  studies,  two groups  have  reported  the  occurrence  of  pouchitis  in 
patients  treated with azathioprine for primary sclerosing cholangitis  (Rowley,  Candinas et  
al.1995; Zins, Sandborn et al.1995) suggesting that they may not be effective.
In  conclusion  ESBL-producing  bacteria  occur  in  35%  of  our  patients  with  recurrent  or 
refractory pouchitis. Further research is required to establish whether ESBL are common in 
all  RPC patients  or as is  more  likely,  occur only in those who have received  antibiotics. 
Because ESBL pouchitis is difficult to treat, longitudinal studies are warranted to establish 
whether the presence of ESBL-producing bacteria predisposes to pouch failure. Although the 
present study supports the policy that antibiotics for pouchitis should be limited wherever 
possible it is, however, unlikely that they can be avoided in most patients with recurrent or 
refractory pouchitis.
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Discussion and proposals for future work
The studies presented in this thesis have increased our understanding of both the pathogenesis 
and treatment of pouchitis. 
We have increased our understanding of the role of antibiotic therapy in the management of 
pouchitis and importantly describe a new clinical approach using faecal coliform sensitivity 
testing  to  treat  patients  who  would  previously  have  been  described  as  having  antibiotic 
refractory pouchitis. We hope this will prevent pouch failure (conversion to end-ileostomy) in 
a significant proportion of patients with refractory pouchitis.  The appreciation that patients 
failed treatment with empirical antibiotic therapy because of antibiotic-resistant coliforms and 
that treatment with an antibiotic guided by sensitivity testing is effective suggests that the 
mechanism of action by which antibiotic therapy is effective in the treatment of pouchitis is 
due to the reduction in bacterial load and consequent reduction in stimulus to the immune 
system rather than the elimination of a particular species or group of bacteria.
The analysis of the mucosal associated microbiota using 16s rRNA sequencing has produced 
a  detailed  description  of  the  microbiota  found  in  both  patients  with  pouchitis  and  non-
pouchitis. In this study we found a reduction in bacterial diversity in patients with pouchitis 
but only minor differences in the microbiota between UC pouchitis and non-pouchitis groups, 
this data and the findings from the faecal coliform sensitivity testing study both demonstrate 
that pouchitis is not due to a specific organism. 
We did  however  identify  significant  differences  in  microbiota  between the  UC and FAP 
patient cohorts, with reduction in bacterial diversity and also a reduction in F. prausnitzii and 
B.  vulgatus  in  the UC  RPC  patient  group.  This  is  an  interesting  finding,  given  that  F. 
prausnitzii  has previously been postulated to have anti-inflammatory properties and may be 
reduced in IBD patients (Sokol, Pigneur et al.2008; Sokol, Seksik et al.2009). It is therefore 
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possible that this may in part explain the increased frequency of pouchitis  in UC patients 
compared to FAP patients.
The  pathogenesis  and  implications  of  pre-pouch  ileitis  have  not  been  well  described 
previously;  our  research  group have  previously  shown that  pre-pouch  ileitis  is  a  distinct 
histological  entity  different  from  Crohn’s  disease.  The  work  outlined  in  this  thesis  has 
increased our understanding of this condition and its clinical implications; we have shown 
that pre-pouch ileitis does not predict a missed diagnosis of Crohn’s disease or an increased 
risk of pouch failure and like pouchitis it can be asymptomatic. Furthermore in common with 
pouchitis it can be treated with antibiotic therapy, this suggests that the aetiology of pouchitis 
and pre-pouch ileitis is similar. 
We have also shown that antibiotic maintenance therapy is effective in both uncomplicated 
chronic antibiotic dependent pouchitis and also pouchitis complicated by pre-pouch ileitis but 
that  pre-pouch  ileitis  is  associated  with  an  increased  risk  of  relapse  secondary  to  the 
development of antibiotic resistant organisms. 
Pre-pouch ileitis  is  also associated  with  an increased  risk of  developing  ESBL-producing 
bacteria. These findings further implicate bacteria in the pathogenesis of pre-pouch ileitis and 
suggest that an increased bacterial load or perhaps more pathogenic bacteria are present in 
those with pre-pouch ileitis. 
Much of the focus of our studies has included treatment with antibiotics, however the finding 
that resistant organisms and more importantly the presence of ESBL-producing bacteria in 
patients  who  did  not  respond  to  empirical  antibiotic  therapy  prompted  us  to  study  the 
prevalence of ESBL-producing organisms in patients with chronic relapsing and refractory 
pouchitis. Our finding that treatment with long-term antibiotic therapy was associated with an 
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increased  risk  of  developing  ESBL-producing  organisms  is  important  and  should  prompt 
clinicians to reduce antibiotic usage in patients with pouchitis wherever possible. We further 
investigated the probiotic VSL#3 in patients with chronic relapsing and refractory pouchitis as 
an alternative to maintenance antibiotic therapy, but found this to be an effective maintenance 
treatment in only 18% of the patients studied. We also studied the efficacy of an elemental 
diet  as  treatment  in  patients  with chronic  relapsing  or  antibiotic  refractory pouchitis,  and 
whilst this improved symptoms in some patients it did not induce remission and cannot be 
recommended as an alternative to antibiotic therapy. 
Future bacteriology studies should focus on studying the changes in microbiota  following 
antibiotic treatment to establish whether there are differences in the microbiota between those 
who do and those who do not achieve mucosal healing following antibiotic treatment and 
establish  whether  successful  remission  is  achieved  by  a  reduction  in  the  overall  pouch 
microbial  population  or  whether  specific  changes  in  the  microbiota  are  associated  with 
successful  remission.  A  further  study  should  evaluate  whether  the  mucosa-associated 
microbiota in pre-pouch ileitis is different or whether there is an increased bacteria load in 
this group of patients compared to those with pouchitis only. 
Clinical  studies  should  focus  on  establishing  the  optimal  length  of  time  that  antibiotic 
maintenance therapy is required and a formal study of the efficacy of immunomodulators in 
chronic antibiotic dependent pouchitis with the aim to reduce antibiotic usage is long overdue.
 A larger study of the incidence of ESBL-producing bacteria should be performed to include 
all RPC patients (including FAP patients) with the aim to establish whether ESBL-producing 
bacteria  are common in the RPC population and if there is an association with long-term 
pouch failure (secondary to refractory pouchitis).  Finally research should focus on finding 
alternatives to antibiotics for the treatment of acute pouchitis.
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Table 10.1
UC pouchitis and UC non-pouchitis family level data
Family UC non-pouchitis UC pouchitis  
Mean Median Range 
(lower)
Range 
(upper)
Mean Median Range 
(lower)
Range 
(upper)
P-value
Lachnospiraceae 14.00 0.97 0.00 54.81 10.19 3.12 0.00 35.00 0.492
Ruminococcaceae 2.81 0.00 0.00 10.08 1.07 0.00 0.00 3.33 0.763
Veillonellaceae 2.48 1.69 0.00 6.73 2.97 0.31 0.00 18.89 0.584
Clostridiaceae 0.72 0.27 0.00 3.18 8.27 2.78 0.00 40.85 0.154
Erysipelotrichaceae 1.16 0.00 0.00 5.41 0.21 0.00 0.00 1.67 0.441
Lactobacillaceae 0.11 0.00 0.00 0.91 0.00 0.00 0.00 0.00 0.317
Steptococcaceae 4.49 2.70 0.00 10.81 0.83 0.31 0.00 2.61 0.040
Enterococcaceae 0.00 0.00 0.00 0.00 0.62 0.00 0.00 1.96 0.064
Peptostreptococcaceae 1.83 0.00 0.00 10.65 3.36 1.81 0.00 10.37 0.340
Staphylococcaceae 0.29 0.00 0.00 1.18 0.26 0.00 0.00 2.06 0.644
Bacillaceae 0.50 0.00 0.00 2.25 0.58 0.00 0.00 3.09 0.702
Carnobacteriaceae 0.00 0.00 0.00 0.00 0.15 0.00 0.00 1.22 0.317
Other Firmicutes 0.28 0.00 0.00 1.18 0.23 0.00 0.00 1.83 0.644
Fusobacteriaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Coriobacteriaceae 0.37 0.00 0.00 2.52 0.00 0.00 0.00 0.00 0.144
Microbacteriaceae 0.21 0.00 0.00 1.12 0.23 0.00 0.00 1.83 0.644
Propionibacteriaceae 8.19 3.47 0.00 31.25 3.37 2.30 0.00 14.43 0.399
Gordoniaceae 0.07 0.00 0.00 0.53 0.00 0.00 0.00 0.00 0.317
Corynebacteriaceae 0.12 0.00 0.00 0.96 0.26 0.00 0.00 2.06 0.927
Actinomycetaceae 0.00 0.00 0.00 0.00 0.44 0.00 0.00 2.44 0.144
Intrasporangiaceae 0.00 0.00 0.00 0.00 0.25 0.00 0.00 1.96 0.317
Nocardioidaceae 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.65 0.317
Micrococcaceae 0.93 0.00 0.00 7.41 0.16 0.00 0.00 1.31 0.927
Other 0.07 0.00 0.00 0.59 0.00 0.00 0.00 0.00 0.317
Rhodobacteraceae 0.83 0.72 0.00 2.25 0.56 0.00 0.00 1.98 0.466
Caulobacteraceae 0.38 0.00 0.00 1.35 0.73 0.50 0.00 1.96 0.487
Sphingomonadaceae 1.09 0.56 0.00 4.05 2.62 1.21 0.00 9.52 0.388
Bradyrhizobiaceae 0.93 0.00 0.00 6.25 0.26 0.00 0.00 2.06 0.538
Aurantimonadaceae 0.14 0.00 0.00 1.12 0.00 0.00 0.00 0.00 0.317
Methylobacteriaceae 0.28 0.00 0.00 1.68 0.76 0.00 0.00 3.09 0.783
Rhodospirillaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Acetobacteraceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Comamonadaceae 2.64 1.09 0.00 10.81 5.23 3.55 0.83 20.73 0.141
Burkholderiaceae 0.96 0.76 0.00 2.70 0.97 0.52 0.00 3.57 0.826
Rhodocyclaceae 0.90 0.00 0.00 4.05 0.12 0.00 0.00 0.93 0.441
Alcaligenaceae 1.01 1.27 0.00 2.25 0.12 0.00 0.00 0.93 0.026
Neisseriaceae 0.07 0.00 0.00 0.53 0.08 0.00 0.00 0.61 0.927
Oxalobacteraceae 0.35 0.00 0.00 1.59 0.71 0.47 0.00 2.22 0.334
Desulfobulbaceae 0.00 0.00 0.00 0.00 1.60 0.00 0.00 12.80 0.317
Desulfovibrionaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Enterobacteriaceae 17.56 20.69 0.84 27.68 32.77 40.89 0.61 62.62 0.248
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Moraxellaceae 15.32 13.46 0.00 36.49 15.50 13.10 0.00 49.48 0.793
Pseudomonadaceae 2.68 0.45 0.00 17.99 0.53 0.00 0.00 2.38 0.487
Xanthomonadaceae 1.01 0.45 0.00 3.17 0.97 0.42 0.00 3.74 0.911
Pasteurellaceae 2.83 0.00 0.00 17.99 0.52 0.00 0.00 1.83 0.763
Bacteroidaceae 5.74 0.27 0.00 25.45 0.82 0.00 0.00 4.76 0.643
Prevotellaceae 4.99 0.00 0.00 28.57 0.75 0.00 0.00 3.09 0.673
Porphyromonadaceae 0.80 0.30 0.00 2.52 0.30 0.00 0.00 0.93 0.418
Flexibacteraceae 0.26 0.00 0.00 1.12 0.26 0.00 0.00 2.06 0.644
Flavobacteriaceae 0.07 0.00 0.00 0.53 0.00 0.00 0.00 0.00 0.317
Rikenellaceae 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.93 0.317
Sphingobacteriaceae 0.00 0.00 0.00 0.00 0.13 0.00 0.00 1.03 0.317
Other Bacteroidetes 0.40 0.00 0.00 2.25 0.00 0.00 0.00 0.00 0.144
Verrucomicrobiaceae 0.14 0.00 0.00 1.12 0.08 0.00 0.00 0.65 0.927
Table 10.2
FAP pouchitis and FAP non-pouchitis family level data
Family FAP non-pouchitis FAP pouchitis  
Mean Median Range 
(lower)
Range 
(upper)
Mean Median Range 
(lower)
Range 
(upper)
P-value
Lachnospiraceae 16.16 17.06 7.69 25.35 28.88 28.22 27.38 31.03 0.025
Ruminococcaceae 9.64 4.27 1.65 27.46 5.23 2.59 0.00 13.10 0.655
Veillonellaceae 1.33 1.10 0.00 3.42 1.64 0.00 0.00 4.91 0.647
Clostridiaceae 4.37 0.56 0.00 18.01 3.38 0.61 0.00 9.52 0.879
Erysipelotrichaceae 0.22 0.00 0.00 1.10 0.79 0.00 0.00 2.38 0.558
Lactobacillaceae 0.00 0.00 0.00 0.00 0.57 0.00 0.00 1.72 0.197
Steptococcaceae 1.60 1.90 0.00 3.85 5.09 0.61 0.00 14.66 0.879
Enterococcaceae 0.11 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.439
Peptostreptococcaceae 0.11 0.00 0.00 0.55 0.00 0.00 0.00 0.00 0.439
Staphylococcaceae 1.10 0.47 0.00 2.75 0.00 0.00 0.00 0.00 0.124
Bacillaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Carnobacteriaceae 0.11 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.439
Other Firmicutes 0.19 0.00 0.00 0.95 0.00 0.00 0.00 0.00 0.439
Fusobacteriaceae 0.52 0.00 0.00 2.11 0.00 0.00 0.00 0.00 0.242
Coriobacteriaceae 0.23 0.00 0.00 1.13 0.40 0.00 0.00 1.19 0.558
Microbacteriaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Propionibacteriaceae 4.13 0.55 0.00 15.82 0.00 0.00 0.00 0.00 0.124
Gordoniaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Corynebacteriaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Actinomycetaceae 0.52 0.00 0.00 2.11 0.98 1.23 0.00 1.72 0.525
Intrasporangiaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Nocardioidaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Micrococcaceae 0.57 0.56 0.00 1.42 0.00 0.00 0.00 0.00 0.124
Other 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Rhodobacteraceae 2.32 0.00 0.00 10.17 0.29 0.00 0.00 0.86 0.608
Caulobacteraceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Sphingomonadaceae 0.53 0.00 0.00 1.69 0.20 0.00 0.00 0.61 0.608
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Bradyrhizobiaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Aurantimonadaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Methylobacteriaceae 0.53 0.55 0.00 1.13 0.00 0.00 0.00 0.00 0.124
Rhodospirillaceae 2.31 0.00 0.00 11.54 0.00 0.00 0.00 0.00 0.439
Acetobacteraceae 0.11 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.439
Comamonadaceae 0.94 0.00 0.00 2.82 0.20 0.00 0.00 0.61 0.608
Burkholderiaceae 3.60 1.71 0.95 12.09 0.20 0.00 0.00 0.61 0.024
Rhodocyclaceae 0.22 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.242
Alcaligenaceae 3.58 4.40 0.47 5.63 2.40 2.45 0.00 4.76 0.456
Neisseriaceae 0.42 0.00 0.00 1.65 0.00 0.00 0.00 0.00 0.242
Oxalobacteraceae 0.30 0.00 0.00 0.95 0.20 0.00 0.00 0.61 0.864
Desulfobulbaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Desulfovibrionaceae 0.14 0.00 0.00 0.70 0.00 0.00 0.00 0.00 0.439
Enterobacteriaceae 8.06 5.65 0.00 21.33 17.40 10.71 1.84 39.66 0.456
Moraxellaceae 6.00 0.00 0.00 18.64 3.48 0.00 0.00 10.43 0.608
Pseudomonadaceae 0.11 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.439
Xanthomonadaceae 0.31 0.00 0.00 1.10 0.20 0.00 0.00 0.61 0.864
Pasteurellaceae 0.20 0.00 0.00 0.55 0.20 0.00 0.00 0.61 0.864
Bacteroidaceae 11.18 12.09 3.95 17.95 12.81 7.76 0.00 30.67 0.655
Prevotellaceae 15.85 13.38 0.00 41.03 15.43 15.34 0.00 30.95 1.000
Porphyromonadaceae 2.27 0.56 0.47 6.34 0.00 0.00 0.00 0.00 0.022
Flexibacteraceae 0.09 0.00 0.00 0.47 0.00 0.00 0.00 0.00 0.439
Flavobacteriaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Rikenellaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Sphingobacteriaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Other Bacteroidetes 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
Verrucomicrobiaceae 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.000
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Table 10.3
Total UC and total FAP family level data
Family UC All FAP All  
Mean Median Range 
(lower)
 Range 
(upper)
Mean Median Range 
(lower)
 Range 
(upper)
P-value
Lachnospiraceae 12.09 2.16 0.00 54.81 20.93 23.79 7.69 31.03 0.075
Ruminococcaceae 1.94 0.00 0.00 10.08 7.98 3.43 0.00 27.46 0.024
Veillonellaceae 2.72 1.10 0.00 18.89 1.44 0.90 0.00 4.91 0.824
Clostridiaceae 4.49 0.71 0.00 40.85 4.00 0.59 0.00 18.01 0.824
Erysipelotrichaceae 0.68 0.00 0.00 5.41 0.44 0.00 0.00 2.38 0.863
Lactobacillaceae 0.06 0.00 0.00 0.91 0.22 0.00 0.00 1.72 0.566
Steptococcaceae 2.66 1.71 0.00 10.81 2.91 1.26 0.00 14.66 0.875
Enterococcaceae 0.31 0.00 0.00 1.96 0.07 0.00 0.00 0.56 0.604
Peptostreptococcaceae 2.59 0.33 0.00 10.65 0.07 0.00 0.00 0.55 0.049
Staphylococcaceae 0.27 0.00 0.00 2.06 0.69 0.00 0.00 2.75 0.277
Bacillaceae 0.54 0.00 0.00 3.09 0.00 0.00 0.00 0.00 0.085
Carnobacteriaceae 0.08 0.00 0.00 1.22 0.07 0.00 0.00 0.56 0.655
Other Firmicutes 0.25 0.00 0.00 1.83 0.12 0.00 0.00 0.95 0.604
Fusobacteriaceae 0.00 0.00 0.00 0.00 0.32 0.00 0.00 2.11 0.041
Coriobacteriaceae 0.19 0.00 0.00 2.52 0.29 0.00 0.00 1.19 0.451
Microbacteriaceae 0.22 0.00 0.00 1.83 0.00 0.00 0.00 0.00 0.201
Propionibacteriaceae 5.78 2.59 0.00 31.25 2.58 0.00 0.00 15.82 0.086
Gordoniaceae 0.03 0.00 0.00 0.53 0.00 0.00 0.00 0.00 0.480
Corynebacteriaceae 0.19 0.00 0.00 2.06 0.00 0.00 0.00 0.00 0.307
Actinomycetaceae 0.22 0.00 0.00 2.44 0.69 0.24 0.00 2.11 0.064
Intrasporangiaceae 0.12 0.00 0.00 1.96 0.00 0.00 0.00 0.00 0.480
Nocardioidaceae 0.04 0.00 0.00 0.65 0.00 0.00 0.00 0.00 0.480
Micrococcaceae 0.55 0.00 0.00 7.41 0.35 0.00 0.00 1.42 0.227
Other 0.04 0.00 0.00 0.59 0.00 0.00 0.00 0.00 0.480
Rhodobacteraceae 0.70 0.27 0.00 2.25 1.56 0.00 0.00 10.17 0.689
Caulobacteraceae 0.56 0.00 0.00 1.96 0.00 0.00 0.00 0.00 0.033
Sphingomonadaceae 1.86 1.12 0.00 9.52 0.41 0.00 0.00 1.69 0.082
Bradyrhizobiaceae 0.59 0.00 0.00 6.25 0.00 0.00 0.00 0.00 0.201
Aurantimonadaceae 0.07 0.00 0.00 1.12 0.00 0.00 0.00 0.00 0.480
Methylobacteriaceae 0.52 0.00 0.00 3.09 0.33 0.00 0.00 1.13 0.760
Rhodospirillaceae 0.00 0.00 0.00 0.00 1.44 0.00 0.00 11.54 0.157
Acetobacteraceae 0.00 0.00 0.00 0.00 0.07 0.00 0.00 0.56 0.157
Comamonadaceae 3.94 2.12 0.00 20.73 0.67 0.00 0.00 2.82 0.009
Burkholderiaceae 0.96 0.74 0.00 3.57 2.33 1.04 0.00 12.09 0.529
Rhodocyclaceae 0.51 0.00 0.00 4.05 0.14 0.00 0.00 0.56 0.931
Alcaligenaceae 0.56 0.00 0.00 2.25 3.14 3.43 0.00 5.63 0.002
Neisseriaceae 0.07 0.00 0.00 0.61 0.27 0.00 0.00 1.65 0.451
Oxalobacteraceae 0.53 0.00 0.00 2.22 0.27 0.00 0.00 0.95 0.573
Desulfobulbaceae 0.80 0.00 0.00 12.80 0.00 0.00 0.00 0.00 0.480
Desulfovibrionaceae 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.70 0.157
Enterobacteriaceae 25.16 22.75 0.61 62.62 11.57 8.18 0.00 39.66 0.098
Moraxellaceae 15.41 13.10 0.00 49.48 5.06 0.00 0.00 18.64 0.026
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Pseudomonadaceae 1.60 0.00 0.00 17.99 0.07 0.00 0.00 0.56 0.086
Xanthomonadaceae 0.99 0.42 0.00 3.74 0.27 0.00 0.00 1.10 0.230
Pasteurellaceae 1.67 0.00 0.00 17.99 0.20 0.00 0.00 0.61 0.526
Bacteroidaceae 3.28 0.00 0.00 25.45 11.79 10.31 0.00 30.67 0.012
Prevotellaceae 2.87 0.00 0.00 28.57 15.70 14.36 0.00 41.03 0.015
Porphyromonadaceae 0.55 0.00 0.00 2.52 1.42 0.51 0.00 6.34 0.578
Flexibacteraceae 0.26 0.00 0.00 2.06 0.06 0.00 0.00 0.47 0.604
Flavobacteriaceae 0.03 0.00 0.00 0.53 0.00 0.00 0.00 0.00 0.480
Rikenellaceae 0.06 0.00 0.00 0.93 0.00 0.00 0.00 0.00 0.480
Sphingobacteriaceae 0.06 0.00 0.00 1.03 0.00 0.00 0.00 0.00 0.480
Other Bacteroidetes 0.20 0.00 0.00 2.25 0.00 0.00 0.00 0.00 0.307
Verrucomicrobiaceae 0.11 0.00 0.00 1.12 0.00 0.00 0.00 0.00 0.307
Table 10.4
16slp100 - UC non-pouchitis 1 (GQ156578-GQ156797)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 6 2.73 Streptococcus 
bovis
16slp100-1c03.p1k,16slp100-3a08.w2k,16slp100-1h09.p1k,16slp100-
3f01.p1k,16slp100-2f03.p1k,16slp100-1b08.p1k
2 2 0.91 Lactobacillus iners 16slp100-3c09.p1k,16slp100-3e08.p1k
3 13 5.91 SJTU_B_15_23, 
Faecalibacterium 
prausnitzii  A2-165 
(98%)
16slp100-3a02.p1k,16slp100-3d07.p1k,16slp100-1g03.w2k,16slp100-
3c11.w2k,16slp100-2a06.p1k,16slp100-3g12.p1k,16slp100-2c04.p1k,16slp100-
1c01.p1k,16slp100-3a11.w2k,16slp100-3f12.p1k,16slp100-3c02.p1k,16slp100-
3e01.p1k,16slp100-3d11.p1k
4 3 1.36 Faecalibacterium 
prausnitzii clone 1-
84,  S.  variabile 
(95%)
16slp100-1c12.p1k,16slp100-3c04.w2k,16slp100-2h07.p1k
5 2 0.91 001B-e1,  O. 
valericigenes 
(96%)
16slp100-3h03.p1k,16slp100-3h04.p1k
6 1 0.45 Clostridium 
orbiscindens
16slp100-2d11.w2k
7 1 0.45 014C-E4, Butyrate-
producer  A2-207 
(97%)
16slp100-3d10.p1k
8 14 6.36 Dialister invisus 16slp100-2c02.w2k,16slp100-2c09.p1k,16slp100-1h12.p1k,16slp100-
1a06.p1k,16slp100-1a10.w2k,16slp100-2e05.w2k,16slp100-1c04.w2k,16slp100-
2a11.w2k,16slp100-1d11.w2k,16slp100-2e08.w2k,16slp100-3d03.p1k,16slp100-
2h06.w2k,16slp100-3f05.w2k,16slp100-2f07.p1k
9 1 0.45 SJTU_D_10_31,  C. 
straminisolvens 
(88%)
16slp100-1h07.w2k
10 5 2.27 SJTU_D_14_82, 
Clostridium 
disporicum (98%)
16slp100-2a01.w2k,16slp100-3g03.p1k,16slp100-3a01.w2k,16slp100-
2f02.w2k,16slp100-3g08.p1k
11 2 0.91 Clostridium 
perfringens
16slp100-1h02.p1k,16slp100-2a07.p1k
12 1 0.45 SJTU_C_06_41, 
Eubacterium 
eligens (98%)
16slp100-1e02.w2k
13 1 0.45 Roseburia faecis 16slp100-2a08.w2k
14 4 1.82 SJTU_G_09_66, 
Butyrate-producer 
GM2/1 (96%)
16slp100-2a02.w2k,16slp100-2b05.p1k,16slp100-3g05.w2k,16slp100-1a08.p1k
15 1 0.45 SJTU_A1_1_42  , 
Butyrate-producer 
GM2/1 (98%)
16slp100-1a11.w2k
16 1 0.45 SJTU_C_09_53, 16slp100-2c01.p1k
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D.guttoideum 
(93%)
17 1 0.45 SJTU_C_02_42, 
Desulfotomaculum 
sp. CYP1 (94%)
16slp100-2c12.p1k
18 2 0.91 SJTU_D_05_70,  C. 
indolis (94%)
16slp100-3c03.p1k,16slp100-3f10.p1k
19 1 0.45 Clostridium 
aldenense
16slp100-1h03.p1k
20 2 0.91 013C-B11, 
Butyrate-producer 
SR1/1 (96%)
16slp100-2d12.p1k,16slp100-2f05.p1k
21 1 0.45 SJTU_A2_03_69, 
Ruminococcus  sp. 
K-1 (97%)
16slp100-1g09.w2k
22 2 0.91 Butyrate-producer 
SSC/2
16slp100-2d06.p1k,16slp100-3c08.p1k
23 14 6.36 SJTU_F_14_32, 
R.gnavus (96%)
16slp100-1b02.p1k,16slp100-3h02.w2k,16slp100-2b08.w2k,16slp100-
2a10.p1k,16slp100-2a04.w2k,16slp100-3f04.p1k,16slp100-2e09.p1k,16slp100-
3b07.w2k,16slp100-3e06.w2k,16slp100-3d08.w2k,16slp100-
3h01.w2k,16slp100-1f04.p1k,16slp100-2d10.p1k,16slp100-2d08.p1k
24 4 1.82 Dorea longicatena 16slp100-1a04.w2k,16slp100-3d01.p1k,16slp100-1d08.p1k,16slp100-2d09.p1k
25 1 0.45 SJTU_A1_4_17, 
Dorea 
formicigenerans 
(98%)
16slp100-3c05.w2k
26 6 2.73 Ruminococcus 
gnavus
16slp100-1c08.w2k,16slp100-2a05.w2k,16slp100-3e03.p1k,16slp100-
2g12.p1k,16slp100-3d06.p1k,16slp100-2g02.w2k
27 13 5.91 M0027_107, 
Ruminococcus 
gnavus (98%)
16slp100-1c02.w2k,16slp100-2c03.w2k,16slp100-3g10.w2k,16slp100-
1e03.p1k,16slp100-1b10.p1k,16slp100-2f12.p1k,16slp100-3h08.p1k,16slp100-
3h05.w2k,16slp100-1b01.p1k,16slp100-1e04.w2k,16slp100-3d04.w2k,16slp100-
2c06.w2k,16slp100-2h10.p1k
28 1 0.45 Eggerthella lenta 16slp100-3g09.p1k
29 16 7.27 Acinetobacter  sp. 
N12,  A. 
haemolyticus 
(97%)
16slp100-2g04.w2k,16slp100-2b03.w2k,16slp100-1b07.w2k,16slp100-
1c10.w2k,16slp100-2f08.p1k,16slp100-2b11.p1k,16slp100-2b04.p1k,16slp100-
3a10.p1k,16slp100-3a03.p1k,16slp100-3d02.p1k,16slp100-3g11.p1k,16slp100-
3b01.w2k,16slp100-3e11.p1k,16slp100-3c01.p1k,16s
30 10 4.55 Escherichia  coli  or 
Shigella sp.
16slp100-3h06.p1k,16slp100-1b06.p1k,16slp100-1a01.p1k,16slp100-
3b02.p1k,16slp100-3g06.p1k,16slp100-2b10.p1k,16slp100-1d09.q1k,16slp100-
3f07.p1k,16slp100-3f02.p1k,16slp100-3c06.p1k
31 3 1.36 Sutterella 
wadsworthensis
16slp100-1e05.p1k,16slp100-2e01.p1k,16slp100-1h04.p1k
32 1 0.45 Ralstonia 
detusculanense
16slp100-3c07.p1k
33 1 0.45 Delftia 
acidovorans
16slp100-2d03.p1k
34 2 0.91 Paracoccus 
marinus
16slp100-1d07.p1k,16slp100-2g07.p1k
35 51 23.18 Bacteroides dorei 16slp100-1e01.p1k,16slp100-1d10.p1k,16slp100-1h11.p1k,16slp100-
1g06.w2k,16slp100-3e12.w2k,16slp100-3h12.w2k,16slp100-1g04.w2k,16slp100-
2a09.w2k,16slp100-3g07.w2k,16slp100-3d09.w2k,16slp100-2g01.w2k,16slp100-
2b09.w2k,16slp100-1a12.w2k,16slp100-3f11.w2k,16s
36 5 2.27 Bacteroides 
thetaiotaomicron
16slp100-2e10.p1k,16slp100-3a04.w2k,16slp100-1f06.p1k,16slp100-
2e06.p1k,16slp100-1a03.w2k
37 15 6.82 Prevotella  sp.  BI-
42
16slp100-2c05.p1k,16slp100-2c08.w2k,16slp100-1g11.p1k,16slp100-
3f06.w2k,16slp100-1g12.p1k,16slp100-1e06.p1k,16slp100-1e07.p1k,16slp100-
3f08.w2k,16slp100-1d02.w2k,16slp100-2h09.w2k,16slp100-1d06.p1k,16slp100-
2h08.p1k,16slp100-1c06.w2k,16slp100-2g05.w2k,16s
38 3 1.36 001B-e9, 
Prevotella  copri 
(98%)
16slp100-1d03.p1k,16slp100-3h09.p1k,16slp100-2h03.w2k
39 2 0.91 Prevotella disiens 16slp100-2b02.p1k,16slp100-3g02.p1k
40 3 1.36 SJTU_B_11_66, 
Parabacteroides 
distasonis (98%)
16slp100-1g07.w2k,16slp100-2g03.w2k,16slp100-3h11.w2k
41 2 0.91 Candidatus Bifissio 
spartinae
16slp100-1f02.p1k,16slp100-2b06.w2k
Total 220 100   
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Table 10.5
16slp106 - UC non-pouchitis 2 (GQ156798-GQ156871)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 3 4.05 Streptococcus 
salivarius
16slp106-1h08.p1k,16slp97-1c06.p1k,16slp97-1c04.p1k
2 2 2.70 Streptococcus 
bovis
16slp97-1g10.w2k,16slp97-1h02.p1k
3 2 2.70 Streptococcus 
sanguinis
16slp97-1b04.w2k,16slp97-1d02.w2k
4 1 1.35 Streptococcus 
mitis
16slp97-1e02.p1k
5 4 5.41 Turicibacter 
sanguinis
16slp97-1c02.w2k,16slp97-1g04.p1k,16slp97-1f07.p1k,16slp97-1f12.p1k
6 1 1.35 Ruminococcus 
gnavus
16slp106-1g09.p1k
7 1 1.35 BF0001D037,  C. 
glycolicum (97%)
16slp106-1h06.p1k
8 3 4.05 Propionibacteriu
m acnes
16slp97-1a02.w2k,16slp97-1b05.w2k,16slp106-1h11.p1k
9 2 2.70 Sphingomonas 
paucimobilis
16slp106-1a04.p1k,16slp97-1e09.w2k
10 1 1.35 Sphingomonas sp. 
YT0136  (98%),  S. 
subterranea (97%)
16slp106-1g02.p1k
11 1 1.35 Brevundimonas 
nasdae
16slp97-1b10.p1k
12 5 6.76 Delftia 
acidovorans
16slp106-1e01.p1k,16slp97-1c10.p1k,16slp97-1a10.p1k,16slp97-
1c09.p1k,16slp97-1b09.p1k
13 2 2.70 Acidovorax facilis 16slp97-1b01.w2k,16slp97-1e03.p1k
14 1 1.35 Acidovorax 
temperans
16slp97-1g06.p1k
15 2 2.70 Ralstonia 
detusculanense/pi
ckettii
16slp97-1e12.p1k,16slp97-1h06.p1k
16 2 2.70 HOClCi25, 
Methyloversatilis 
universalis (98%)
16slp97-1b03.p1k,16slp97-1f08.p1k
17 1 1.35 MKC12  (96%),  D. 
oestradiolicum 
(91%)
16slp97-1c07.w2k
18 12 16.22 Escherichia coli or 
Shigella sp.
16slp97-1a08.q1k,16slp97-1c01.w2k,16slp106-1b08.p1k,16slp97-
1c08.w2k,16slp97-1b07.w2k,16slp106-1d01.p1k,16slp106-1d07.p1k,16slp97-
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1a07.p1k,16slp97-1d12.p1k,16slp97-1b08.w2k,16slp97-1g07.w2k,16slp106-
1b11.w2k
19 1 1.35 Pseudomonas 
fluorescens
16slp106-1d12.p1k
20 1 1.35 Moraxella 
osloensis
16slp97-1f09.p1k
21 25 33.78 Acinetobacter  sp. 
N12,  A.  johnsonii 
(97%)
16slp106-1f01.p1k,16slp97-1f02.w2k,16slp97-1g01.p1k,16slp97-
1b02.w2k,16slp106-1a10.p1k,16slp97-1e08.p1k,16slp97-1g05.p1k,16slp97-
1f11.w2k,16slp97-1f06.w2k,16slp97-1h04.p1k,16slp97-1a06.p1k,16slp97-
1d03.p1k,16slp97-1c05.w2k,16slp97-1d07.p1k,16slp106-1a09.p
22 1 1.35 Acinetobacter 
calcoaceticus/rhiz
osphaerae
16slp106-1c12.p1k
Total 74 100   
Table 10.6
16slp99 - UC non-pouchitis 3 (GQ156872-GQ156983)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 1 0.89 Streptococcus 
sanguinis
16slp99-1h01.p1k
2 1 0.89 Streptococcus 
parasanguis
16slp99-2b08.p1k
3 1 0.89 Streptococcus 
salivarius
16slp99-3e03.p1k
4 2 1.79 Veillonella parvula 16slp99-2d09.p1k,16slp99-3a10.p1k
5 1 0.89 D1-45, 
Clostridium 
disporicum (98%)
16slp99-2f02.p1k
6 34 30.36 Propionibacteriu
m acnes
16slp99-2a07.p1k,16slp99-2f08.p1k,16slp99-2a12.p1k,16slp99-
2g05.p1k,16slp99-2g09.p1k,16slp99-2f03.p1k,16slp99-2c10.p1k,16slp99-
2d12.p1k,16slp99-3c05.p1k,16slp99-2e06.p1k,16slp99-2h01.p1k,16slp99-
3b08.p1k,16slp99-2f01.p1k,16slp99-3d02.p1k,16slp99-3c02.p1k,
7 1 0.89 Propionibacteriu
m sp.  V07/12348, 
P. acnes (98%)
16slp99-2d05.p1k
8 4 3.57 Afipia 
lausannensis
16slp99-2b03.w2k,16slp99-2b12.p1k,16slp99-3a05.w2k,16slp99-2d08.p1k
9 3 2.68 Bradyrhizobium 
elkanii
16slp99-2d04.w2k,16slp99-3b01.w2k,16slp99-2f10.w2k
10 1 0.89 Paracoccus  sp. 
SA5, P. alcaliphilus 
(96%)
16slp99-3d12.p1k
11 1 0.89 Paracoccus yeei 16slp99-3g04.p1k
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12 1 0.89 Sphingomonas 
paucimobilis
16slp99-1b08.p1k
13 1 0.89 Sphingomonas 
panni
16slp99-2c04.w2k
14 5 4.46 Delftia 
acidovorans
16slp99-2c03.p1k,16slp99-2e12.p1k,16slp99-2b02.p1k,16slp99-
2a03.p1k,16slp99-2b01.p1k
15 1 0.89 Stenotrophomona
s maltophilia
16slp99-3a07.p1k
16 22 19.64 Acinetobacter  sp. 
N12,  A. 
haemolyticus 
(97%)
16slp99-2d02.p1k,16slp99-3c04.p1k,16slp99-2b05.p1k,16slp99-
2e09.p1k,16slp99-3b03.p1k,16slp99-2c02.p1k,16slp99-2e05.p1k,16slp99-
2h02.p1k,16slp99-2c07.p1k,16slp99-2e10.p1k,16slp99-3f02.p1k,16slp99-
1e08.p1k,16slp99-2h05.p1k,16slp99-3a01.p1k,16slp99-2c05.p1k,
17 1 0.89 Pseudomonas 
japonica
16slp99-2b06.p1k
18 2 1.79 Shigella 
sonnei/boydii  or 
Escherichia coli
16slp99-3c07.p1k,16slp99-1a12.p1k
19 12 10.71 Escherichia coli or 
Shigella sp.
16slp99-1c02.p1k,16slp99-1f11.p1k,16slp99-1f02.p1k,16slp99-1c04.p1k,16slp99-
1e11.p1k,16slp99-1h10.p1k,16slp99-1g12.p1k,16slp99-1f10.p1k,16slp99-
2c12.p1k,16slp99-2h03.p1k,16slp99-2f06.p1k,16slp99-1f03.p1k
20 17 15.18 Shigella 
dysenteriae/sp. or 
Escherichia coli
16slp99-3c12.p1k,16slp99-1c05.p1k,16slp99-1b01.p1k,16slp99-
1h09.p1k,16slp99-1d06.p1k,16slp99-1f09.p1k,16slp99-1g11.p1k,16slp99-
1c08.w2k,16slp99-1d08.p1k,16slp99-1e02.p1k,16slp99-1h12.q1k,16slp99-
1a08.p1k,16slp99-1h02.p1k,16slp99-1c12.w2k,16slp99-1c11.p1k,
Total 112 100   
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Table 10.7 
16slp107 - UC non-pouchitis 4 (GQ156984-GQ157072)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 3 3.37 Streptococcus 
mitis
16slp107-1e02.p1k,16slp107-3a07.p1k,16slp107-1e08.p1k
2 1 1.12 Streptococcus 
mitis
16slp107-1g04.p1k
3 2 2.25 Streptococcus 
thermophilus
16slp107-1d02.p1k,16slp107-2a04.p1k
4 2 2.25 LC3  (97%),  B. 
humi (96%)
16slp107-1d01.p1k,16slp107-1e01.p1k
5 1 1.12 Staphylococcus 
epidermidis
16slp107-1d12.p1k
6 1 1.12 SJTU_F_15_19 
(98%),  Veillonella 
parvula (98%)
16slp107-1f05.p1k
7 1 1.12 Veillonella atypica 16slp107-1h01.p1k
8 1 1.12 clone rRNA336, D. 
invisus (94%)
16slp107-3a05.p1k
9 15 16.85 Propionibacteriu
m acnes
16slp107-2e02.p1k,16slp107-3a10.p1k,16slp107-2a03.p1k,16slp107-
3a06.p1k,16slp107-3c02.p1k,16slp107-2d01.p1k,16slp107-2e01.p1k,16slp107-
2c02.p1k,16slp107-2c06.p1k,16slp107-2g03.p1k,16slp107-2b01.p1k,16slp107-
2a01.p1k,16slp107-3b01.p1k,16slp107-1b06.p1k,16s
10 1 1.12 Microbacterium 
chocolatum
16slp107-1f09.p1k
11 1 1.12 Paracoccus  sp. 
YT0095,  P. 
thiophilus (96%)
16slp107-1c02.p1k
12 1 1.12 Paracoccus yeei 16slp107-1f04.p1k
13 1 1.12 Brevundimonas 
vesicularis
16slp107-1b09.p1k
14 1 1.12 Aurantimonas 
altamirensis
16slp107-1b04.p1k
15 1 1.12 Sphingomonas 
paucimobilis
16slp107-2c04.p1k
16 11 12.36 Klebsiella 
pneumoniae
16slp107-2c11.p1k,16slp107-2e08.p1k,16slp107-1e09.p1k,16slp107-
1h05.p1k,16slp107-1c11.p1k,16slp107-1f03.p1k,16slp107-2d07.p1k,16slp107-
2f01.p1k,16slp107-2c01.p1k,16slp107-2d05.p1k,16slp107-2e04.p1k
17 4 4.49 Shigella  sonnei  or 
Escherichia coli
16slp107-1c12.p1k,16slp107-1e11.w2k,16slp107-1d03.p1k,16slp107-1g06.p1k
18 3 3.37 Escherichia coli or 
Shigella sp.
16slp107-1d11.p1k,16slp107-3b05.p1k,16slp107-1f02.p1k
19 1 1.12 Haemophilus 16slp107-1a01.p1k
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parainfluenzae
20 1 1.12 Ralstonia pickettii 16slp107-2a02.p1k
21 1 1.12 Ralstonia 
metallidurans
16slp107-2b11.p1k
22 1 1.12 M4-27  (97%),  S. 
stercoricanis 
(96%)
16slp107-1e04.p1k
23 1 1.12 Delftia 
acidovorans
16slp107-1e06.p1k
24 1 1.12 Alcaligenes 
faecalis
16slp107-2f02.p1k
25 2 2.25 Stenotrophomona
s maltophilia
16slp107-2b03.p1k,16slp107-3d12.p1k
26 24 26.97 Acinetobacter  sp. 
N12, 
Acinetobacter 
haemolyticus 
(97%)
16slp107-1c10.p1k,16slp107-1d06.p1k,16slp107-1f01.p1k,16slp107-
1b01.p1k,16slp107-2b05.p1k,16slp107-2g02.p1k,16slp107-3h06.p1k,16slp107-
2g04.p1k,16slp107-3b03.p1k,16slp107-3a08.p1k,16slp107-2d08.p1k,16slp107-
2f04.p1k,16slp107-2b02.p1k,16slp107-2c03.p1k,16s
27 2 2.25 CLi112  (98%),  S. 
salmoneum (96%)
16slp107-1d09.p1k,16slp107-1g07.p1k
28 1 1.12 Dyadobacter  sp. 
PF-B,  D. 
fermentans (97%)
16slp107-1h09.p1k
29 2 2.25 SJTU_G_01_85, 
Prevotella  copri 
(98%)
16slp107-2b04.p1k,16slp107-2b06.p1k
30 1 1.12 Prosthecobacter 
fluviatilis (98%)
16slp107-1a02.p1k
Total 89 100   
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Table 10.8
16slp101 - UC non-pouchitis 5 (GQ157073-GQ157261)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 15 7.94 Streptococcus 
thermophilus
16slp101-1a09.w2k,16slp101-1e06.w2k,16slp101-2c08.p1k,16slp101-
3e07.w2k,16slp101-1b08.w2k,16slp101-2d02.w2k,16slp101-3d05.w2k,16slp101-
2c02.p1k,16slp101-2a05.p1k,16slp101-3h02.w2k,16slp101-3h11.p1k,16slp101-
2e11.w2k,16slp101-3f08.p1k,16slp101-1h11.w2k,16s
2 1 0.53 Streptococcus 
salivarius
16slp101-1c01.p1k
3 3 1.59 Streptococcus 
mitis
16slp101-1a10.w2k,16slp101-2h02.w2k,16slp101-3b08.p1k
4 1 0.53 Streptococcus 
cristatus
16slp101-3a09.p1k
5 2 1.06 Gemella 
haemolysans 
16slp101-3f11.p1k,16slp101-3h01.w2k
6 2 1.06 Veillonella atypica 16slp101-2a02.p1k,16slp101-3g03.w2k
7 1 0.53 Veillonella parvula 16slp101-3e05.p1k
8 5 2.65 Clostridium 
bartlettii
16slp101-1g03.w2k,16slp101-3e06.w2k,16slp101-3h08.w2k,16slp101-
1d07.w2k,16slp101-3f02.w2k
9 1 0.53 Clostridium 
disporicum
16slp101-3a04.p1k
10 12 6.35 Kocuria rhizophila 16slp101-2e12.w2k,16slp101-2g11.w2k,16slp101-1g09.q1k,16slp101-
2g05.p1k,16slp101-3c05.p1k,16slp101-2d10.w2k,16slp101-2f04.w2k,16slp101-
1b03.w2k,16slp101-2c10.w2k,16slp101-3b01.p1k,16slp101-3a01.w2k,16slp101-
3d04.p1k
11 2 1.06 Kocuria palustris 16slp101-1f08.p1k,16slp101-2g12.w2k
12 3 1.59 Propionibacteriu
m acnes
16slp101-1a01.w2k,16slp101-3f09.p1k,16slp101-1g06.p1k
13 1 0.53 Gordonia terrae 16slp101-2d06.p1k
14 1 0.53 Paracoccus 
carotinifaciens
16slp101-3a06.w2k
15 6 3.17 HOClCi25,  S. 
denitrificans 
(93%)
16slp101-1e01.w2k,16slp101-2e02.p1k,16slp101-2g04.w2k,16slp101-
1e08.p1k,16slp101-3b02.p1k,16slp101-3g10.p1k
16 3 1.59 Massilia 
brevitalea
16slp101-1h05.w2k,16slp101-1h09.w2k,16slp101-3h06.w2k
17 3 1.59 Alcaligenes 
faecalis
16slp101-3d02.w2k,16slp101-2h04.w2k,16slp101-3g12.p1k
18 1 0.53 Ralstonia 
detusculanense
16slp101-2d08.w2k
19 1 0.53 Ralstonia pickettii 16slp101-3c06.w2k
20 1 0.53 Delftia 16slp101-3a12.w2k
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acidovorans
21 1 0.53 Acidovorax 
temperans
16slp101-3h12.p1k
22 1 0.53 AP085,  N. 
meningitidis (95%)
16slp101-3b11.p1k
23 6 3.17 Stenotrophomona
s maltophilia
16slp101-2c06.p1k,16slp101-3h04.p1k,16slp101-3g04.w2k,16slp101-
2a03.p1k,16slp101-1g08.p1k,16slp101-2a09.w2k
24 25 13.23 Pseudomonas 
rhizosphaerae/gra
minis
16slp101-1d04.p1k,16slp101-2d07.p1k,16slp101-1c06.p1k,16slp101-
1g01.w2k,16slp101-1b07.p1k,16slp101-2e01.p1k,16slp101-1c12.p1k,16slp101-
1g07.p1k,16slp101-1c08.p1k,16slp101-1e02.p1k,16slp101-3d06.w2k,16slp101-
3e01.w2k,16slp101-2h10.q1k,16slp101-2d01.p1k,16s
25 6 3.17 Pseudomonas 
japonica
16slp101-1b09.p1k,16slp101-3a11.w2k,16slp101-3g02.p1k,16slp101-
3a02.w2k,16slp101-2c07.p1k,16slp101-2g08.p1k
26 1 0.53 Pseudomonas 
fluorescens
16slp101-3h03.w2k
27 1 0.53 Pseudomonas 
mendocina
16slp101-1e03.w2k
28 1 0.53 Pseudomonas 
azelaica/aerugino
sa
16slp101-3d01.w2k
29 34 17.99 Haemophilus 
parainfluenzae
16slp101-2f07.p1k,16slp101-3c04.p1k,16slp101-1b02.w2k,16slp101-
1f04.w2k,16slp101-2c05.p1k,16slp101-1f07.p1k,16slp101-1h08.p1k,16slp101-
2h03.q1k,16slp101-3e02.p1k,16slp101-3a03.p1k,16slp101-2h12.p1k,16slp101-
3h09.w2k,16slp101-2f06.q1k,16slp101-2f05.p1k,16s
30 9 4.76 Enterobacter 
asburiae
16slp101-1f10.q1k,16slp101-3f01.w2k,16slp101-1d03.p1k,16slp101-
1f11.w2k,16slp101-2e04.q1k,16slp101-2b07.q1k,16slp101-2b03.w2k,16slp101-
3c12.p1k,16slp101-1f05.w2k
31 2 1.06 Kluyvera 
cryocrescens
16slp101-1h10.q1k,16slp101-2a08.q1k
32 33 17.46 Escherichia coli or 
Shigella sp.
16slp101-2d04.q1k,16slp101-1b05.q1k,16slp101-2h09.q1k,16slp101-
2e06.q1k,16slp101-2c12.w2k,16slp101-2f03.q1k,16slp101-1b12.w2k,16slp101-
2a11.p1k,16slp101-1f03.p1k,16slp101-2a12.p1k,16slp101-1h03.p1k,16slp101-
3g06.p1k,16slp101-1a05.w2k,16slp101-2b09.w2k,16s
33 2 1.06 Shigella flexneri or 
Escherichia coli
16slp101-1g10.p1k,16slp101-1h07.p1k
34 1 0.53 Bacteroides 
vulgatus
16slp101-1d09.w2k
35 1 0.53 Chryseobacterium 
hominis/isbiliense
16slp101-3h05.p1k
Total 189 100   
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Table 10.9
16slp120 - UC non-pouchitis 6 (GQ157262-GQ157380)
Phylotype No.  of 
each
%  of 
clones
 Clones in Phylotype
1 9 7.56 SJTU_D_05_70,  C. 
indolis (94%)
16slp120-1a05.p1k,16slp120-1h05.w2k,16slp120-1e03.p1k,16slp120-
3c07.p1k,16slp120-1d07.p1k,16slp120-1a09.p1k,16slp120-1b01.p1k,16slp120-
1c10.w2k,16slp120-1c12.p1k
2 8 6.72 SJTU_D_05_70,  C. 
amygdalinum 
(94%)
16slp120-1h08.w2k,16slp120-3c01.p1k,16slp120-3f08.p1k,16slp120-
3a09.p1k,16slp120-1a12.p1k,16slp120-1a08.p1k,16slp120-1b09.p1k,16slp120-
1h12.p1k
3 1 0.84 001C-g4,  C. 
saccharolyticum 
(94%)
16slp120-1h07.w2k
4 7 5.88 SJTU_A1_7_60,  C. 
amygdalinum 
(94%)
16slp120-1a10.w2k,16slp120-1b11.w2k,16slp120-3b02.p1k,16slp120-
3f12.p1k,16slp120-3a10.p1k,16slp120-1g02.w2k,16slp120-3b06.p1k
5 1 0.84 SJTU_E_11, 
Butyrate-producer 
GM2/1 (98%)
16slp120-3d04.p1k
6 4 3.36 SJTU_C_11_74,  C. 
symbiosum (95%)
16slp120-1f03.w2k,16slp120-3d02.p1k,16slp120-3d07.p1k,16slp120-1d05.p1k
7 1 0.84 SJTU_A2_01_03, 
Dorea 
formicigenerans 
(98%)
16slp120-1f08.w2k
8 2 1.68 SJTU_B_09_77,  R. 
obeum (95%)
16slp120-3b09.p1k,16slp120-3g11.p1k
9 1 0.84 RL203_aai61b07, 
Butyrate-producer 
SR1/1 (97%)
16slp120-1a11.w2k
10 2 1.68 Eubacterium 
rectale
16slp120-1a07.p1k,16slp120-3d08.p1k
11 4 3.36 SJTU_G_06_83, 
Faecalibacterium 
prausnitzii  L2-6 
(98%)
16slp120-1f01.p1k,16slp120-3d05.p1k,16slp120-1f04.p1k,16slp120-3b07.p1k
12 1 0.84 SJTU_G_09_29, 
Faecalibacterium 
prausnitzii  A2-165 
(98%)
16slp120-1d04.w2k
13 6 5.04 HuCB5, 
Subdoligranulum 
variabile (98%)
16slp120-3b01.w2k,16slp120-3h06.p1k,16slp120-3a02.p1k,16slp120-
1c02.w2k,16slp120-1g11.w2k,16slp120-1e01.p1k
14 1 0.84 Clostridium 
leptum
16slp120-1d01.w2k
15 3 2.52 Collinsella 
aerofaciens
16slp120-1c03.w2k,16slp120-1f10.w2k,16slp120-1h04.p1k
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16 2 1.68 SJTU_C_10_19,  S. 
stercoricanis 
(98%)
16slp120-1b12.p1k,16slp120-1g03.w2k
17 1 0.84 Delftia 
acidovorans
16slp120-3h12.p1k
18 2 1.68 Acinetobacter  sp. 
N12,  A. 
haemolyticus 
(97%)
16slp120-1c07.w2k,16slp120-3e12.p1k
19 1 0.84 Enterobacter 
hormaechei
16slp120-1f02.p1k
20 2 1.68 Methylobacteriu
m extorquens
16slp120-1d12.p1k,16slp120-1e11.w2k
21 22 18.49 Bacteroides 
vulgatus
16slp120-1e02.w2k,16slp120-3f01.p1k,16slp120-1g01.p1k,16slp120-
3a06.p1k,16slp120-3f03.p1k,16slp120-1a04.p1k,16slp120-1f11.p1k,16slp120-
1a02.w2k,16slp120-1c11.p1k,16slp120-1d10.p1k,16slp120-1b07.p1k,16slp120-
3g12.p1k,16slp120-1e08.p1k,16slp120-1h11.p1k,16s
22 1 0.84 Bacteroides 
caccae
16slp120-1b10.p1k
23 3 2.52 Parabacteroides 
distasonis
16slp120-1e09.p1k,16slp120-3a04.p1k,16slp120-1h10.p1k
24 12 10.08 adhufec43, 
Prevotella  sp.  BI-
42 (98%)
16slp120-1c08.p1k,16slp120-1d09.p1k,16slp120-1e05.p1k,16slp120-
1c05.w2k,16slp120-1f12.w2k,16slp120-1e12.p1k,16slp120-1f07.p1k,16slp120-
1c04.w2k,16slp120-1b04.p1k,16slp120-1d06.w2k,16slp120-1b05.w2k,16slp120-
3c06.p1k
25 22 18.49 adhufec94, 
Prevotella  copri 
(98%)
16slp120-3b05.p1k,16slp120-1e07.w2k,16slp120-3h11.p1k,16slp120-
3e01.p1k,16slp120-3g09.p1k,16slp120-3e03.p1k,16slp120-3b08.p1k,16slp120-
3e06.p1k,16slp120-1g10.p1k,16slp120-1d11.w2k,16slp120-1g12.w2k,16slp120-
1e04.p1k,16slp120-1a01.w2k,16slp120-1e06.p1k,16s
Total 119 100   
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Table 10.10
16slp124 - UC non-pouchitis 7 (GQ157381-GQ157549)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 18 10.65 SJTU_C_06_20, 
C.lituseburense 
(98%)
16slp124-3d08.p1k,16slp124-4e03.p1k,16slp124-4c01.p1k,16slp124-
3f07.p1k,16slp124-4b03.p1k,16slp124-4d07.p1k,16slp124-3e07.p1k,16slp124-
3g05.w2k,16slp124-1b02.w2k,16slp124-1b05.p1k,16slp124-3b10.p1k,16slp124-
4d02.p1k,16slp124-1e07.w2k,16slp124-1b09.w2k,16s
2 1 0.59 Eubacterium sulci 16slp124-4a04.p1k
3 2 1.18 Clostridium 
paraputrificum
16slp124-3d10.p1k,16slp124-4f04.p1k
4 3 1.78 LC3 (97%), B. humi 
(96%)
16slp124-3b02.w2k,16slp124-3c06.p1k,16slp124-1c12.p1k
5 2 1.18 Staphylococcus 
epidermidis
16slp124-1a06.p1k,16slp124-3g03.p1k
6 1 0.59 EHFS1_S01h, 
Gemella  sanguinis 
(98%)
16slp124-3g11.p1k
7 2 1.18 Streptococcus 
parasanguis
16slp124-4g12.w2k,16slp124-4h10.w2k
8 1 0.59 Streptococcus 
thermophilus
16slp124-4g04.p1k
9 1 0.59 Streptococcus 
anginosus
16slp124-4g07.p1k
10 1 0.59 Roseburia faecis 16slp124-1e05.p1k
11 15 8.88 Propionibacterium 
acnes
16slp124-4b12.p1k,16slp124-4f06.p1k,16slp124-4a12.p1k,16slp124-
1c03.p1k,16slp124-3h02.w2k,16slp124-3g09.p1k,16slp124-3a04.w2k,16slp124-
1d06.w2k,16slp124-4c09.p1k,16slp124-4f09.p1k,16slp124-4g09.p1k,16slp124-
4b11.p1k,16slp124-4a03.p1k,16slp124-4f08.w2k,16s
12 1 0.59 clone 411, D. maris 
(94%)
16slp124-1d05.p1k
13 1 0.59 Gram-positive 
bacterium YT0045, 
Parkia  alkaliphila 
(98%)
16slp124-4a01.w2k
14 2 1.18 Afipia lausannensis 16slp124-4e06.w2k,16slp124-4h06.w2k
15 1 0.59 Methylobacterium 
extorquens
16slp124-4a10.p1k
16 1 0.59 Brevundimonas 
intermedia
16slp124-3h03.p1k
17 2 1.18 clone  654940 
(98%),  R.  blasticus 
(96%)
16slp124-1a05.p1k,16slp124-1b03.p1k
18 1 0.59 DSSF72  (96%), 
S.asaccharolytica 
16slp124-1e08.p1k
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(95%)
19 2 1.18 3C002467, 
Sphingomonas 
paucimobilis (98%)
16slp124-3a05.p1k,16slp124-3c08.p1k
20 1 0.59 C-CY80,  A. 
autotrophicum 
(97%)
16slp124-1c05.w2k
21 1 0.59 Massilia aurea 16slp124-1e10.p1k
22 1 0.59 Limnobacter 
thiooxidans
16slp124-3h12.p1k
23 1 0.59 Ralstonia pickettii 16slp124-4d06.p1k
24 4 2.37 Delftia 
acidovorans
16slp124-1d09.p1k,16slp124-1e03.p1k,16slp124-1c11.p1k,16slp124-3d03.p1k
25 2 1.18 Alcaligenes 
faecalis
16slp124-4f05.p1k,16slp124-4h09.p1k
26 1 0.59 Stenotrophomona
s maltophilia
16slp124-3b04.p1k
27 1 0.59 Stenotrophomona
s  sp.  FB206, 
Stenotrophomona
s maltophilia (98%)
16slp124-4f02.p1k
28 1 0.59 EME044,  T. 
dokdonensis (94%)
16slp124-4c07.p1k
29 30 17.75 Escherichia  coli  or 
Shigella sp.
16slp124-1c08.p1k,16slp124-1c10.w2k,16slp124-4g01.p1k,16slp124-
1d03.p1k,16slp124-4f11.p1k,16slp124-4h07.p1k,16slp124-4a06.p1k,16slp124-
4e02.p1k,16slp124-3a10.p1k,16slp124-3g02.p1k,16slp124-3e02.w2k,16slp124-
3c05.p1k,16slp124-1b01.w2k,16slp124-1d11.w2k,16s
30 13 7.69 Shigella  sonnei  or 
Escherichia coli
16slp124-1c09.p1k,16slp124-3a12.p1k,16slp124-4g05.w2k,16slp124-
4c02.p1k,16slp124-1a09.p1k,16slp124-3d06.p1k,16slp124-4g02.p1k,16slp124-
3h04.p1k,16slp124-1e09.w2k,16slp124-1a08.w2k,16slp124-3h10.p1k,16slp124-
4b07.p1k,16slp124-1a11.p1k
31 6 3.55 Haemophilus 
parainfluenzae
16slp124-1d10.p1k,16slp124-3e01.p1k,16slp124-3g04.p1k,16slp124-
4b06.p1k,16slp124-4e09.p1k,16slp124-3b07.p1k
32 1 0.59 Pseudomonas 
fluorescens
16slp124-4a05.p1k
33 1 0.59 Pseudomonas 
azelaica
16slp124-4h01.w2k
34 45 26.63 Acinetobacter  sp. 
N12,  A. 
haemolyticus 
(96%)
16slp124-4d05.w2k,16slp124-4h11.w2k,16slp124-3h06.p1k,16slp124-
4g03.p1k,16slp124-3h08.p1k,16slp124-1a03.w2k,16slp124-4d03.w2k,16slp124-
4e04.p1k,16slp124-1e11.p1k,16slp124-4g08.p1k,16slp124-1e02.p1k,16slp124-
4c06.p1k,16slp124-1d01.w2k,16slp124-4d09.w2k,16s
35 1 0.59 16saw35-
1c02.w2k,  B. 
viscericola (86%)
16slp124-3f10.p1k
36 1 0.59 Bacteroides 
uniformis
16slp124-3g08.p1k
Total 169 100   
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Table 10.11
16slp90 - UC non-pouchitis 8 (GQ157550-GQ157653)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 6 5.77 Veillonella ratti 16slp90-01a01.p1k,16slp90-01d02.p1k,16slp90-01h01.w2k,16slp90-
01d07.p1k,16slp90-01c11.p1k,16slp90-01b06.p1k
2 1 0.96 Veillonella parvula 16slp90-2d03.p1k
3 1 0.96 Clostridium 
orbiscindens
16slp90-01b03.p1k
4 1 0.96 SJTU_D_09_24, 
Butyrate-producer 
A2-207 (97%)
16slp90-2h02.p1k
5 1 0.96 AP07K.52,  C. 
Straminisolvens 
(88%)
16slp90-01b09.w2k
6 3 2.88 Clostridium 
ramosum
16slp90-01b10.p1k,16slp90-01a09.p1k,16slp90-01g04.p1k
7 1 0.96 SDG-Mt85-3Db,  C. 
cocleatum (96%)
16slp90-01f02.p1k
8 2 1.92 SJTU_A1_6_37  ,  R. 
obeum (95%)
16slp90-01a04.p1k,16slp90-01f03.p1k
9 1 0.96 SJTU_C_05_30,  R. 
obeum (97%)
16slp90-2b02.p1k
10 3 2.88 Clostridium 
clostridioforme
16slp90-01a12.p1k,16slp90-2d04.p1k,16slp90-2f04.p1k
11 6 5.77 SJTU_D_09_24, 
Butyrate-producer 
M62/1 (95%)
16slp90-01h02.p1k,16slp90-2c02.p1k,16slp90-01f07.p1k,16slp90-
01a10.p1k,16slp90-01a11.p1k,16slp90-01g08.p1k
12 2 1.92 M0014_123, 
Butyrate-producer 
SS3/4 (97%)
16slp90-01g10.w2k,16slp90-2a01.w2k
13 6 5.77 SJTU_C_02_59, 
Eubacterium eligens 
(98%)
16slp90-01e05.p1k,16slp90-01e09.p1k,16slp90-2g01.p1k,16slp90-
2g06.p1k,16slp90-2e07.w2k,16slp90-01g06.p1k
14 4 3.85 Roseburia faecalis 16slp90-01f06.p1k,16slp90-01h06.p1k,16slp90-01h09.p1k,16slp90-2g12.p1k
15 1 0.96 Roseburia 
inulinivorans
16slp90-01h12.p1k
16 2 1.92 Clostridiaceae 
DJF_LS13,  Dorea 
formicigenerans 
(98%)
16slp90-01b04.p1k,16slp90-2b09.p1k
17 9 8.65 SJTU_D_15_47, 16slp90-01e08.w2k,16slp90-01f04.w2k,16slp90-2c01.w2k,16slp90-
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Ruminococcus 
gnavus (98%)
01h03.p1k,16slp90-01d04.p1k,16slp90-01d10.p1k,16slp90-
01e02.p1k,16slp90-01c07.w2k,16slp90-01h11.p1k
18 1 0.96 Ruminococcus 
gnavus
16slp90-01e04.p1k
19 20 19.23 SJTU_F_11_28, 
Clostridium  nexile 
(98%)
16slp90-01h07.p1k,16slp90-01c03.p1k,16slp90-01b12.p1k,16slp90-
01c12.w2k,16slp90-01f09.w2k,16slp90-01f10.p1k,16slp90-01b01.p1k,16slp90-
2d02.p1k,16slp90-01a07.p1k,16slp90-01d11.p1k,16slp90-01e10.p1k,16slp90-
2c04.p1k,16slp90-01c02.p1k,16slp90-2a06.w2k,16slp9
20 3 2.88 Propionibacterium 
acnes
16slp90-01h04.p1k,16slp90-2f02.p1k,16slp90-2f01.w2k
21 1 0.96 Corynebacterium 
sp.  S18-03,  C. 
auriscarnis (97%)
16slp90-01e07.p1k
22 17 16.35 Escherichia  coli  or 
Shigella sp.
16slp90-01e11.p1k,16slp90-01e03.p1k,16slp90-01g01.p1k,16slp90-
01d08.p1k,16slp90-01f12.q1k,16slp90-01g12.p1k,16slp90-01c08.q1k,16slp90-
2g04.p1k,16slp90-01f01.p1k,16slp90-01g11.q1k,16slp90-01h08.p1k,16slp90-
01b05.p1k,16slp90-01h10.q1k,16slp90-2b01.p1k,16slp
23 5 4.81 Shigella 
sonnei/dysenteriae 
or Escherichia coli
16slp90-01g09.p1k,16slp90-2a07.p1k,16slp90-2g05.p1k,16slp90-
01g02.p1k,16slp90-2c06.p1k
24 4 3.85 Acinetobacter  sp. 
N12,  A. 
haemolyticus (97%)
16slp90-2a02.p1k,16slp90-2a08.p1k,16slp90-2e03.p1k,16slp90-2e02.p1k
25 1 0.96 16saw12-2b11.p1k  , 
B.  intestinihominis 
(86%)
16slp90-01c05.p1k
26 1 0.96 7days-A12  ,  B. 
viscericola (86%)
16slp90-2b04.p1k
27 1 0.96 BF0002C006  (97%), 
H. soli (91%)
16slp90-2b03.q1k
Total 104 100   
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Table 10.12
16slp118 - UC pouchitis 1 (GQ157654-GQ157760)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 2 1.87 Enterococcus 
faecium
16slp118-1a07.w2k,16slp118-1d04.p1k
2 1 0.93 LC3  (97%),  B.  humi 
(96%)
16slp118-1a04.p1k
3 2 1.87 Veillonella dispar 16slp118-1b06.p1k,16slp118-1f12.p1k
4 3 2.80 Propionibacterium 
acnes
16slp118-2c11.p1k,16slp118-2d10.w2k,16slp118-3a08.p1k
5 2 1.87 Brevundimonas 
nasdae
16slp118-1b09.w2k,16slp118-1h09.p1k
6 1 0.93 clone  654940,  R. 
blasticus (96%)
16slp118-1e12.p1k
7 1 0.93 Paracoccus marinus 16slp118-1g09.w2k
8 2 1.87 Sphingomonas 
paucimobilis
16slp118-1b05.p1k,16slp118-1c06.p1k
9 2 1.87 Limnobacter 
thiooxidans
16slp118-1b08.w2k,16slp118-1b11.w2k
10 1 0.93 Ultramicrobacter 
hongkongensis
16slp118-2c06.p1k
11 1 0.93 Alcaligenes faecalis 16slp118-1g02.w2k
12 1 0.93 Massilia aurea 16slp118-1e01.w2k
13 2 1.87 Delftia acidovorans 16slp118-1b03.p1k,16slp118-1d11.w2k
14 2 1.87 Acetobacter 
pasteurianus
16slp118-1h10.p1k,16slp118-3h06.p1k
15 1 0.93 Stenotrophomonas 
maltophilia
16slp118-1f09.w2k
16 1 0.93 EME044  ,  T. 
dokdonensis (94%)
16slp118-1e03.w2k
17 12 11.21 Acinetobacter  sp. 
N12, A. haemolyticus 
(96%)
16slp118-1h11.w2k,16slp118-2b09.p1k,16slp118-1c07.p1k,16slp118-
1c12.w2k,16slp118-2d11.p1k,16slp118-3a01.p1k,16slp118-
1f06.p1k,16slp118-3f04.p1k,16slp118-1f10.w2k,16slp118-
1d02.w2k,16slp118-1h08.p1k,16slp118-1e10.p1k
18 67 62.62 Escherichia  coli  or 
Shigella sp.
16slp118-1h02.p1k,16slp118-1h04.p1k,16slp118-1a12.p1k,16slp118-
1e02.w2k,16slp118-2a11.p1k,16slp118-3d03.p1k,16slp118-
1c03.p1k,16slp118-3d01.p1k,16slp118-1d06.p1k,16slp118-
1g03.w2k,16slp118-1f03.w2k,16slp118-2a12.p1k,16slp118-
1d03.p1k,16slp118-1e07.p1k,16s
19 1 0.93 5.17F,  B. 
intestinihominis 
(87%)
16slp118-1d07.p1k
20 1 0.93 Bacteroides vulgatus 16slp118-2c08.p1k
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21 1 0.93 16saw31-1d10.p1k, 
A. massiliensis (95%)
16slp118-1a09.w2k
Total 107 100   
Table 10.13
16slp114 - UC pouchitis 2 (GQ157761-GQ157844)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 8 9.52 AP07K.76,  C. 
lituseburense (97%)
16slp114-1d02.p1k,16slp114-1e12.p1k,16slp114-1h12.p1k,16slp114-
1g12.p1k,16slp114-1d05.q1k,16slp114-1b03.w2k,16slp114-
1d11.w2k,16slp114-1a12.p1k
2 2 2.38 Ruminococcus gnavus 16slp114-1d03.w2k,16slp114-3e05.p1k
3 1 1.19 BF0001C098,  C.  boltei 
(94%)
16slp114-1a04.p1k
4 2 2.38 Veillonella dispar 16slp114-1d09.w2k,16slp114-3a05.p1k
5 1 1.19 Streptococcus 
salivarius
16slp114-2d04.p1k
6 2 2.38 Propionibacterium 
acnes
16slp114-1g04.q1k,16slp114-1h09.q1k
7 2 2.38 Sphingomonas panni 16slp114-1d12.w2k,16slp114-1e11.w2k
8 3 3.57 Sphingomonas 
paucimobilis
16slp114-3b01.p1k,16slp114-1g05.p1k,16slp114-3c12.p1k
9 3 3.57 APe4_19  (97%),  S. 
asaccharolytica (95%)
16slp114-1f05.q1k,16slp114-1h06.q1k,16slp114-1e02.w2k
10 3 3.57 Ralstonia pickettii 16slp114-1f03.w2k,16slp114-1g11.w2k,16slp114-1c04.w2k
11 1 1.19 Massilia aurea 16slp114-1c02.p1k
12 1 1.19 Delftia acidovorans 16slp114-1b08.w2k
13 1 1.19 Stenotrophomonas 
maltophilia
16slp114-3h12.p1k
14 14 16.67 Acinetobacter sp. N12, 
A. haemolyticus (97%)
16slp114-3b12.p1k,16slp114-3h01.p1k,16slp114-1a10.p1k,16slp114-
1b10.w2k,16slp114-1b02.p1k,16slp114-1c09.w2k,16slp114-
1a08.w2k,16slp114-1g01.p1k,16slp114-2c05.p1k,16slp114-
2d03.p1k,16slp114-1h01.p1k,16slp114-1f09.p1k,16slp114-
1f10.p1k,16slp114-1f07.p1k
15 1 1.19 Pseudomonas 
fluorescens
16slp114-1a06.q1k
16 1 1.19 Pseudomonas stutzeri 16slp114-1d08.w2k
17 1 1.19 Haemophilus 
parainfluenzae
16slp114-2g01.p1k
18 1 1.19 Proteus mirabilis 16slp114-1a11.p1k
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19 1 1.19 Kluyvera ascorbata 16slp114-1b12.w2k
20 3 3.57 Escherichia coli 16slp114-1g08.q1k,16slp114-1h11.p1k,16slp114-1b01.w2k
21 28 33.33 Escherichia  coli  or 
Shigella sp.
16slp114-1c07.p1k,16slp114-1e08.p1k,16slp114-1a01.p1k,16slp114-
2b06.p1k,16slp114-1a09.w2k,16slp114-1c10.q1k,16slp114-
1c08.q1k,16slp114-1a02.w2k,16slp114-1e01.w2k,16slp114-
1e09.q1k,16slp114-1e04.q1k,16slp114-3d12.p1k,16slp114-
2c02.p1k,16slp114-3c02.p1k,16s
22 4 4.76 Bacteroides fragilis 16slp114-1a05.q1k,16slp114-3b03.p1k,16slp114-1c12.p1k,16slp114-
1b09.p1k
Total 84 100   
Table 10.14
16slp117 - UC pouchitis 3 (  GQ157845-GQ157945)  
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 5 4.95 Clostridium 
perfringens
16slp117-1a02.p1k,16slp117-1d06.p1k,16slp117-1e10.p1k,16slp117-
1f03.p1k,16slp117-1b12.p1k
2 2 1.98 SJTU_D_11_67, 
Clostridium 
disporicum (98%)
16slp117-1h06.p1k,16slp117-2g11.p1k
3 1 0.99 SJTU_D_15_24,  C. 
disporicum (97%)
16slp117-2a12.p1k
4 2 1.98 SJTU_D_14_82,  C. 
disporicum (98%)
16slp117-1e07.w2k,16slp117-1h12.w2k
5 1 0.99 Bacterium  FN062, 
Clostridium 
subterminale (98%)
16slp117-2d01.p1k
6 3 2.97 Clostridium bartlettii 16slp117-1g06.w2k,16slp117-2a01.p1k,16slp117-1f08.p1k
7 1 0.99 Clostridium 
lactatifermentans
16slp117-1g12.p1k
8 2 1.98 M0027_107, 
Ruminococcus  gnavus 
(98%)
16slp117-1c04.w2k,16slp117-1c12.w2k
9 1 0.99 aab48e08  (98%), 
Butyrate-producer  L1-
92 (90%)
16slp117-1c05.w2k
10 2 1.98 aab24b10  (98%),  B. 
capillosus (94%)
16slp117-1a07.w2k,16slp117-1f11.w2k
11 1 0.99 16saw20-1e08.w2k,  R. 
bromii (88%)
16slp117-1d07.p1k
12 1 0.99 Propionibacterium 
acnes
16slp117-1b08.w2k
13 3 2.97 Methylobacterium 16slp117-2d12.p1k,16slp117-2h03.p1k,16slp117-2h05.p1k
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extorquens
14 1 0.99 Brevundimonas 
nasdae
16slp117-1f09.p1k
15 1 0.99 654940  (98%),  R. 
blasticus (96%)
16slp117-1c01.w2k
16 1 0.99 Paracoccus marinus 16slp117-1d11.w2k
17 1 0.99 3C002467, 
Sphingomonas 
paucimobilis (98%)
16slp117-1a12.w2k
18 3 2.97 Delftia acidovorans 16slp117-1b02.w2k,16slp117-2a02.p1k,16slp117-1d10.w2k
19 13 12.87 Acinetobacter sp. N12, 
A. haemolyticus (97%)
16slp117-1f04.p1k,16slp117-1g11.p1k,16slp117-1e12.w2k,16slp117-
2f02.p1k,16slp117-1a05.p1k,16slp117-1d08.p1k,16slp117-
1e01.w2k,16slp117-1h07.p1k,16slp117-1d02.w2k,16slp117-
1e02.p1k,16slp117-1h10.w2k,16slp117-1a09.w2k,16slp117-1a10.p1k
20 2 1.98 Hafnia alvei 16slp117-1b09.w2k,16slp117-1g01.w2k
21 4 3.96 Escherichia  coli  or 
Shigella sp.
16slp117-1c06.w2k,16slp117-1e04.p1k,16slp117-2e05.p1k,16slp117-
1b11.q1k
22 2 1.98 Enterobacter sp. B901-
2,  Enterobacter 
hormaechei (98%)
16slp117-1d01.p1k,16slp117-1e06.p1k
23 48 47.52 Enterobacter 
hormaechei
16slp117-1e03.p1k,16slp117-1g04.p1k,16slp117-1a06.p1k,16slp117-
1h11.p1k,16slp117-1h09.p1k,16slp117-1c10.p1k,16slp117-
1h05.p1k,16slp117-1d09.p1k,16slp117-2a09.p1k,16slp117-
1f02.w2k,16slp117-1d04.q1k,16slp117-1e09.w2k,16slp117-
1h01.w2k,16slp117-1f12.w2k,16s
Total 101 100   
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Table 10.15
16slp108 - UC pouchitis 4 (GQ157946-GQ158042)
Phylotype No.  of 
each
%  of 
clones
Identity Clones in Phylotype
1 3 3.09 Bacillus koguryoae 16slp108-1d06.w2k,16slp108-1e09.w2k,16slp108-1d05.w2k
2 2 2.06 Staphylococcus 
epidermidis
16slp108-1c03.p1k,16slp108-1g08.w2k
3 1 1.03 SJTU_F_08_03, 
Clostridium  boltei 
(98%)
16slp108-1h02.p1k
4 14 14.43 Propionibacterium 
acnes
16slp108-2e08.p1k,16slp108-2e12.p1k,16slp108-2a02.p1k,16slp108-
2f04.p1k,16slp108-2b08.p1k,16slp108-2d12.p1k,16slp108-
1e12.w2k,16slp108-2c10.p1k,16slp108-1c02.p1k,16slp108-
1g02.p1k,16slp108-1g11.p1k,16slp108-1g12.p1k,16slp108-
1g03.p1k,16slp108-1g04.p1k
5 2 2.06 Corynebacterium 
durum
16slp108-1e08.w2k,16slp108-1f01.w2k
6 3 3.09 Methylobacterium 
extorquens
16slp108-1f02.w2k,16slp108-1f08.w2k,16slp108-2a12.p1k
7 2 2.06 Bradyrhizobium 
elkanii
16slp108-2b03.p1k,16slp108-2d07.p1k
8 1 1.03 Brevundimonas 
nasdae
16slp108-1h05.p1k
9 4 4.12 DSSF72 (96%), S. mali 
(95%)
16slp108-1b01.w2k,16slp108-1b07.w2k,16slp108-2c01.p1k,16slp108-
2a03.p1k
10 1 1.03 3C002467, 
Sphingomonas 
paucimobilis (98%)
16slp108-1h09.w2k
11 1 1.03 Sphingomonas panni 16slp108-2d10.p1k
12 3 3.09 Delftia acidovorans 16slp108-1d11.p1k,16slp108-1c06.w2k,16slp108-1f06.p1k
13 1 1.03 Acidovorax 
temperans
16slp108-2c02.p1k
14 1 1.03 Ralstonia 
detusculanense  or 
pickettii
16slp108-1h03.p1k
15 2 2.06 Shigella  sp.  or 
Escherichia coli
16slp108-1c10.w2k,16slp108-2d01.p1k
16 1 1.03 Escherichia coli 16slp108-2e04.p1k
17 1 1.03 Pseudomonas 
fluorescens
16slp108-1g06.w2k
18 48 49.48 Acinetobacter  sp. 
N12,  A.  haemolyticus 
(97%)
16slp108-2a01.p1k,16slp108-2c08.p1k,16slp108-1e11.w2k,16slp108-
1h06.p1k,16slp108-1d08.p1k,16slp108-1e01.w2k,16slp108-
1e02.p1k,16slp108-1a05.w2k,16slp108-1d09.w2k,16slp108-
2h11.p1k,16slp108-1g09.w2k,16slp108-1c04.w2k,16slp108-
2d03.p1k,16slp108-2c06.p1k,16s
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19 2 2.06 Prevotella bivia 16slp108-1a04.w2k,16slp108-1g01.w2k
20 1 1.03 C1-34,  Prevotella 
copri (98%)
16slp108-1b08.w2k
21 2 2.06 Bifissio spartinae 16slp108-1e03.p1k,16slp108-2f08.p1k
22 1 1.03 Pedobacter 
daejeonensis
16slp108-1b03.w2k
Total 97 100   
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1. Phosphate buffered saline (PBS)
Commercially available tablets were used (Sigma)
0.001M phosphate buffer
0.0027M potassium chloride
0.137M sodium chloride
Each tablet was dissolved in 200ml of distilled water
2. Tris buffered saline (TBS)
Distilled water 1000ml
Sodium chloride 87.66g
Tris (hydroxymethyl aminomethane) 60.55g
Hydrochloric acid or sodium hydroxide was used to adjust the pH to 7.4
3. 4% paraformaldehyde (PFA)
PFA was dissolved in PBS and 100μl of 5M sodium hydroxide added, stirring at 60°C.
 
4. Preparation of LB agar plates
 17.5g of LB (Luria Bertani) agar was added to 500ml of distilled water, this was then 
sterilised in an autoclave. Following cooling 2.5ml of 0.1 M IPTG (isopropyl-beta-D-
Reagents Appendix 2
thiogalactopyranoside)  and  500µl  of  ampicillin  (100mg/ml)  was  added  to  the 
agar.800µl  of  X-gal  (5-Bromo-4-Chloro-3-Indoyl-beta  -D-Galactopyranoside) 
(Promega) was then added to the agar and mixed by inversion of the bottles. The agar 
mixture was then added to sterile agar plates which were left to set and stored at 4°C.
5. Agarose gel
40ml of 1x TBE (Tris Borate EDTA buffer) was added to a glass flask containing 4g 
of Agarose. The mixture was heated in a microwave for 1 minute. 2 µl of 10mg/ml 
Ethidium bromide was added
.
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Suppliers
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Quiagen
Fleming Way 
Crawley 
West Sussex 
RH10 9NQ
Promega UK
Delta House
Chilworth Science Park
Southampton
SO16 7NS
Applied Biosystems
Lingley House
120 Birchwood Boulevard
Warrington
WA3 7QH
Suppliers Appendix 3
Sigma-Aldrich Co. Ltd
The Old Brickyard, New Road
Gillingham
Dorset
SP8 4XT 
Nutricia Ltd. 
White Horse Business Park 
Newmarket Avenue 
Trowbridge 
Wiltshire
BA 14 OXQ
Meridian Bioscience 
3471 River Hills Drive
Cincinnati
OH 45244-3023 
USA
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Oxoid
Wade Road
Basingstoke
Hampshire
RG248PW
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Harrow Research Ethics Committee
The Old Refectory
Central Middlesex Hospital
Acton Lane
Park Royal
Middlesex
NW10 7NS
Telephone: 020 8453 2461 
11 January 2007
Ms Sue Clark
Consultant Colorectal Surgeon
St Mark's Hospital
Watford Road
Harrow
Middlesex
HA1 3UJ
Dear Ms Clark
Full title of study: A study of the bacterial and cytokine changes during treatment 
of inflammation of the ileal reservoir with elemental diet
REC reference number: 06/Q0405/89
Thank you for your letter of 22 December 2006, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair. 
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation as 
revised.
Ethical review of research sites
The favourable opinion applies to the research sites listed on the attached form. 
Conditions of approval
The favourable opinion is given provided that you comply with the conditions set out in the attached 
document.  You are advised to study the conditions carefully.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
 
Document   Version   Date   
Application 5.2 03 November 2006 
Investigator CV  03 November 2006 
Protocol 2 22 December 2006 
Covering Letter  09 January 2007 
Covering Letter  06 November 2006 
Letter of invitation to participant    
GP/Consultant Information Sheets 1 03 November 2006 
Ethical permission Appendix 4
Participant Information Sheet 3 09 January 2007 
Participant Consent Form: Consent form for use of tissues and 
Biomaterials for Research and Teaching Purposes 
1 03 November 2006 
Response to Request for Further Information  22 December 2006 
Summary C.V for Supervisor (student research)  10 September 2006 
Referees' or other scientific critique report (Reviewer: Alison Culkin)    
Referees' or other scientific critique report (Reviewer: James 
Lindsay) 
   
Letter from funder  16 October 2006 
Summary CV for Principal Investigator    
Non-validated questionnaire (Patient diary sheet)    
Research governance approval
The study should not commence at any NHS site until the local Principal Investigator has obtained 
final research governance approval from the R&D Department for the relevant NHS care organisation.
Statement of compliance
 The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK.
06/Q0405/89 Please quote this number on all correspondence
With the Committee’s best wishes for the success of this project
Yours sincerely
Dr Gwen Sayers
Chair
Email: Mona.Shah@nwlh.nhs.uk
Enclosures: Standard approval conditions - SL-AC2 for other studies
Site approval form
 
Copy to: Mr Alan Warnes
North West London Hospitals trust.
Research and development department
Watford road
Harrow
HA1 3UJ
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Harrow Research Ethics Committee
Room 007, Level 5, L Block
Northwick Park Hospital
Watford Road
Harrow
Middlesex  HA1 3UJ
Tel: 020 8869 3805
Fax: 020 8869 5222 
15 January 2008
Miss Sue Clark
Colorectal Surgeon
NWLH NHS Trust
St. Mark’s Hospital
Level 5, CRUK Corridor
Harrow,  
Middx  HA1 3UJ
Dear Miss Clark
Study title: Investigation of the Bacterial Pathogenesis of Pouchitis and the 
Development of Novel Therapy Using Probiotics    
REC reference: 3238
Amendment number: 01
Amendment date: 07 January 2008
The above amendment was reviewed at the meeting of the Sub-Committee of the REC.
Ethical opinion
The members of the Sub-Committee gave a favourable ethical opinion of the amendment on the basis 
described in the notice of amendment form and supporting documentation.
Approved documents
The documents reviewed and approved at the meeting were:
 Document Version Date 
Notice of Substantial Amendment (non-CTIMPs)  04January 2008
Covering Letter  04 January 2008 
R&D approval
All investigators and research collaborators in the NHS should notify the R&D office for the relevant 
NHS care organisation of this amendment and check whether it affects R&D approval of the research.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK.
227
Ethical permission Appendix 4
3238:  Please quote this number on all correspondence
Yours sincerely
Mrs Alka Bhayani
Committee Administrator
E-mail: alka.bhayani@nwlh.nhs.uk 
Copy to: Dr S McLaughlin
St Mark's Academic Institute
St Mark’s Hospital,
Watford Rd,
Harrow,
Middlesex   HA1 3UJ
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         Harrow Local Research Ethics Committee
Northwick Park Hospital
Level 5BB Room 015
Watford Road
Harrow
Middlesex
HA1 3UJ
Tel: 020 8453 2461
Fax: 020 453 2466
Website: www.nwlh.nhs.uk/research 
08 June 2006
Dr Simon McLaughlin
St Mark’s Academic Institute
St Mark’s Hospital
Watford Road
Harrow
HA1 3UJ
Dear Dr McLaughlin
Study title: Investigation of the Bacterial Pathogenesis of Pouchitis and the Development 
of Novel Therapy Using Probiotics    
REC reference: 3238
Amendment date: April 2006
The above amendment was reviewed by the Chair of the Harrow Research Ethics Committee.
Ethical opinion
The Chair gave a favourable ethical opinion of the amendment on the basis described in the notice of 
amendment form and supporting documentation. The Chair noted that you have replaced Dr Matt 
Johnson as the Research Registrar was happy to consider this as a non-substantial amendment.
Approved documents
The documents reviewed and approved at the meeting were:
1. CV for Dr Simon McLaughlin
2. GP letter showing revised contact details
3. Patient Volunteer Consent Form showing revised contact details
4. Notice of Amendment Form
Research governance approval
All investigators and research collaborators in the NHS should notify the R&D Department for the 
relevant NHS care organisation of this amendment and check whether it affects research governance 
approval of the research.
229
Ethical permission Appendix 4
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The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees (July 2001) and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK.
3238: Please quote this number on all correspondence
Yours sincerely
Mona Shah
Committee Co-ordinator
E-mail: mona.shah@nwlh.nhs.uk
Copy To: Dr Alan Warnes, R&D Department, NWLH NHS Trust.
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